Tuesday, December 2, 2003

12:00-10:00 REGISTRATION – East Registration and Bridge Hall

Pre-registered attendees can obtain badges & materials.Those who havenot yet registered may do so.

Wednesday, December 3

8:45-9:00 WELCOME – Ballroom C

Opening RemarksCharles A. Coltman, Jr., MDC. Kent Osborne, MD

9:00-9:30 PLENARY LECTURE 1 – Ballroom C

Stem Cells in the Normal and Cancerous Human BreastMax S. Wicha, MDUniversity of Michigan Comprehensive Cancer CenterAnn Arbor, MI

9:30-12:00 GENERAL SESSION 1 – Ballroom C

9:30 1. Comparison of anastrozole vs tamoxifen alone and incombination as neoadjuvant treatment of estrogen receptor-positive (ER+) operable breast cancer in postmenopausal women:the IMPACT trial. Smith I, on Behalf of the IMPACT Trialists. Royal Marsden Hospital,London, United Kingdom.

9:45 2. Greater Ki67 response after 2 weeks neoadjuvant treatmentwith anastrozole (A) than with tamoxifen (T) or anastrozole plustamoxifen (C) in the IMPACT trial: a potential predictor ofrelapse-free survival. Dowsett M, on Behalf of the IMPACT Trialists. Royal Marsden Hospital,London, United Kingdom.

10:00 3. Anastrozole appears to be superior to tamoxifen in womenalready receiving adjuvant tamoxifen treatment.Boccardo F, Rubagotti A, Amoroso D, Mesiti M, Massobrio M, PorpigliaM, Rinaldini M, Paladini G, Distante V, Franchi R, Failla G, Bordonaro R,Sismondi P, on Behalf of the Italian Tamoxifen Arimidex (ITA) Trial. NCRIand University of Genoa, Italy; University of Messina, Italy; University ofTurin, Italy; General Hospital, Arezzo, Italy; Policlinico S. Orsola-Malpighi,Italy; University of Florence, Italy; General Hospital, Casalpusterlengo, Italy;San Luigi Hospital, Catania, Italy; Mauriziano Hospital, Turin, Italy.

10:15 4. Analysis of time to recurrence in the ATAC (arimidex,tamoxifen, alone or in combination) trial according to estrogenreceptor and progesterone receptor status. Dowsett M, on Behalf of the ATAC Trialists' Group. Royal MarsdenHospital, London, United Kingdom.

10:30 5. Ten-year outcome of breast-conserving surgery (BCS) andradiotherapy (RT) in women with breast cancer (BC) and germlineBRCA 1/2 mutations: results from an international collaboration. Pierce L, Levin A, Rebbeck T, Kardia S, BenDavid M, Harris E, Solin L,Haffty B, Wynen E, Gaffney D, Narod S, Metcalfe K, Dawson L, Eisen A,Whelan T, Olivotto I, Galinsky D, Meirovitz A, Olopade O, Garber J, NixonA, Merajver S, Isaacs C, Weber B. U Michigan, Ann Arbor, MI; UPennsylvania, Philadelphia, PA; Sheba Medical Ctr, Ramat-Gan, Israel; Yale

U, New Haven, CT; U Utah, Salt Lake City, UT; U Toronto, Toronto,Canada; Hamilton Regional Cancer Ctr, ON, Canada; BC Cancer Agency,BC, Canada; Hadassah Medical Ctr, Jerusalem, Israel; U Chicago, Chicago,IL; Dana-Farber, Boston, MA; Georgetown U, Wash, DC.

10:45 6. Breast-conserving therapy after neoadjuvant chemotherapy:the M. D. Anderson Cancer Center experience. Chen AM, Meric F, Hunt KK, Thames HD, Outlaw ED, Strom EA,McNeese MD, Kuerer HM, Ross MI, Singletary SE, Ames FC, Feig B,Hortobagyi GN, Sahin AA, Perkins GH, Schechter NR, Buchholz TA. TheUniversity of Texas M.D. Anderson Cancer Center, Houston, TX.

11:00 7. Pooled analysis of prognostic impact of bone marrowmicrometastasis: 10-year survival of 4199 breast cancer patients.Braun S, Vogl FD, Schlimok G, Diel IJ, Janni W, Gerber B, Gebauer G,Coombes RC, Pierga J-Y, Naume B, Pantel K, Collaborative Group BoneMarrow Micrometastasis. Dept. Ob/Gyn, Innsbruck, Austria; Bozen, Italy;Dept. Hem/Oncol, Augsburg, Germany; Dept. Ob/Gyn, Heidelberg,Germany; Dept. Ob/Gyn, Munich, Germany; Dept. Ob/Gyn, Rostock,Germany; Dept. Ob/Gyn, Nuernberg-Erlangen, Germany; Div. Med.,London, United Kingdom.

11:15 8. The presence of isolated tumor cells in bone marrow threeyears after diagnosis in disease free breast cancer patientspredicts an unfavourable outcome.Wiedswang G, Borgen E, Karensen R, Qvist H, Naume B. UllevaalUniversity Hospital, Oslo; The Norwegian Radium Hospital, Oslo.

11:30 9. Micrometastases in sentinel lymph nodes of patients withductal carcinoma in situ of the breast have no clinical relevance. Wijsman JH, Broekhuizen LN, Peterse HL, Rutgers EJT. Netherlands CancerInstitute/Antoni van Leeuwenhoekhuis, Amsterdam, Netherlands.

11:45 37. Cytokeratin 5/6 in normal breast lobules: lack of evidence fora stem cell phenotype.Clarke CL, Sandle J, Parry SC, Reis-Filho JS, Lakhani SR. Institute of CancerResearch, London, United Kingdom; The Royal Marsden NHS Trust,London, United Kingdom.

12:00-1:30 LUNCH [Ticket Required] – Exhibit Hall D

1:30-3:00 MINI-SYMPOSIUM 1 – Ballroom C

CELL CYCLE REGULATORS – TARGETS FOR THERAPY?Powel Brown, MD, PhD, Co-ModeratorBaylor College of Medicine, Houston, TXandAdrian Lee, PhD, Co-ModeratorBaylor College of Medicine, Houston, TX

1:30 Introduction

1:30 Control of cell cycle progression in breast cancerRichard Pestell, MD, PhDGeorgetown University Medical CenterWashington, DC

2:00 Tumor-specific low molecular weight forms of cyclin E inducegenomic instability and resistance to anti-estrogens, p21, and p27in breast cancerKhandan Keyomarsi, PhDMD Anderson Cancer CenterHouston, TX

2:30 Clinical development of targeted cell cycle inhibitorsSandra M. Swain, MDNational Cancer InstituteBethesda, MD

3:00-4:30 GENERAL SESSION 2 – Ballroom C

3:00 10. Randomized trial comparing docetaxel and paclitaxel inpatients with metastatic breast cancer.Jones S, Erban J, Overmoyer B, Budd GT, Hutchins XL, Lower E, Laufman L,Sundaram S, Urba W, Olsen S, Meyers ML, Ravdin PM. US Oncology,Houston, TX; Tufts-New England Med Ctr, MA, Boston, MA; Ireland CancerCenter, Cleveland, OH; Cleveland Clinic, Cleveland, OH; Univ Arkansas MedCtr, Little Rock, AR; Univ of Cincinnati Med Ctr, Cincinnati, OH; Hem/OncConsultants Inc, Columbus, OH; Sharp Rees-Stealy Medical Grp, San Diego,CA; Providence Med Ctr, Portland, OR; Aventis Pharmaceuticals Inc,Bridgewater, NJ; Univ Texas Health Science Ctr, San Antonio, TX.

SAN ANTONIO BREAST CANCER SYMPOSIUM v

26th Annual SanAntonio Breast

Cancer SymposiumProgram Schedule

Room Locations

Exhibit Halls C & D: Street LevelEast Registration and Bridge Hall: Street Level

Ballroom C : Ballroom (3rd) Level

3:15 11. Docetaxel primary chemotherapy in breast cancer: a five yearupdate of the Aberdeen trial.Hutcheon AW, Heys SD, Sarkar TK, Ogston KN, Eremin O, Walker LG,Miller ID. University of Aberdeen, Scotland, United Kingdom.

3:30 12. Phase III adjuvant trial comparing standard versus acceleratedFEC regimen in early breast cancer patients. Results from GONO -MIG1 study.Venturini M, Aitini E, Del Mastro L, Sertoli MR, Conte P, Olmeo N,Mammoliti S, Cavazzini G, Pastorino S, Bruzzi P, Rosso R. National CancerResearch Institute, Genova, Italy; AO Poma, Mantova, Italy; AO SantaChiara, Pisa, Italy; AO 1 Sassari, Sassari, Italy; Ospedale Galliera, Genova,Italy.

3:45 13. Genetic differences between ductal carcinoma in situ andinvasive breast cancer.Allred DC, Tsimelzon A, Mohsin SK, Hilsenbeck SG, Medina D, OsborneC, O'Connell P. Baylor College of Medicine, Houston, TX; VirginiaCommonwealth University, Richmond, VA.

4:00 14. Randomised, double-blind, placebo-controlled trial of short-term effects of gefitinib ('Iressa', ZD1839) on ductal carcinoma in situ.Bundred NJ, Anderson EA, Gee J, Barr L, Baildam A, Zeiton A, Byrne G,Grassby S, Nicholson RI, Koehler M. South Manchester UniversityHospital, Manchester, United Kingdom; Christie Hospital, Manchester,United Kingdom; Welsh School of Pharmacy, Cardiff, United Kingdom;AstraZeneca Pharmaceuticals, Wilmington, DE.

4:15 15. Wide excision alone for ductal carcinoma in situ (DCIS) of thebreast.Wong JS, Gadd MA, Gelman R, Kaelin CM, Lester S, Schnitt SJ, Sgroi DC,Smith BL, Troyan SL, Harris JR. Dana-Farber/Harvard Cancer Center,Boston, MA.

4:30-6:30 POSTER DISCUSSION 1 and 2– Park View Atrium

(#1001-1013)

Signaling, Crosstalk, and Treatment Resistance

1001 Phosphorylation of estrogen receptor � as a potential mechanismunderlying resistance to endocrine therapies.Sarwar N, Chen D, Constantinidou D, Coombes RC, Ali S. ImperialCollege London, London, United Kingdom.

1002 Estrogen’s ability to stimulate breast cancer growth does notrequire ER DNA binding.DeNardo DG, Kim HT, Thorn CA, Wu K, Lee AV, Brown PH. BaylorCollege of Medicine, Houston, TX.

1003 Withdrawn

1004 Phospho-serine 118 estrogen receptor-� in human breast tumorsin vivo.Cherlet TC, Adeyinka A, Niu Y, Snell L, Watson P, Murphy L. University ofManitoba, c/o Cancer Care Manitoba, Winnipeg, MB, Canada; Universityof Manitoba, Winnipeg, MB, Canada.

1005 The combination of taxol and a selective retinoid X receptor(RXR) ligand targretin prevents and overcomes acquired taxolresistance in breast carcinoma.Yen W-C, Prudente RY, Roegner KR, Reid BP, William LW. LigandPharmaceuticals, Inc., San Diego, CA.

1006 Activation of the MAPK pathway with letrozole treatment in nudemice.Jelovac D, Long BJ, Brodie AMH. University of Maryland, Baltimore,Baltimore, MD.

1007 Resistance to endocrine therapy in a xenograft model of HER-2overexpressing breast cancer is accompanied by increased HER-2but loss of IGF-1 receptor expression.Massarweh SA, Jiang S, Mohsin SK, DiPietro M, Wakeling AE, OsborneCK, Schiff R. Baylor College of Medicine, Houston, TX; AstraZeneca,Macclesfield, United Kingdom.

1008 Heregulin-induced AKT activation promotes growth of gefitinib(‘Iressa’, ZD1839)-treated, tamoxifen-resistant breast cancer cells.Hutcheson IR, Knowlden JM, Barrow D, Gee JMW, Robertson JF, WakelingAE, Nicholson RI. Tenovus Centre for Cancer Research, Cardiff, UnitedKingdom; City Hospital, Nottingham, United Kingdom; AstraZenecaPharmaceuticals, Alderley Edge, United Kingdom.

1009 IGF-IR and EGFR crosstalk in tamoxifen resistant MCF-7 breastcancer cells.Knowlden JM, Iain HR, Denise B, Robert NI. Cardiff University, Cardiff,United Kingdom.

1010 The novel dual kinase inhibitor GW572016 is particularly active inHER2-positive and trastuzumab-conditioned breast cancer cells.Konecny G, Finn R, Venkatesan N, Rusnak D, Gilmer T, Berger M, Chen J,Slamon DJ, Pegram M. University of California Los Angeles, CA;GlaxoSmithKline, Research Triangle Park, NC.

1011 Insulin-like growth factor-1 receptor signalling and acquiredresistance to gefitinib (‘Iressa’, ZD1839) in MCF-7 human breastcancer cells.Nicholson RI, Jones HE, Gee JMW, Barrow D, Hiscox S, Harper M, RubiniM, Guy S, Wakeling A. Tenovus Centre for Cancer Research, Cardiff,United Kingdom; University of Ferrara, Ferrara, Italy; AstraZeneca,Alderley Edge, United Kingdom.

1012 DNA replication licensing proteins in breast cancer.Hughan I, Stoiber K, Williams G, Lodo M, Sainsbury R. University College,London, United Kingdom.

1013 A possible molecular mechanism of action for the potentialtumor suppressor gene INT6 provided by studies in fission yeast.Yen H-CS, Ren G, Nelson L, Sha Z, Sap J, Chang E. Breast Center,Methodist Hospital, Baylor College of Medicine, Houston, TX; New YorkUniversity School of Medicine, New York, NY.

(#1014-1025)

Axillary Nodes, Ductal Lavage

1014 Optical biopsy : a novel intraoperative diagnostic tool todetermine sentinel lymph node status instantly in breast cancer.Chicken DW, Lee AC, Briggs GM, Keshtgar MRS, Johnson KS, PickardDDO, Bigio IJ, Bown SG. University College London, London, UnitedKingdom; University of Boston, Boston, MA.

1015 The number of resected axillary lymph nodes (ALN) influences therisk for axillary recurrences in node-positive, but not in node-negative patients.Janni W, Gerber B, Rack B, Strobl B, Rjosk D, Thieleke W, Sommer H, FrieseK. LMU, Munich, Germany.

1016 Decreased identification rate of sentinel lymph node afterneoadjuvant chemotherapy.Kang SH, Kim SK, Kwon Y, Ro JS, Kang HS, Lee ES. National CancerCenter, Goyang, Gyeonggi, Korea.

1017 Improved accuracy of sentinel lymph node biopsy followingneoadjuvant chemotherapy for breast cancer.Lang JE, Esserman LJ, Ewing CA, Rugo HS, Jaaj NM, Leong SP, Hwang E-SS.University of California, San Francisco, CA.

1018 An interim analysis of a prospective multi-institutional cohortstudy: quantitative real-time RT-PCR provides a statisticalvalidation for the molecular detection of micrometastatic disease.Mitas M, Mikhitarian K, Herbert R, Urist MM, Mann BG, Doherty G,Hermann VM, Hill AD, Eremin O, Orr RK, Steinberg S, Valle AA,Henderson MA, Adams-Campell L, Sugg SL, Frykberg E, Yeh K, Bell RM,Metcalf JS, Elliott B, Brothers T, Robison J, Mauldin PD, Palesch Y, GillandersWE, Cole DJ. MUSC, Charleston, SC; Royal Melbourne Hosp, Victoria,Australia; Washington Univ, St. Louis, MO; St Vincent’s Univ Hosp, Dublin,Ireland; Lincoln & Louth County Hosp, Lincoln, United Kingdom;Spartanburg Reg Med Ctr, Spartanburg, SC; Univ Tennessee, Chattanooga,TN; St Vincent’s Hosp, Victoria, Australia; Howard University CancerCenter, Wash, DC; Med Col Wisconsin, Milwaukee, WI; Univ Florida Hosp,Jacksonville, FL; Med Col Georgia, Augusta, GA; Palmetto Health Alliance,Columnbia, SC; Univ Alabama, Birmingham, AL,.

SAN ANTONIO BREAST CANCER SYMPOSIUM - Wednesdayvi

1019 Prediction of axillary lymph node involvement of women withinvasive breast cancer.Goyal A, Mansel RE. on Behalf of ALMANAC Trialists Group, Universityof Wales College of Medicine, Cardiff, South Glamorgan, UnitedKingdom.

1020 Is axillary lymph node dissection necessary for all T1a-b breastcancer patients? Use of common pathologic findings to predict anegative dissection.Williams WH, Holladay D, Sheikh AA, Holladay CT, Critz FA, Shrake PD,Benton JB, Maxa LS, Gargus JN, Tarlton RS, Rosenbaum SE. RadiotherapyClinics of Georgia, Decatur, GA.

1021 Morbidity of axillary node sampling versus axillary nodeclearance for nodal staging in breast cancer-a multicentre trial.Goyal A, Mansel RE. on Behalf of ALMANAC Trialists Group, Universityof Wales College of Medicine, Cardiff, South Glamorgan, UnitedKingdom.

1022 Ductal lavage specimens can be successfully split at the bedsidewithout compromising cytologic diagnosis.Clark PM, Michael CW, Merajver SD, Smith GL, Griffith KA, Milliron KJ,Schott AF, Diehl KM, Cimmino VM, Sabel MS, Hayes DF. University ofMichigan, Ann Arbor, MI.

1023 Nuclear chromatin characteristics of breast epithelial cellsobtained by ductal lavage.Walling E, Frank DH, Thompson P, Davis J, Thompson D, Bartels PH,Ranger-Moore J, Kim C, Warneke J, Crane T, Alberts DS, Thomson C.University of Arizona, Tucson, AZ; Arizona Cancer Center, Tucson, AZ.

1024 Technical modifications of ductal lavage to improve cell yield.Golewale NH, Bryk M, Nayar R, Didwania A, Hou N, Khan SA.Northwestern University Feinberg School of Medicine, Chicago, IL.

1025 Feasibility of proteomic evaluation of ductal lavage fluid forbreast diseases.Fournier KF, Mendrinos SE, Ritchie J, Lewis M, Vlahoua A, Gregory B,Schiller A, Perry RR, Wright, Jr. G, Semmes OJ, Drake R, Laronga C.Eastern Virginia Medical School, Norfolk, VA; Emory University School ofMedicine, Atlanta, GA.

4:30-7:00 POSTER SESSION 1 AND RECEPTION – Exhibit Hall C

(#101-178)

Detection/Diagnosis: Mammography / Imaging

101 MRI patterns predict ability to perform breast conservationfollowing neoadjuvant therapy for locally advanced breast cancer.Kaplan E, Yu E, Tripathy D, Rugo H, Park J, Hwang S, Ewing C, Hylton N,Esserman L. University of California, San Francisco, San Francisco, CA.

102 Magnetic resonance imaging of the breast: clinical indications.Smith JP. First Hill Diagnostic Imaging, Seattle, WA.

103 Dynamic contrast enhanced magnetic resonance imagingfacilitates successful breast conservation following neoadjuvantchemotherapy.Kneeshaw PJ, Kemp SEG, Turnbull LW, Drew PJ. Castle Hill Hospital,Cottingham, East Yorkshire, United Kingdom; Hull Royal Infirmary, Hull,East Yorkshire, United Kingdom.

104 Dynamic contrast enhanced magnetic resonance imaging is ableto differentiate benign from malignant disease associated withscreening detected microcalcification.Kneeshaw PJ, Lowry M, Hubbard A, Turnbull LW, Drew PJ. Castle HillHospital, Cottingham, East Yorkshire, United Kingdom; Hull RoyalInfirmary, Hull, East Yorkshire, United Kingdom.

105 Can a single reader with CAD replace double reading in breastscreening?Iyengar GV, Duncan KA, Gilbert FJ, Deans HE. Grampian Primary CareNHS Trust, Aberdeen, United Kingdom.

106 Impact of breast density on the performance of a computer-aideddetection (CAD) system.Brem RF, Hoffmeister J, Jindal G. George Washington University,Washington, DC; CADx Systems, Beavercreek, OH.

107 Imaging tumor angiogenesis distributions of breast cancer byoptical tomography with ultrasound localization.Kurtzman SH, Hegde P, Zarfos K, Jagjivan B, Kane M, Zhu Q. University ofConnecticut Health Center, Storrs, CT; University of Connecticut, Storrs,CT.

108 Breast imaging with 3D/4D ultrasound: towards a newsonographic semeiography.Duchesne N. Ottawa Hospital, Civic Campus, Ottawa, ON, Canada.

109 Mammography use in males with breast masses.Lee KB, Rim A, Elson P, DiNunzio A, Crowe JP. Cleveland ClinicFoundation, Cleveland, OH.

110 Immunohistochemical detection for micrometastasis of sentinellymph nodes biopsy in carcinoma of the breastGanchev G, Aleksandrova E. National Center of Oncology, Sofia, Bulgaria.

111 Neoadjuvant endocrine therapy: exemestane (E) vs tamoxifen (T)in postmenopausal ER+ breast cancer patients (T1-4N1-2MO)Semiglazov VF, Semiglazov VV, Ivanov VG, Ziltzova EK, Dashyan GA,Kletzel A, Bozhok AA, Nurgaziev KS, Tzyrlina EV, Berstein LM, Petrov NN.Research Institute of Oncology, St. Petersburg, Russia.

Detection/Diagnosis: Screening

112 Practical impact of screening mammography: analysis ofpathologic factors and treatment utilization for womenundergoing breast conservation therapy at a large radiationtherapy center.Holladay DA, Williams WH, Sheikh A, Holladay CT, Critz FA, Shrake PD,Benton JB, Maxa LS, Gargus JN, Tarlton RS, Rosenbaum SE. RadiotherapyClinics of Georgia, Decatur, GA.

113 Clinical utility of breast sonography in BI-RADS category 0,manifesting as dense breasts, especially in the detection of breastmalignancies.Ham S-Y, Chung S, Yang I, Kim H, Kim J, Kim SJ. KangnamSacred HeartOspita Hallym Univ., Seoul, Republic of Korea.

114 Results from a pilot breast cancer screening trial using acombination of clinical breast exam, mammography, breast MRI,and ductal lavage in a high-risk population.Hartman A-R, Kurian A, Mills MA, Daniel BL, Ford JM, Kingham KE, ChunNM, Nowels KW, Herfkens RJ, Dirbas FM, Plevritis SK. Stanford University,Stanford, CA.

Risk and Prevention: Risk Factors

115 Risk of breast cancer following benign biopsy.Ashbeck EL, Hunt WC, Stauber PM, Rosenberg RD, Key CR. University ofNew Mexico Health Sciences Center, Albuquerque, NM.

116 Estrogen metabolism via D-ring pathway is associated with ahigher susceptibility to breast cancer.Huober J, Diesing D, Zimmermann B, Mueck AO, Wallwiener D, Duerr H-P, Seeger H. University Women’s Hospital, Tuebingen, Germany;University, Tuebingen, Germany.

117 Antidepressant use and the risk of breast cancer: a prospectivestudy.Jackman M, George R, Walker R, Henson J, Warner J, Wintonic A, Lloyd S.Hotel Dieu Hospital/Kingston Regional Cancer Centre, Kingston, ON,Canada.

118 Breast cancer in Hawaii: the significance of marital status.Hoque LW, Loscalzo AE, Cooper L, Shaha SH. Kapiolani Breast Center,Honolulu, HI.

119 Breast cancer environmental risk factors among Eastern EuropeanJewish immigrants and first generation descents in Rio de Janeiro,Brazil.Koifman S, Marins V, Mukim V, Rozantul P, Koifman RJ. Nat. School of P.Health, Oswaldo Cruz Foundation, Ministry of Health of Brazil, Rio deJaneiro, RJ, Brazil; Fluminense Federal University, Niteroi, RJ, Brazil.

SAN ANTONIO BREAST CANCER SYMPOSIUM - Wednesday vii

120 Smoking history and breast cancer among Hispanic and non-Hispanic persons.Gurdin JB, Morewitz SJ. J. Barry Gurdin, Ph.D., San Francisco, CA; StephenJ. Morewitz, Ph.D., & Assocs., IL & CA, Buffalo Grove, IL.

121 Association of Apolipoprotein E polymorphism with sporadicbreast cancer in Taiwanese patients.Hou M-F, Ou-Yang F, Chen F-M, Tsai S-M, Lin S-K, Hsiao J-K, Yuan S-SF,Wu S-H, Wu S-H, Hou LA, Huang T-J, Hsieh J-S, Tsai L-Y. KaohsiungMedical University, Kaohsiung, Taiwan, Taiwan; Taipei Veterans GeneralHospital, Kaohsiung, Taiwan, Taiwan; Southern California University, LosAngeles, CA.

122 Environmental risk factors associated to early age breast cancer:an exploratory case series in Rio de Janeiro, Brazil.Ortega GP, Hatagima A, Koifman RJ, Martins E, Carmo PAO, Koifman S.National School of P. Health, Oswaldo Cruz Foundation, Ministry ofHealth of Brazil, Rio de Janeiro, RJ, Brazil; Oswaldo Cruz Foundation,Ministry of Health of Brazil, Rio de Janeiro, RJ, Brazil; National CancerInstitute, Rio de Janeiro, RJ, Brazil.

123 Smoking history and breast cancer: African-American/Whitedifferences.Morewitz SJ, Gurdin JB. Stephen J. Morewitz, Ph.D., & Assocs., IL & CA,Buffalo Grove, IL; J. Barry Gurdin, Ph.D., San Francisco, CA.

124 Alcohol history and breast cancer: African-American/Whitedifferences.Morewitz SJ, Gurdin JB. Stephen J. Morewitz, Ph.D., & Assocs., IL & CA,Buffalo Grove, IL; J. Barry Gurdin, Ph.D., San Francisco, CA.

Risk and Prevention: Prevention

125 Vitamin E succinate decreases tamoxifen-induced proliferationand VEGF expression in mouse uterus and human endometrialcarcinoma.Engle DL, Litwiller AR, Rao NS, Peralta EA. Southern Illinois UniversitySchool of Medicine, Springfield, IL.

126 Phase II chemoprevention trial of celecoxib using ductal lavage.Arun B, Babiera G, Lammey J, Hortobagyi G, Sneige N. The University ofTexas MD Anderson Cancer Center, Houston, TX.

127 Risk reduction clinic: the clinical breast care project experience.Arciero CA, Weiss R, Jorgenson J, Shriver C. Walter Reed Army MedicalCenter, Washington, DC.

128 Feasibility study of a computerized decision aid for breast cancerprevention.Ozanne EM, Adduci KM, Esserman LJ. UCSF Medical Center, SanFrancisco, CA.

Treatment: Adjuvant Therapy

129 Effect of anastrozole on bone mineral density: 2-year results ofthe ‘arimidex’ (anastrozole), tamoxifen, alone or in combination(ATAC) trial.Howell A, on Behalf of the ATAC Trialists’ Group. Christie Hospital NHSTrust, University of Manchester, Manchester, United Kingdom.

130 Delivery of adjuvant chemotherapy for breast cancer more than12 weeks after definitive surgery may compromise survival.Lohrisch C, Gelmon K, Speers C, Paltiel C, Taylor S, Barnett J, Olivotto I.British Columbia Cancer Agency, Vancouver, BC, Canada.

131 Same gain, less pain? The preferences of premenopausal womenfor either adjuvant chemotherapy or goserelin.Fallowfield LJ, McGurk R. University of Sussex, Brighton, East Sussex,United Kingdom.

132 Long-term followup of SWOG 8313: CMFVP vs FAC-M as adjuvanttherapy of node-positive, ER-negative breast cancer.Budd GT, Green S, Livingston RB, O’Bryan R, Martino S, Abeloff MD,Rinehart J, Harris JJ, Tormey D, Osborne CK. Cleveland Clinic Foundation,Cleveland, OH; Seattle, WA; University of Washington, Seattle, WA;Grosse Point, MI; John Wayne Cancer Institute, Sana Monica, CA; JohnsHopkins University, Baltimore, MD; University of Alabama, Birmingham,AL; Rush-Presbyterian St Lukes Medical Center, Chicago, IL; Baylor Collegeof Medicine, Houston, TX.

133 THE extent of axillary lymph nodes involvement in pre-menopausal breast cancer determines risk of recurrence, but notmicro-metastatic tumour burden - new insights from an oldstudy.Cameron DA, Shochat E, Thompson C, Mallon E, Twelves CJ. WesternGeneral Hospital, Edinburgh, Scotland, United Kingdom; WesternInfirmary, Glasgow, Scotland, United Kingdom.

134 The endometrial cancer data from the ATAC (arimidex,tamoxifen, alone or in combination) trial indicates a protectiveeffect of anastrozole (arimidex) upon the endometrium.Duffy SR, Greenwood M. St James University Hospital, Leeds, UnitedKingdom; AstraZeneca, Alderley Park, United Kingdom.

135 Comparison of ‘three weekly’ (q3w) vs ‘four weekly’ (q4w)adjuvant CMF chemotherapy in operable breast cancer.Miles DW, Ryder K, Rubens RD, Leonard RC, Cameron DA. Guy’sHospital, London, United Kingdom; Singleton Hospital, Swansea, UnitedKingdom; Western General Hospital, Edinburgh, United Kingdom.

136 Multicenter, randomized phase III study of adjuvantchemotherapy for axillary positive breast cancer (APBC)comparing 6 cycles (cy) of FEC vs 4 cy of FEC followed by 8 weeklypaclitaxel (T) administrations: first safety analysis of GEICAM9906 trial.Martin M, Rodriguez-Lescure A, Ruiz A, Alba E, Calvo L, Ruiz-Borrego M,Munarriz B, Lopez-Vega JM, Rodriguez CA, Crespo C, Ramos M, Gracia-Marco JM, Lluch A, Mayordomo JI, Alvarez I, Segui MA, Aranda E, AntonA, Plazaola A, Baena JM, Modolell A, Pelegri A, Mel JR, Sanchez-Rovira P,Alvarez JV. Spanish Breast Cancer Research Group (GEICAM), Madrid,Spain.

137 Adjuvant tamoxifen to premenopausal women reducescontralateral breast cancer. Results from a prospectiverandomized multicenter study with long-time follow-up.Rydén L, Chebil G, Dufmats M, Fernö M, Jönsson P-E, Källström A-C,Landberg G, Stål O, Thorstenson S, Nordenskjold B. Helsingborg Hospital,Helsingborg, Sweden.

138 Role of chemo-induced amenorrhea in premenopausal, node-positive, operable breast cancer patients: 9-year follow-up resultsof French Adjuvant Study Group (FASG) data base.Borde F, Chapelle-Marcillac I, Fumoleau P, Hery M, Bonneterre J, Kerbrat P,Namer M, Fargeot P, Roche H. Institut Claudius Regaud, Toulouse, France;Pharmacia SA, Guyancourt, France; Centre Rene Gauducheau, Nantes,France; Centre Hospitalier Princesse Grace, Monaco; Centre Oscar Lambret,Lille, France; Centre Eugene Marquis, Rennes, France; Centre AntoineLacassagne, Nice, France; Centre Georges-Francois Leclerc, Dijon, France.

139 Long-term results of patients with breast cancer with 10 or morepositive axillary lymph node treated with adjuvant anthracycline-containing therapy. The University of Texas M.D. Anderson CancerCenter (MDACC) experience.Valero V, Buzdar AU, Kau S-W, Theriault RL, Booser D, McNeese MD,Singletary SE, Hortobagyi GN. The University of Texas M. D. AndersonCancer Center, Houston, TX.

140 Disease-free survival improvement with an epirubicin-basedchemotherapy in poor prognosis, node-negative breast cancerpatients: 10-year follow-up results of French Adjuvant StudyGroup 03 trial.Hery M, Schraub S, Bonneterre J, Roche H, Luporsi E, Kerbrat P, FumoleauP, Monnier A, Fargeot P, Goudier M-J, Chapelle-Marcillac I. CentreHospitalier Princesse Grace, Monaco; Centre Paul Strauss, Strasbourg,France; Centre Oscar Lambret, Lille, France; Institut Claudius Regaud,Toulouse, France; Centre Alexis Vautrin, Nancy, France; Centre EugeneMarquis, Rennes, France; Centre Rene Gauducheau, Nantes, France;Centre Hospitalier Andre Boulloche, Montbeliard, France; CentreGeorges-Francois Leclerc, Dijon, France; Centre Hospitalier de BretagneSud, Lorient, France; Pharmacia SA, Guyancourt, France.

141 A planned comparison of menopausal symptoms during year 1 inpatients receiving either exemestane or tamoxifen in a double-blind adjuvant hormonal study.Jones S, Vukelja S, Cantrell J, O’Shaughnessy J, Pippen J, Brooks R, Blum J,Canfield V, Chittoor S, Gore I, Mull S, Guo H, Asmar L. US Oncolology,Inc., Houston, TX.

SAN ANTONIO BREAST CANCER SYMPOSIUM - Wednesdayviii

142 Heterogeneity in breast cancer survivors’ perceptions of adjuvantsystemic therapy options after verbal counseling from a physicianpanel in a “town meeting”.Love NH, Paley MF, Borgen PI, Fox KR, Grana G, Hortobagyi GN, WeissMC. Breast Cancer Update Working Group, Miami, FL.

143 Effect of anastrozole and tamoxifen on serum lipid levels inJapanese postmenopausal women with early breast cancer.Sawada S, Sato K. National Defense Medical College, Tokorozawa, Japan.

144 Safety analysis of the PACS 01 adjuvant trial comparing 6 cycles ofFEC 100 to 3 cycles of FEC 100 followed by 3 cycles of docetaxel(Taxotere®) for node positive breast cancer.Roche H, Spielmann M, Fumoleau P, Canon JL, Bravo P, Orfreuvre H, PiotG, Kerbrat P, Serin D, Viens P, Geneve J, Asselain B, PACS Study Group.Institut Claudius Regaud, Toulouse, France; Paris, France.

145 Variation in adjuvant breast cancer chemotherapy dosing inoverweight and obese women.Griggs JJ, Sorbero MS, Lyman GH. University of Rochester, Rochester, NY;RAND, Pittsburgh, PA.

146 LH-RH analogues (LHRHa) as ovarian protection during adjuvantchemotherapy of premenopausal breast cancer patients.Recchia F, Sica G, De Filippis S, Saggio G, Di Blasio A, Cesta A, Amiconi G,Rea S. Civilian Hospital, Avezzano, AQ, Italy; Monterotondo, Roma, Italy;Università Cattolica del Sacro Cuore, Roma, Roma, Italy; Università deL’Aquila, L’Aquila, AQ, Italy.

147 Neutropenic events as a risk factor for incomplete chemotherapydelivery in breast cancer patients.Schwenkglenks M, Constenla M, Leonard R, Paridaens R, Bosly A, JackischC, Pettengell R, Szucs T, for the Impact of Neutropenia in ChemotherapyEuropean Study Group (INC-EU). Basel, Switzerland; Pontevedra, Spain;Swansea, UK; Leuven, Belgium; Mont-Godinne, Belgium; Marburg,Germany; London, United Kingdom.

Treatment: DCIS

148 Does the hormonal milieu influence the biology of DCIS?Nakhlis F, Hou N, Bilimoria M, Acharya S, Alwawi E, Khan SA, Sener SS,Staradub VL, Rademaker A, Winchester DJ, Winchester DP, Morrow M.Northwestern University Feinberg School of Medicine, Chicago, IL;Evanston Northwestern Healthcare, Northwestern University FeinbergSchool of Medicine, Evanston, IL.

149 Characteristics of primary ductal carcinoma in situ of the breastin comparison with metachronous ipsi- and contralateral lesions.Idvall I, Ringberg AM, Anderson H, Ferno M. Helsingborg Hospital,Helsingborg, Sweden; University Hospital MAS, Malmo, Sweden;University Hospital, Lund, Sweden.

150 A prospective study of oestrogen and progesterone receptorstatus in ductal carcinoma in situ.Barnes NLP, Boland G, Davenport A, Knox WF, Bundred NJ. SouthManchester University Hospital, Manchester, United Kingdom.

151 Core biopsy diagnosis of ductal carcinoma in situ: an indicationfor sentinel lymph node biopsy.Mittendorf EA, Arciero C, Gutchell V, Shriver CD. Walter Reed ArmyMedical Center, Washington, DC.

152 The influence of comedo histology on the treatment of ductalcarcinoma in situ.Baxter NN, Virnig BA, Durham SB, Tuttle TM. University of Minnesota,Minneapolis, MN.

153 Tissue microarray analyses of G1/S-regulatory proteins in ductalcarcinoma in situ of the breast indicate that cyclin D1 is aprognostic factor for local recurrence.Jirström K, Ringberg A, Fernö M, Anagnostaki L, Landberg G. LundUniversity, Malmö University Hospital, Malmö, Sweden; Lund UniversityHospital, Lund, Sweden.

Treatment: Breast Conservation

154 Randomized trials of omission vs. delivery of radiotherapy inbreast conserving surgery: pooled analysis for risks of recurrenceand mortality.Verschraegen C, Vinh-Hung V. The University of New Mexico,Albuquerque, NM; AZ-VUB, Jette, Belgium.

155 Results of breast conservation in patients with multifocal invasivecarcinoma.Halyard MY, Forstner-Barthell AW, Pockaj BA, Gray RJ, Wong WW, VoraSA, Schild SE. Mayo Clinic, Scottsdale, AZ.

156 Therapeutic options for Paget’s disease: an update.Joseph K-AP, Komenaka I, Ditkoff BA, Estabrook A, Schnabel F. New-YorkPresbyterian Medical Center, New York, NY; St-Luke’s-Roosevelt HospitalCenter, New York, NY.

157 Relationship between systemic therapy, radiotherapy timing, andresults of breast conservation.Smitt MC, Nowels K, Jeffrey S, Carlson R. Stanford University, Stanford,CA.

158 Reconstruction with sub-axillary flap for outer and upperquadrent of breast following quadrentectomy for breast cancers.Chaturvedi S, Heys S. Aberdeen University Medical School, Aberdeen,Scotland, United Kingdom; Aberdeen Royal Infirmary, Aberdeen, Scotland,United Kingdom.

159 Laser ablation of mammographically detected breast cancer.Dowlatshahi K, Dieschbourg J, Bloom KJ. Rush Presbyterian St. Luke’sMedical Center, Chicago, IL; US Labs, Irvine, CA.

160 Scarless breast reconstruction post-quadrantectomy: a newtechnique.Shrotria S. Ashford and St. Peter’s Hospital, Ashford, Middlesex, UnitedKingdom.

161 A new protocol for investigation of suspected local recurrenceafter breast conservation.Shrotria S, Bellamy EA, Chitra A. Ashford and St.Peter’s Hospital, Ashford,Middlesex, United Kingdom.

Treatment: Radiation Therapy

162 Image guided external radiotherapy with Intensity modulatedradiation therapy for breast cancer treatment.McCauley SE, Cicchetti MG, Mayo C, DeGaspe B, Lo YC, Urie M,FitzGerald TJ. UMass Memorial Health Care, Worcester, MA.

163 An observational study on local recurrence rates in breast cancerpatients treated with postoperative external electron beam boostradiation versus intraoperative electron boost radiotherapy.Reitsamer R, Peintinger F, Sedlmayer F, Kopp M, Menzel C, Cimpoca W.General Hospital Salzburg, Salzburg, Austria; General Hospital Leoben,Leoben, Austria.

164 Loco-regional relapses and survival after breast–conservingsurgery and hypofractionated radiation therapy in elderly womenwith invasive breast cancer. Analysis of 152 cases.de Lafontan B, Lozano J, Soum F, Matsuda T. Institut Claudius Regaud,Toulouse, France.

165 Management of suspicious or indeterminate calcifications andimpact upon local control.Lally BE, Haffty BG, Moran MS, Higgins SA. Yale University School ofMedicine, New Haven, CT.

166 Effect of surgical volume of resection on potential applicability ofballoon intracavitary irradiation in breast conservation therapy.Pawlik TM, Perry A, Hunt K, Babiera G, Meric F, Ross M, Ames F, Feig B,Strom E, Kuerer H. University of Texas, MD Anderson Cancer Center,Houston, TX.

167 How will treatment guidelines for postmastectomy radiationchange radiation practices for breast cancer patients?White JR, Moughan J, Pierce LJ, McNeese MD, Winchester DP, Owen JB,Wilson JF. Medical College of Wisconsin, Milwaukee, WI; AmericanCollege of Radiology, Philadelphia, PA; University of Michigan, Ann Arbor,MI; M.D. Anderson Cancer Center, Houston, TX; Northwestern Universtiy,Evanston, IL.

SAN ANTONIO BREAST CANCER SYMPOSIUM - Wednesday ix

168 Breast radiotherapy treatment: routine non-medical weeklypatient review.McIlroy P, Catherine Y, McIntyre A, Audrey R, Chris G, Catherine B.Western Infirmary, Glasgow, United Kingdom; Gartnavel General Hospital,Glasgow, United Kingdom.

169 Capecitabine is safe and tolerable in combination with radiationtherapy in breast cancer.Vishnubhotla PS, Alsukhun S, Washington T, Freidman L, Flaherty L,Simon M, Yu B, Philip PA. Karmanos Cancer Institute, Wayne StateUniversity, Detroit, MI.

170 5-FU-docetaxel and concurrent radiation as salvage therapy afterfailure of neo-adjuvant chemotherapy for locally advancedprimary breast cancer : a faisability study.Berger A, Chambeau-Ferru A, Chieze S, Coulaud-Pasdeloup F, Chabrun V,Gaci Z, Daban A, Bourgeois H. University Hospital La Miletrie, Poitiers,France.

171 Improved dose homogeneity with forward planning IMRT (f-IMRT) for intact breast and axillary/supraclavicular fieldirradiation.Cavey ML, Pena J, Endres EJ, Bayouth JE, Hatch S. University of TexasMedical Branch, Galveston, TX.

172 Accelerated partial breast irradiation using intensity modulatedradiotherapy.LaCombe MA, Al-Najjar W, Bloomer WD, Raghavan VT. EvanstonNorthwestern Healthcare, Evanston, IL.

173 Thyroid dysfunction following postoperative radiation therapy inpatients treated for breast cancer.de Lafontan B, Demange L, Héry M, Schvartz C, Eche N, Matsuda T.Institut Claudius Regaud, Toulouse, France; Hôpital Princesse Grace,Monaco, Monaco; Institut Jean Godinot, Reims, France.

174 Letrozole sensitizes aromatase-expressing breast tumour cells togamma irradiation.Azria D, Larbouret C, Cunat S, Evans DB, Romieu G, Pujol P, Pelegrin A.CRLC Val d’Aurelle, Montpellier, France; Novartis Pharma AG, Basel,Switzerland; Montpellier, France.

175 Results from a subgroup analysis of patients with metastaticbreast cancer (MBC) in a phase 3, randomized, open-label,comparative study of standard whole brain radiation therapy(WBRT) with supplemental oxygen, with or without RSR13, inpatients with brain metastases.Suh J, Stea BD, Kresl JJ, Nabid A, Fortin A, Mercier J, Pinter T, Monnier A,Henke M, Holz JB, Boyd A, Craig M, Cagnoni PJ, Shaw E. Cleveland ClinicHospital, Celeveland; The University of Arizona Health Sciences Center,Tucson; St. Joseph’s Hospital and Medical Center, Phoenix; CentreHospitalier Universitarie de Sherbrooke, Sherbrooke, Canada; Hotel-Dieude Quebec, Quebec City, Canada; Hopital Maisonneuve-Rosemont,Montreal, Canada; Petz Aladar Hospital of Gyor-Moson-Sopron County,Gyor, Hungary; Hopital de Montbeliard, Montbeliard, France;Radiologische Uniklinik, Freiburg, Germany; Allos Therapeutics, Inc.,Westminster, CO; Baptist Medical Center, Wake Forest University,Winston-Salem.

Treatment: Male Breast Cancer

176 HER-2/neu gene amplification and protein expression in primarymale breast cancer.Rudlowski C, Friedrichs N, Faridi A, Bastert G, Buttner R. UniversityHospital, Heidelberg, Germany; University Bonn, Bonn, Germany;University Hospital, Aachen, Germany.

177 Male breast cancer: The MD Anderson experience with adjuvanttherapy.Giordano SH, Perkins GH, Garcia SM, Middleton LP, Buzdar AU,Hortobagyi GN. UT MD Anderson Cancer Center, Houston, TX.

178 Sentinel lymph node biopsy in male breast cancer patients.Giron GL, Boolbol SK, Tartter PI, Petersen B, Rosenbaum Smith SM,Estabrook A, Feldman S. Beth Israel Medical Center, New York, NY; St.Luke-Roosevelt Hospital Center, New York, NY.

Thursday, December 4

7:00-9:00 POSTER SESSION 2 & CONTINENTAL BREAKFAST

(#201-284) – Exhibit Hall C

Detection/Diagnosis: Axillary/Sentinel Nodes

201 Effect of tumour burden in the sentinel lymph node on blue dyeuptake, radioisotope uptake and internal mammary drainage.Goyal A, Mansel RE, Douglas-Jones A. UWCM, Cardiff, United Kingdom.

202 Detection of micrometastases in paraffin embedded lymph nodesby methylation-specific PCR (MSP) in patients with breastcarcinoma.Goyal A, Douglas-Jones A, Watkins G, Jiang WG, Mansel RE. University ofWales College of Medicine, Cardiff, Wales, United Kingdom.

203 Reliability of intraoperative frozen section analysis of sentinellymph nodes in breast cancer.Wada N, Imoto S, Hasebe T. National Cancer Center Hospital East,Kashiwa, Chiba, Japan; National Cancer Center Research Institute East,Kashiwa, Chiba, Japan.

204 Touch imprint cytology and immunohistochemistry for theassessment of sentinel lymph nodes in patients with breast cancer.Aihara T, Munakata S, Morino H, Takatsuka Y. Kansai Rosai Hospital,Amagasaki, Hyogo, Japan.

205 Lymphatic mapping and sentinel lymphadectomy prior toneoadjuvant chemotherapy in locally advanced breast cancerpatients.Ollila DW, Neuman H, Dees EC, Sartor C, Metzger R, Carey LA. Universityof North Carolina, Chapel Hill, Chapel Hill, NC.

206 The intraoperative cytological evaluation of sentinel lymph nodein patients with breast cancer.Batista do Prado LC, Martorelli Filho B, Carvalho FM, Pincerato KM,Buchipigel CA, Hegg R, Barros N, Pinotti JA. University of Sao Paulo,Medical School, Sao Paulo, SP, Brazil.

207 Suspicion of microinvasion in patients with core biopsy provenductal carcinoma in situ: pathologic predictor of invasive cancer.Horton JK, Halle JS, Fried DB, Ollila DW. University of North Carolina atChapel Hill, Chapel Hill, NC.

208 Characteristics of breast cancer patients whose lymph nodeinvolvement was defined to sentinel lymph nodes only.Jinno H, Ikeda T, Kitajima M, Fujii H, Mukai M. Keio University School ofMedicine, Shinjuku, Tokyo, Japan.

209 General practitioners’ choice between axillary node clearance andsentinel node biopsy for early breast cancer.Mokbel K, Tamer M. The Princess Grace Hospital, London, England,United Kingdom.

Detection/Diagnosis: Biopsy Techniques

210 High risk lobular lesions diagnosed at vacuum-assisted biopsy:results at surgical excision.Copit DS, Brown KJ, Summerton SL. Albert Einstein Medical Center,Philadelphia, PA.

211 480 patients with microcalcifications: stereotactic directionalvacuum-assisted breast biopsy with radiological and pathologicalcorrelation.Kettritz U, Decker T, Morack G. Berlin-Buch Breast Unit, HELIOS KlinikumBerlin, Berlin, Germany.

212 Pathologic assessment of intact biopsy specimens removed with anew RF wire loop core biopsy device.Bloom KJ, Fine RE, Boyd B, Lerner AG. US Labs, Irvine, CA; The BreastCenter, Marietta, GA; White Plains Hospital Center, White Plains, NY.

Detection/Diagnosis: Detection

213 Utilization of Mammographic Smart View for three-dimensionallocation of breast abnormalities seen only on a singlemammographic view.Whitaker M, Graham J. Madigan Army Medical Center, Tacoma, WA;Uniformed Services University of the Health Sciences.

SAN ANTONIO BREAST CANCER SYMPOSIUM - Wednesdayx

214 Impact of detection method on the course of breast cancer.Kaplan HG, Malmgren JA, Atwood M. Swedish Cancer Institute, Seattle,WA; HealthStat Consulting, Inc., Seattle, WA.

215 Correlation of nipple aspiration and ductal lavage withhistopathologic findings for patients prior to scheduled breastbiopsy.Gabram SGA, Wojcik EM, Dougherty TA, West K, Siziopikou KP. LoyolaUniversity Medical Center, Maywood, IL.

Treatment: Antibody-Based Regimens

216 N98-32-52: efficacy and tolerability of two schedules of paclitaxel,carboplatin and trastuzumab in women with HER2 positivemetastatic breast cancer: a North Central Cancer TreatmentGroup randomized phase II trial.Perez EA, Rowland KM, Suman VJ, Ingle JN, Salim M, Loprinzi CL, Flynn PJ,Mailliard JA, Kardinal CG, Krook JE, Wiesenfeld M. Mayo Clinic,Jacksonville, FL; Carle Cancer Center CCOP, Urbana, IL; Mayo Clinic,Rochester, MN; Saskatchewan Cancer Foundation, Saskatoon,Saskatchewan, Canada; Metro-Minnesosta Community CommunityClinical Oncology Program, St. Louis Park, MN; Missouri Valley CancerConsortium, Omaha, NE; Ochsner CCOP, New Orleans, LA; Cedar RapidsOncology Project CCOP, Ceder Rapids, IA.

217 First-line trastuzumab (Herceptin® plus docetaxel versusdocetaxel alone in women with HER2-positive metastatic breastcancer (MBC): results from a randomised phase II trial (M77001).Extra JM, Cognetti F, Chan S, Maraninchi D, Synder R, Anton A, Mefti F,Grimes D, Mayne K, Meyer-Wenger A, Marty M. Institut Curie, Paris,France; Regina Elena Cancer Institute, Rome, Italy; Nottingham CityHospital, Nottingham, United Kingdom; Institut Paoli Calmettes,Marseille, France; St Vincent’s Hospital, Fitzroy, VIC, Australia; HospitalMiguel Servet, Zaragoza, Spain; Centre Rene Huguenin, Saint-Cloud,France; Wesley Medical Centre, Auchenflour, Australia; Roche ProductsLimited, Welwyn Garden City, United Kingdom; F. Hoffmann-La Roche,Basel, Switzerland; Institut Gustave Roussy, Villejuif, France.

218 Pooled analysis of six trials of trastuzumab (Herceptin®):exploratory analysis of changes in left ventricular ejectionfraction (LVEF) as a surrogate for clinical cardiac events.Marty M, Baselga J, Gatzemeier U, Leyland-Jones B, Suter T, KlingelschmittG, Barton C. Institut Gustave Roussy, Villejuif, France; Vall d’HebronUniversity Hospital, Barcelona, Spain; Krankenhaus Grosshansdorf,Grosshansdorf, Germany; McGill University, Montreal, QC, Canada;University Hospital, Bern, Switzerland; F. Hoffmann-La Roche Ltd, Basel,Switzerland; Roche Products Ltd, Welwyn Garden City, United Kingdom.

219 Navelbine and Herceptin combination as first line therapy for HER2-overexpressing metastatic breast cancer is a highly active andsafe regimen. Final results of multinational trial.Chan A, Untch M, Petruzelka L, Martin M, Guillem-Porta V, Gil M,Kellokumpu-Lehtinen P, Bourrillon O, Aubert D, Gasmi J, on Behalf ofNavelbine-Herceptin Study Group. Mount Hospital, Perth, Australia;Klinikum Grosshadern, Munchen, Germany; General Teaching Hospital,Praha, Czech Republic; Hospital Clinico San Carlos, Madrid, Spain;Instituto Valenciano de Oncologia, Valencia, Spain; Institut Catala deOncologia, L’Hospitalet Llobregat, Spain; Tampere University Hospital,Pikonlinna, Finland; Institut de Recherche Pierre Fabre, Boulogne, France.

220 Interleukin-2 and trastuzumab: preliminary results in clinicalresponse and natural killer cell expansion in advanced Her2/neupositive metastatic breast cancer patients.Chang JC, Kalidas M, Zhou L, Yu S, Cate E, Lowe A, Wilson S, Bedell L,Milan S, Brufsky A, Garino LA, Miller J, Hutchins L, Lee M. Baylor Collegeof Medicine, Houston, TX; Chiron Corporation, Emeryville, CA; Universityof Pittsburgh, Pittsburgh, PA; Hubert H. Humphrey Cancer Center,Robbinsdale, MN; University of Minnesota, Minneapolis, MN; Universityof Arkansas, Little Rock, AR; Park Nicollet Institute, St. Louis Park, MN.

221 Weekly paclitaxel plus trastuzumab shows promising efficacy inadvanced breast cancer.John M, Kriebel-Schmitt R, Stauch M, Wolf H, Mohr B, Klare P, Hinke R,Schlosser J. for the FAKT Study Group, Glauchau, Germany.

222 Complex formation between the shed antigen of HER-2/neu andthe monoclonal anti-HER-2/neu antibody trastuzumab.Lueftner DI, Schaller G, Henschke P, Amin R, Geppert R, Wernecke K,Possinger K. Charité, Campus Mitte, Berlin, Germany; MarienhospitalHerne, Herne, Germany; Charité, Campus Virchow, Berlin, Germany.

223 A prospective study of NT-pro brain natriuretic peptide andtroponin T in the HERCULES study (epirubicin +cyclophosphamide with or without herceptin) in patients withmetastatic breast cancer.Langer B, Muscholl M, Pauschinger M, Thomssen C, Eidtmann H, UntchM, Meerpohl HG, du Bois A, Schaller G, Kuhn W, Jakisch C, Kreienberg R,Wallwiener D, Weise W, Emons G, Weber H, Lueck HJ. Hoffmann-LaRoche Ltd, Basel, Switzerland; Munchen, Germany; University HospitalBenjamin Franklin, Berlin, Germany; University Hospital Eppendorf,Hamburg, Germany; University Hospital, Kiel, Germany; UniversityHospital Grosshadern, Munchen, Germany; St. Vincentius-Hospital,Karlsruhe, Germany; Dr. Horst-Schmidt Hospital, Wiesbaden, Germany;University Hospital, Munchen, Germany; University Hospital, Munster,Germany; University Hospital, Ulm, Germany; University Hospital,Tubingen, Germany; University Hospital, Magdeburg, Germany; UniversityHospital, Gottingen, Germany; Medical University Hospital, Hannover,Germany.

224 CTEP-sponsored phase II trial of bevacizumab (Avastin™) incombination with docetaxel (Taxotere®) in metastatic breastcancer.Ramaswamy B, Rhoades CA, Kendra K, Hauger M, Allen J, Jhaveri S, ChenH, Cagnoni P, Eckhardt GS, Elias A, Shapiro CL. Ohio State UniversityMedical Center, Columbus, OH; Cancer Therapy Evaluation Program,Bethesda, MD; University of Colorado, Denver, CO.

225 Combination radioimmunotherapy (RAIT) and chemotherapy ofbreast cancer: in vitro effects of scheduling on efficacy and theexpression of Bcl-2 and IAP family members.Blumenthal RD, Knox K, Leone E, Taylor A, Goldenberg DM. GardenState Cancer Center, Belleville, NJ.

226 Isolated central nervous system metastases in patients with HER2overexpressing advanced breast cancer treated with first-linetrastuzumab-based therapy.Burstein HJ, Lieberman G, Slamon DJ, Winer EP, Klein P. Dana-FarberCancer Institute, Boston, MA; Genentech, South San Francisco, CA;UCLA, Los Angeles, CA.

227 Preliminary clinical results of a randomized phase IIb study ofweekly paclitaxel (PCT) ± trastuzumab (T) as first-line therapy ofpatients (pts) with HER–2/neu positive metastatic breast cancer(MBC).Gasparini G, Morabito A, De Sio L, Carillio G, Gion M, Zancan M, RoccoS, Crivellari D, Spada A, Veronesi A, Filippelli G, Silingardi V, Cognetti F,Papaldo P, Amadori D. San Filippo Neri Hospital, Roma, Italy; GeneralRegional Hospital, Venezia, Italy; CRO, Aviano, Italy; Ospedale Civile, Paola,Italy; Università, Modena, Italy; Istituto Regina Elena, Roma, Italy; OspedaleMorgagni-Pierantoni, Forlì, Italy.

Treatment: Neoadjuvant Therapy

228 Adapting in-vivo-chemosensitivity for further evaluation ofpreoperative chemotherapy in patients with operable primarybreast cancer. Interim analysis of the gepartrio-trial.Jackisch C, v. Minckwitz G, Costa SD, Raab G, Blohmer JU, Loehr A,Gerber B, Eidtmann H, Hilfrich J, Kaufmann M, German Adjuvant BreastCancer Group (GABG). University Marburg, Marburg, Germany;Frankfurt, Germany; Markus Hospital, Frankfurt, Germany; Red CrossHospital, Munic, Germany; Charite, Berlin, Germany; Horst-Schmidt-Clinic,Wiesbaden, Germany; Munic, Germany; Univ., Kiel, Germany;Henriettenstift, Hannover, Germany.

229 Phase II study of the preoperative use of celecoxib (CELEBREX™)and FEC for the treatment of locally advanced breast cancer.Chow LWC, Toi M, Takebayashi Y, Sasano H. University of Hong KongMedical Center, Hong Kong; Tokyo Metropolitan Cancer & InfectiousDisease Center, Tokyo, Japan; Fukushima University, Fukushima, Japan;Tohoku University, Sendai, Japan.

SAN ANTONIO BREAST CANCER SYMPOSIUM - Thursday xi

230 Accuracy of physical examination (PE), ultrasonography (US) andmammography (M) in predicting residual pathological tumor size(RPTS) in patients treated with neoadjuvant chemotherapy(NAC).Chagpar AB, Mirza AN, Buzdar AU, Dempsey PJ, Ames FC, Babiera GV,Feig BW, Hunt KK, Kuerer HM, Meric-Bernstam F, Middleton LP, Ross MI,Sahin AA, Singletary SE. The University of Texas M. D. Anderson CancerCenter, Houston, TX.

231 Good clinical response by breast cancers to neoadjuvantchemoendocrine therapy is associated with superior overallsurvival after 10 years follow-up.Cleator SJ, Lal KR, Ashley S, Makris A, Powles TJ. Institute of CancerResearch, London, United Kingdom; Royal Marsden Hospital, Sutton,Surrey, United Kingdom; Mount Vernon Hospital, Rickmansworth,Middlesex, United Kingdom; Parkside Hospital, London, United Kingdom.

232 Tumor cellularity of breast cancer as a variable in the pathologicalassessment of response following noadjuvant chemotherapy.Rajan R, Poniecka A, Smith TL, Yang Y, Whitman G, Fiterman DJ, PusztaiL, Kuerer H, Hortobagyi G, Symmans WF. MD Anderson Cancer Center,Houston, TX; University of Miami, Maimi, FL.

233 Can breast MRI help the clinical management of women withbreast cancer treated with neoadjuvant chemotherapy?Warren RM, Earl HM, Bobrow LG, Benson JR, Purushotham AD, WishartGC, Britton PD, Hollingworth W. Addenbrooke’s Hospital, Cambridge,United Kingdom; University of Washington, Seattle, WA.

234 Withdrawn

235 Neoadjuvant chemotherapy with gemcitabine(G), epirubicin(E),and paclitaxel(T) in locally advanced breast cancer(LABC): aphase II trial of the NSABP Foundation Research Group.Hamm J, Wilson J, Lembersky BC, Robidoux A, Raymond J, Kardinal C,DiNunno L, Melemed A, Geyer, Jr. CE, Paik S, Wolmark N. NortonHealthcare, Inc, Louisville, KY; NSABP Biostatistical Center, Pittsburgh, PA;University of Pittsburgh Cancer Institute, Pittsburgh, PA; CentreHospitalier de l’Univerisite de Montreal, Montreal, QC, Canada; AlleghenyGeneral Hospital, Pittsburgh, PA; CCOP Alton Ochsner MedicalFoundation, New Orleans, LA; Joe Arrington Cancer Treatment andResearch Center, Lubbock, TX; Eli Lilly, Indianapolis, IN.

236 In vivo chemosensitivity-adapted neoadjuvant chemotherapy(docetaxel-doxorubicin-cyclophosphamide followed byvinorelbine-capecitabine salvage therapy) in patients withprimary breast cancer: results of the GEPAR-TRIO randomizedpilot study.von Minckwitz G, Raab G, Blohmer JU, Gerber B, Lohr A, Costa SD,Eidtmann H, Hilfrich J, Jackisch C, Kaufmann M, the German BreastGroup (GBG). Klinikum der JW Goethe-Universitat, Frankfurt, Germany;Roten Kreuz, Munchen, Germany; Universitat Campus Charite Mitte,Berlin, Germany; I Universitat der Ludwigs Maximilians, Munchen,Germany; Horst Schmidt Kliniken, Wiesbaden, Germany; St MarkusKrankenhauses, Frankfurt, Germany; Universitat Kiel, Germany;Henriettenstiftung, Hannover, Germany; Universitat Marburg, Germany;Universitat Frankfurt, Germany.

237 Neoadjuvant gemcitabine, epirubicin, and docetaxel (GET).Preliminary results from a multicenter phase II trial ininflammatory and locally advanced breast cancer.Yardley DA, Whitworth P, Greco FA, Burris III HA, White M, Thomas M,Dunbar L, Yost K, Hainsworth JD. Sarah Cannon CancerCenter/Tennessee Oncology, PLLC, Nashville, TN; Nashville Breast Center,Nashville, TN; Grand Rapids CCOP, Grand Rapids, MI.

238 Platinum salts and docetaxel as primary therapy of locallyadvanced and inflammatory breast cancer:the final report ofthree sequential studies.Hurley J, Doliny P, De Zarraga F, Welsh C, Gomez C, Powell J, Silva O, LeeY. University of Miami, Miami, FL.

239 Phase II study to define safety and efficacy of exemestane aspreoperative therapy for postmenopausal patients with primarybreast cancer –final results of the German Neoadjuvant AromasinInitiative (GENARI).Krainick U, Astner A, Jonat W, Wallwiener D. Universitäts-FrauenklinikTübingen, Tübingen, Germany; Universitäts-Frauenklinik Kiel, Kiel, Germany.

240 Dose dense neoadjuvant treatment of women with breast cancerutilizing docetaxel, vinorelbine and trastuzumab with growthfactor support.Limentani SA, Brufsky AM, Erban JK, Jahanzeb M, Lewis D. BlumenthalCancer Center, Charlotte, NC; University of Pittsburgh Cancer Center,Pittsburgh, PA; Tufts-New England Medical Center, Boston, MA;University of Tennessee College of Medicine, Memphis, TN.

241 Predictive value of primary systemic chemotherapy-inducedanemia for pathologic complete response in operable breastcancer: results from the GEPAR-DUO trial.Raab G, von Minckwitz G, Schuette M, Blohmer JU, Hilfrich J, Gerber B,Costa SD, Eidtmann H, Lampe D, duBois A, Caputo A, Kaufmann M, theGEPAR-DUO/GABG Study Group. Roten Kreuz, Munchen, Germany;Klinikum der JW Goethe-Universitat, Frankfurt, Germany; Ev. Bethesda-Krankenhaus Essen, Germany; Universitat Campus Charite Mitte, Berlin,Germany; Henriettenstiftung, Hannover, Germany; Universitat der LMU,Munchen, Germany; St Markus Krankenhauses, Frankfurt, Germany;Universitat Kiel, Germany; Asklepios Krankenhaus Weissenfels, Germany;Horst Schmidt Kliniken, Wiesbaden, Germany; Methodisches ZentrumFreiburg, Germany; Universitat Franfurt, Germany.

242 The triplet gemcitabine, epirubicin, and docetaxel as primarysystemic chemotherapy in primary breast cancer T2–4, N0–2, M0:final primary endpoint analysis of a multicentric phase I/II trial.Schneeweiss A, Geberth M, Sinn H-P, Krauss K, Beldermann F, Wagner U,von Fournier D, Hamerla R, Marseille A, Bauknecht T, Wallwiener D,Bastert G, Huober J. University of Heidelberg, Heidelberg, Germany;University of Tübingen, Tübingen, Germany; Community HospitalWeinheim, Weinheim, Germany; Aventis, Bad Soden, Germany; Lilly, BadHomburg, Germany.

243 Weekly docetaxel (Taxotere®) and trastuzumab (Herceptin®) asprimary therapy in stage III, HER-2 overexpressing breast cancer -a Brazilian multicenter study.Bines J, Murad A, Lago S, Ferrari B, Andrade J, Filho EA. Instituto Nacionalde Cancer, Rio de Janeiro, Rio de Janeiro, Brazil; UFMG, Belo Horizonte,Minas Gerais, Brazil; Hospital Vera Cruz, Porto Alegre, Rio Grande do Sul,Brazil; Hospital Mater Dei, Belo Horizonte, Minas Gerais, Brazil; Hospitaldas Clinicas, Ribeirao Preto, SP, Brazil; Centro de Referencia da Mulher, SaoPaulo, SP, Brazil.

244 Is there any possibility to avoid axillary lymph node dissection inlocally advanced breast cancer patients “good responders” toprimary chemotherapy?Ionta T, Scanu A, Atzori F, Esposito I, Deidda C, Pilloni R, Pusceddu V,Urraci Y, Porcu C, Massidda B. University of Cagliari, Monserrato, Cagliari,Italy.

245 Coil insertion prior to neoadjuvant chemotherapy in patientswith breast cancer.Sever AR, Jones SE, Humphreys S, Weeks J, Jones PA. Maidstone Hospital,Maidstone, Kent, United Kingdom.

246 A phase II trial of two different sequences of neoadjuvantdoxorubicin/paclitaxel (AT) and cisplatin/paclitaxel (CT) inpatients with locally advanced breast cancer: expression ofmarkers of resistance over time.Shenkier TN, O’Reilly S, Gelmon K, Allan S, Bryce C, Chia S, Hassell P,Hayes M, Knowling M, Martin LA, Norris B, Ragaz J, Tolcher A. BritishColumbia Cancer Agency, Vancouver, BC, Canada; Institute for DrugDevelopment and Cancer Center and Research Center, San Antonio, TX.

247 Study of dose-dense doxorubin and docetaxel for patients withadvanced operable and inoperable adenocarcinoma of the breast.Cooper BW, Silverman P, Overmoyer BA, Shenk RR, Allen MJ. UniversityHospitals of Cleveland, CWRU, Cleveland, OH.

248 Neoadjuvant chemotherapy with biwweekly docetaxel (D) andgemcitabine (G) in stage II and III breast cancer: a phase II clinicaltrial with pharmacogenomic study.Estevez LG, Sanchez-Rovira P, Domine M, Leon A, Jaen A, Lozano A,Casado V, Rubio G, Diaz-Miguel M, Miro C, Moreno-Bueno G, Palacios J,Lobo F. Fundacion Jimenez Diaz, Madrid, Spain; Hospital Universitario deJaen, Jaen, Spain; Spanish National Cancer Centre (CNIO), Madrid, Spain.

SAN ANTONIO BREAST CANCER SYMPOSIUM - Thursdayxii

249 Biweekly administration of doxorubicin plus docetaxel (AT) asneoadjuvant treatment of stage IIB and III breast cancer (BC).Garcia Mata J, Calvo L, Mel JR, Garcia Palomo A, Ramos M, Antolin S,Vazquez S, Rodriguez R, Rodriguez A, Anton LM. Hospital Santa MariaNai, Ourense, Ourense, Spain; Hospital Juan Canalejo, A Coruña, ACoruña, Spain; Hospital Xeral Calde, Lugo, Lugo, Spain; Hospital de Leon,Leon, Leon, Spain; Centro Oncologico de Galicia, A Coruña, A Coruña,Spain.

250 Discordance between breast magnetic resonance imaging (MRI)and pathologically-determined residual disease in responders toneoadjuvant chemotherapy for stage III breast cancer.Kwong MS, Horvath LJ, Carter D, Hsu AG, Ward BA, Burtness BA. YaleUniversity School of Medicine, New Haven, CT; Greenwich Hospital,Greenwich, CT.

251 Dose dense neoadjuvant treatment of women with breast cancerutilizing docetaxel and vinorelbine with growth factor support.Limentani SA, Brufsky AM, Erban JK, Jahanzeb M, Lewis D. BlumenthalCancer Center, Charlotte, NC; Univrsity of Pittsburgh Cancer Center,Pittsburgh, PA; Tufts-New England Medical Center, Boston, MA;University of Tennessee College of Medicine, Memphis, TN.

252 Multi-functional magnetic resonance imaging predicts for clinico-pathological response to neoadjuvant chemotherapy in primarybreast cancer.Ah-See M-LW, Makris A, Taylor NJ, Harrison M, Richman PI, D’Arcy JA,Burcombe RJ, Pittam MR, Ravichandran D, Stirling JJ, Cladd HJ, Leach MO,Padhani AR. Mount Vernon Hospital, Northwood, Middlesex, UnitedKingdom; Royal Marsden Hospital, Sutton, Surrey, United Kingdom;Luton and Dunstable Hospital, Luton, United Kingdom.

253 Pathological complete response with neoadjuvant (NA)chemotherapy (trastuzumab (T) and docetaxel (D)) in HER2positive (3+) locally advanced (LA) breast cancer (BC) patients.Moluçon C, Vanlemmens L, Chollet P, Weber B, Beal D, Mayer F, Benoit L,Zanetta S, Mery-Mignard D, Vasseur B, Arnould L, Coudert B. Centre GFLeclerc, Dijon, France; Centre O Lambret, Lille, France; Centre J Perrin,Clermond Ferrand, France; Centre A Vautrin, Nancy, France; Clinique desDomes, Clermond Ferrand, France; Laboratoire Aventis, Paris, France;Laboratoire Roche, Neuilly, France.

254 Dose-dense doxorubicin, docetaxel and cyclophosphamide assequential neoadjuvant therapy for high-risk breast cancer: a pilotstudy.Link JS, Forsthoff CA, Ibarra J, Rogers LW, Magy F, Maya KA. Long BeachMemorial Medical Center, Long Beach, CA; Breastlink Medical Group, Inc.,Long Beach, CA; Orange Coast Memorial Medical Center, Fountain Valley,CA.

255 Non-invasive 3-dimensional molecular imaging of early breastcancer with a dedicated mammotomograph.Tornai MP, Archer CN, Bowsher JE. Duke University Medical Center,Durham, NC.

Tumor Cell Biology: Estrogen and Progestin Receptors

256 The hormone receptor status of a contralateral breast cancer isindependent of the first primary in patients not receivingadjuvant systemic therapy.Arpino G, Weiss H, Hilsenbeck S, Osborne K. Baylor College of Medicine,Houston, TX.

257 Estrogen receptor and progesterone receptor status: differencesbetween primary and metastatic breast cancer.Glass EL, Heffelfinger S, Blau R, Lower EE. University of Cincinnati MedicalCenter, Cincinnati, OH; Oncology-Hematology Care, Cincinnati, OH.

258 Estrogen receptor � expression in normal breast epithelium (NBE)and hyperplasia in breast cancer cases and controls.Golewale NH, Bhandare D, Ramakrishnan R, Hou N, Rademaker A, KhanSA. Northwestern University Feinberg School of Medicine, Chicago, IL.

259 Oestrogen receptor phosphorylation in hormone sensitive andanti-hormone resistant breast cancer cells.Britton DJ, Hutcheson IR, Barrow D, McClelland RA, Gee JM, NicholsonRI. Cardiff University, Cardiff, United Kingdom.

260 Expressions of ERa, ERb, ERbcx, PR-A, PR-B and Ki67 in invasiveduct and lobular breast cancer.Cheng G, Joensuu K, Heikkilä P, Warner M, Gustafsson J-A. KarolinskaInstitute, Stockholm, Sweden; Helsinki University Hospital, Helsinki,Finland.

261 Technical differences contribute to hormone receptor negativestatus in African-American underserved patients.Dookeran KA, Gao X, Yang J, Ferrer K, Sekosan M, Sciupokiene E,Mackeviciute A, Rogowski WA, Muthyala N, Koko I, Zaren HA. John H.Stroger Jr. Hospital of Cook County, Chicago, IL.

262 Estrogen-dependent proliferation and estrogen receptor (ER)-mediated gene expression are enhanced in breast cancer cells withelevated levels of inducible heat shock protein 70 (Hsp70).Spears PA, Barnes JA. North Carolina State University, Raleigh, NC.

263 Withdrawn

264 The expression of ER�cx in human breast cancer and therelationship to response to endocrine therapy and survival.Palmieri C, Lam E, Mansi J, Madden P, Warner M, Gustafsson J-A,Coombes RC. Imperial College, London, London, United Kingdom; StGeorge’s Hospital, London, United Kingdom; Karolinska Institute,Stockholm, Sweden.

265 Concordance between estrogen receptor (ER) status of ductalcarcinoma in situ (DCIS) and invasive disease. Analysis of thesurveillance, epidemiology, and end results (SEER) program.Diab SG. Rocky Mountain Cancer Centers-Aurora, Aurora, CO.

266 ER beta expression parallels ER alpha/ PR expression and isinversely related to EGFR expression in African American womenwith breast cancer.Dookeran KA, Gao X, Yang J, Ferrer K, Sekosan M, Sciupokiene E,Mackeviciute A, Zaren HA. John H. Stroger Jr. Hospital of Cook County,Chicago, IL.

267 The role of PR-A or PR-B overexpression on endocrine responseand invasive properties in ER-positive breast cancer.Lalani F, Hopp TA. Houston Baptist University, Houston, TX; BaylorCollege of Medicine, Houston, TX.

268 ER� exerts multiple stimulative effects on human breastcarcinoma cells.Hou Y-F, Yuan S-T, Wu J, Shen Z-Z, Shao Z-M. Cancer Hospital, Shanghai,Shanghai, China.

Tumor Cell Biology: Growth Factors /Inhibitors

269 Association between the EGFR ligand gene polymorphisms andthe risk and severity of breast cancer.Burke MM, Pravica V, Hutchinson IV, Bundred NJ. South ManchesterUniversity Hospital, Manchester, United Kingdom; University ofManchester, Manchester, United Kingdom.

270 Recombinant human insulin-like growth factor binding protein-3(rhIGFBP-3) as a potential therapeutic agent for the treatment ofherceptin-resistant breast cancer.Jerome L, Yu Q, Belanger S, Shiry L, Pegram M, Leyland-Jones B. McGillUniversity, Montreal, QC, Canada; Insmed Incorporated, Richmond, VA;UCLA, Los Angeles, CA.

271 Endometase in human breast carcinomas, selective activation ofprogelatinase B and inhibition by tissue inhibitors ofmetalloproteinases-2 and -4.Zhao Y-G, Xiao A-Z, Park HI, Newcomer RG, Yan M, Man Y-G,Heffelfinger SC, Sang Q-XA. Florida State University, Tallahassee, FL;University of Cincinnati College of Medicine, Cincinnati, OH; The ArmedForces Institute of Pathology, Washington, DC.

272 Is hepatocyte growth factor/scatter factor (HGF/SF)lymphangiogenic?Jiang WG, Parr C, Martin TA, Davies G, Watkins G, Mansel RE. Universityof Wales College of Medicine, Cardiff, Wales, United Kingdom.

273 Expression of PC-cell derived growth factor (PCDGF/progranulin)in breast cancer biopsies and correlation with prognosticmarkers.Serrero G, Ioffe O. A&G Pharmaceutical Inc., Columbia, MD; University ofMaryland School of Medicine, Baltimore, MD.

SAN ANTONIO BREAST CANCER SYMPOSIUM - Thursday xiii

274 Insulin-like growth factor binding protein 3 (IGFBP-3) hasdifferential effects on epidermal growth factor (EGF) mediatedproliferation in normal breast and breast cancer cells, identifyingit as a potential therapeutic target.McIntosh J, Clark M, Perks CM, Holly JM, Winters ZE. University ofBristol, Bristol, United Kingdom.

275 The expression of IGF-1 in normal and malignant breast tissueand its association with ductal carcinoma in situ.Laban CA, McCarthy K, Ogunkolade W, Bustin SA, Jenkins PJ, CarpenterR. St Bartholomew’s Hospital, London, United Kingdom; Bart’s and TheLondon, Queen Mary School of Medicine and Dentistry, London, UnitedKingdom.

276 Serum insulin-like growth factor I and insulin-like growth factorbinding protein 3 levels in women undergoing breast cancersurgery.McVittie CJ, McCarthy K, Laban CA, Bonner SE, Bustin SA, Jenkins PJ,Carpenter R. St Bartholomew’s Hospital, London, United Kingdom; Bart’s& The London, Queen Mary School of Medicine and Dentistry, London,United Kingdom.

277 The effects of IGF-I on the response of breast epithelial cells toDNA damage.Clark MA, Perks CM, Winters ZE, Holly JMP. University of Bristol, Bristol,United Kingdom.

Tumor Cell Biology: Oncogenes/Tumor Suppressor Genes

278 PTEN promoter is methylated in invasive breast cancer.Bose S, Gupta I, Kumagai T, Vohra J, Koeffler PH. Cedars Sinai MedicalCenter, Los Angeles, CA; UCLA School of Medicine, Los Angeles, CA.

279 Hypermethylation of estrogen receptor-alpha promoter isassociated with BRCA1 methylation in estrogen receptor-negativebreast cancers.Wei M-J, Dignam J, Fackenthal J, Sveen L, Hagos F, Grushko T, Olopade OI.Committees on Genetics and Cancer Biology; University of Chicago,Chicago, IL.

280 Mutational analysis of the tumor suppressor gene PTEN/MMAC1in breast carcinomas.Suh K-S, Na S-Y, Kim J-R, Chang E-S. Chungnam National UniversitySchool of Medicine, Daejeon, Korea.

281 Clinical correlation between PTEN and HER-2 in breast cancer.Kim J-S, Kim K-H, Ahn C-H, Kim J-I, Park W-C, Jung S-S, Lim K-W.Uijongbu St.Mary’s Hospital, Uijongbu, Kyunggido, Korea.

282 Overexpression of the novel oncogenic, nuclear pore associatedprotein Nup88 defines a more aggressive tumor phenotype.Agudo D, Martinez-Arribas F, Gomez-Esquer F, Nunez-Villar MJ, Lucas R,Tejerina A, Schneider J. Universidad Rey Juan Carlos, Madrid, Spain;Fundacion Tejerina, Madrid, Spain.

283 Reduction of nuclear peroxisome proliferator activated receptor(PPAR)-gamma coactivator, PGC-1, in human breast cancer.Watkins G, Douglas-Jones AG, Mansel RE, Jiang WG. University of WalesCollege of Medicine, Cardiff, Wales, United Kingdom.

284 Amplification of c-myc is associated with aggressive primarybreast cancer.Schlotter CM, Wassmann K, Bosse U, Vogt U. Klinikum Ibbenbueren,Ibbenbueren, NRW, Germany; Institute of Pathology, Osnabrueck,Germany; European Lab. Association, Ibbenbueren, NRW, Germany.

9:00-9:30 PLENARY LECTURE 2 – Ballroom C

Survival pathway and relationship to breast cancer therapy.John C. Reed, MD, PhDThe Burnham InstituteLa Jolla, CA

9:30-11:00 GENERAL SESSION 3 – Ballroom C

9:30 16. Multi-gene RT-PCR assay for predicting recurrence in nodenegative breast cancer patients-NSABP studies B-20 and B-14.Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner R, Walker M,Watson D, Park T, Bryant J, Wolmark N. NSABP, Pittsburgh, PA; GenomicHealth, Inc., Redwood City, CA.

9:45 17. Multi-gene RT-PCR assay for predicting recurrence in nodenegative breast cancer patients - M. D. Anderson ClinicalValidation Study.Esteva FJ, Sahin AA, Coombes K, Baker J, Cronin M, Walker M, Watson D,Cristofanilli M, Shak S, Hortobagyi GN. The University of Texas M. D.Anderson Cancer Center, Houston, TX; Genomic Health, Inc., RedwoodCity, CA.

10:00 18. Use of automated scanning digital microscopy for the accurateand efficient assessment of HER-2 gene amplification based onanalysis of 391 human breast cancer specimens.Ragaz J, Bauer K, Nielsen T, Webster S, Huntsman D, Bossy B, Lippman M.University of British Columbia, Vancouver, BC, Canada; University ofSouthern California, Los Angeles, CA; ChromaVision Medical Systems,Inc., San Juan Capistrano, CA; University of Michigan, Ann Arbor, MI.

10:15 19. Early placenta insulin-like growth factor (EPIL) indicateshighly motile breast cancer cells and poor prognostic Her2-positive and Her2-negative subgroups of breast cancer. Brandt BH, Packeisen J, Kemming D, Simon R, Bidart J-M, Buerger H.Gerhard-Domagk-Institut of Pathology, Westfälische Wilhelms-Universität, Münster, Germany; Institute of Pathology, University ofBasle,Switzerland, Basle, Switzerland; Institut Gustave-Roussy, Villejuif,France; 1Institute for Clinical Chemistry and Laboratory Medicine,Westfälische Wilhelms-Universität, Münster, Germany.

10:30 20. Expression profiling of purified normal human luminal andmyoepithelial breast cells: identification of novel prognosticmarkers for breast cancer. Jones C, Mackay A, Grigoriadis A, Cossu A, Reis-Filho JS, Fulford LG,Dexter T, Davies S, Bulmer K, Ford E, Parry S, Budroni M, Palmieri G,Neville AM, O’Hare MJ, Lakhani SR. Institute of Cancer Research, London,United Kingdom; University College London, London, United Kingdom;Istituto di Anatomia Patologica, Sassari, Italy; The Royal Marsden Hospital,London, United Kingdom.

10:45 21. Outcome of African Americans on Southwest Oncology Group(SWOG) breast cancer adjuvant therapy trials. Albain KS, Unger JM, Hutchins LF, Rivkin SE, Martino S, Livingston RB,Osborne CK. Southwest Oncology Group, San Antonio, TX.

11:00-12:00 WILLIAM L. MCGUIRE MEMORIAL LECTURE –Ballroom C

Breast Cancer – A Look to the FutureUmberto Veronesi, MDIstituto Europeo di OncologiaMilan, Italy

Supported by an educational grant from Glaxo SmithKline

12:00-1:00 LUNCH [Ticket Required] – Exhibit Hall D

1:00-2:00 CASE DISCUSSION 1 – Ballroom C

2:00-3:30 MINI-SYMPOSIUM 2 – Ballroom C

NEW TECHNIQUES IN BREAST RADIATIONRita Kramer, MD, Co-ModeratorBaylor/Methodist Breast Care Center, Houston, TXandRichard Elledge, MD, Co-ModeratorBaylor/Methodist Breast Care Center, Houston, TX

2:00 Introduction

2:00 Partial breast irradiation: current statusFrank Vicini, MDWilliam Beaumont HospitalRoyal Oak, MI

2:30 Intra-operative breast radiation: the targeted intra-operativeradiotherapy (Targit) trialDr. Jayant S. VaidyaRoyal Free and University CollegeLondon, England, UK

SAN ANTONIO BREAST CANCER SYMPOSIUM - Thursdayxiv

3:00 Intensity-modulated breast radiotherapy: the new standard of care?Lori J. Pierce, MDUniversity of Michigan Medical SchoolAnn Arbor, MI

3:30-4:30 KOMEN FOUNDATION'S BRINKER AWARD LECTURES

– Ballroom C

Join the honorees of the Komen Foundation’s Brinker Award for ScientificDistinction as they discuss important findings in their breast cancer research.

4:30-6:30 POSTER SESSION 3 & RECEPTION – Exhibit Hall C

(#301-382)

Prognosis and Response Predictions: Treatment Response Predictors

301 Prediction of which screen (mammographically) detected breastcancers require chemotherapy: Validation of new index.Bundred NJ, Walton J, Bishop H, Wallis M, Lawrence GM. SouthManchester University Hospital, Manchester, United Kingdom; WestMidlands Breast Screening QA Reference Centre, Birmingham, UnitedKingdom; Royal Bolton Hospital, Bolton, United Kingdom.

302 Pathological complete response to chemotherapy is related tohormone receptor status.Buzdar AU, Valero V, Theriault RL, Frye D, Green M, Booser D, Guerra L,Sahin A, Ames F, Smith T, Singletary E, Hortobagyi GN. UT M.D.Anderson Cancer Center, Houston, TX.

303 HER2 neu and clinical decision making amongst Ontario medicaloncologists: does anyone care?Myers JA, DeBoer G, Warner E. University of Toronto, Toronto, ON,Canada.

304 MR imaging phenotypes predict response and recurrence inlocally advanced breast cancer treated with neoadjuvantchemotherapy.Yu EW, Hylton N, Partridge S, Moore D, Au A, Gibbs J, Hwang E-SS, EwingC, Rugo H, Park J, Tripathy D, Chew K, Esserman LJ. UCSF, San Francisco,CA.

305 HER2 status: A Canadian experience of concordance betweencentral and local testing laboratories.O’Malley F, Thomson T, Julian J, Cosby R, Have C, Dubois S, Whelan T,Gelmon K, Andrulis I. Mount Sinai Hospital, Toronto; University ofToronto; Hamilton Regional Cancer Centre, McMaster University; BritishColumbia Cancer Agency.

306 Prospective and multi-institutional validation of artificial neuralnetworks in predicting axillary lymph node metastasis in breastcancer.Ramesh AN, Kambhampati C, Lansdown M, Hanby A, O’Leary R,Monson JRT, Drew PJ. University of Hull, Hull, United Kingdom; Leeds,United Kingdom.

307 The predictive value of Her2/neu status on clinical outcome intamoxifen-treated breast cancer patients.Hanna W, Wong JW, Zubovits JT, Trudeau M. Sunnybrook and Women’sCollege Health Sciences Centre, University of Toronto, Toronto, ON,Canada; Toronto-Sunnybrook Regional Cancer Centre, Toronto, ON,Canada.

308 Lack of bcl-2 and bax expression correlates with pathologicalcomplete response to doxorubicin-based neoadjuvantchemotherapy in breast cancer.Buchholz TA, Garg A, Esteva FJ, Kuerer HM, Hortobagyi GN, Pusztai L,Singletary SE, Sahin AA. The University of Texas M. D. Anderson CancerCenter, Houston, TX.

309 Does body mass index influence the effectiveness of adjuvanttamoxifen in postmenopausal women with early stage breastcancer?Lee CW, Norris B, Moravan V, Olivotto I. BC Cancer Agency, Surrey, BC,Canada; BC Cancer Agency, Vancourver, BC, Canada; BC Cancer Agency,Victoria, BC, Canada.

310 Evaluation of the predictive significance of serum HER-2/neu andCA15-3 in patients with HER-2 positive breast cancer enrolled in aphase IIb study: paclitaxel (PCT) versus PCT + trastuzumab.Zancan M, Gasparini G, Rocco S, Crivellari D, Filippelli G, Morabito A,Silingardi V, De Sio L, Papaldo P, Carillio G, Spada A, Veronesi A, CognettiF, Amadori D, Gion M. Ospedale Civile di Venezia, Venezia, Italy; SanFilippo Neri Hospital, Rome, Italy; CRO, Aviano, Italy; Presidio Ospedaliero,Paola, Italy; Università, Modena, Italy; Istituto Regina Elena, Roma, Italy;Ospedale Morgagni-Pieraantoni, Forlì.

311 Trastuzumab improves the prognosis in HER2-positive whencompared with HER2-negative patients. Trastuzumab plusvinorelbine in HER2-positive versus vinorelbine alone in HER2-negative metastatic breast cancer patients.Papaldo P, Fabi A, Nardoni C, Pino S, Ferretti G, Carlini P, Mottolese M,Cianciulli AM, Alimonti A, Sperduti I, Di Cosimo S, Cognetti F. ReginaElena Cancer Institute, Rome, Italy, Italy.

312 HER-2 overexpression predicts better response to taxanechemotherapy in patients with advanced breast cancer.Jiang Z, Liu F, Song S, Li X. Chinese Academy of Military Medical Sciences,Beijing, China.

313 Epigenetic signature predicts failure of endocrine therapy inpatients with recurrent breast cancer.Martens JWM, Nimmrich I, Koenig T, Look MP, Harbeck N, Model F, Bolt-de Vries J, Portengen H, Meijer-Van Gelder ME, Piepenbrock C, Olek A,Hoefler H, Kiechle M, Klijn JGM, Schmitt M, Maier S, Foekens JA.Erasmus MC, Rotterdam, Netherlands; Epigenomics AG, Berlin, Germany;Frauenklinik, Technical University of Munich, Munich, Germany; TechnicalUniversity of Munich, Munich, Germany.

314 Differences in response of breast cancer molecular profiles ofpatients likely to respond either to erbB tyrosine kinase inhibitorsor to erbB targeted antibodies.Bacus S, Smith B, Maltzman W, Yarden Y, Spector N. QDL, Westmont, IL;Cell Signaling, Beverly, MA; The Weizmann Institute of Science, Rehovot,Israel; GlaxoSmithKline, Research Triangle Park, NC.

315 Withdrawn

316 Response to herceptin and chemotherapy in herceptin-naïvepatients with HER2 3+/FISH+ breast cancer is modified by patternof expression of insulin-like growth factor-I receptor (IGF-IR) butnot epidermal growth factor receptor (EGFR).Harris LN, Witkiewicz A, Freidman P, Kamma M, Winer EP, Iglehart JD,Schnitt S. Dana-Farber Cancer Institute, Boston, MA; AbbottLaboratories, Chicago, IL; BI Deaconesss Medical Center, Boston, MA.

317 CXCR4 as a potential predictive marker for detection of tumorcells in bone marrow of patients with breast cancer.Cabioglu N, Sahin A, Yavuz E, Igci A, Yildirim EO, Aktas E, Deniz G, PriceJE. MD Anderson Cancer Center, Houston, TX; University of Istanbul,Faculty of Medicine, Istanbul, Turkey; Institute of Experimental MedicalResearch, Istanbul, Turkey.

318 Serial monitoring of serum HER-2 extracellular domain duringherceptin-taxol chemotherapy for metastatic breast cancer:preliminary results from the French experience (HER.ME.Sprotocol).Gligorov J, Brault D, Tse C, Campone M, Kerbrat P, Lortholary A, Brindel I,Launois R, Lotz JP. APHP Tenon, Paris, France; Centre René Gauducheau,Nantes, France; Centre Eugène Marquis, Rennes, France; Centre PaulPapin, Angers, France; APHP, Paris, France; REES, Paris, France.

319 The predictive value of vascular endothelial growth factor (VEGF)plasma levels during therapy of lymph node positive breast cancerpatients.Kuemmel S, Eggemann H, Lueftner D, Ulm K, Breitbach G-P, Elling D,Blohmer J-U. Humboldt-University of Berlin, Charitè; Krankenhaus Berlin-Lichtenberg; Campus Charité Mitte, Humboldt-University of Berlin;Technical University of Munich; Krankenhaus Neunkirchen, Germany.

320 A prognostic model to predict the risk of developing brainmetastasis in patients treated with trastuzumab for HER-2positive metastatic breast cancer.Pansegrau GK, Lohrisch CA, Bajdik CD, Speers CH, Baerg BE, Barnett JB,Gelmon KA, Olivotto IA, Chia SKL. British Columbia Cancer Agency,Vancouver, BC, Canada.

SAN ANTONIO BREAST CANCER SYMPOSIUM - Thursday xv

321 Adjuvant! Version 5. Underlying data and assumptions.Ravdin PM. University of Texas, San Antonio, TX.

322 Microarray expression profiles for predicting response toneoadjuvant AC chemotherapy.Cleator SJ, Powles TJ, Fenwick KI, Dexter TJ, Lakhani SR, Ashworth A,Dowsett M. Institute of Cancer Research, London, United Kingdom;Parkside Hospital, London, United Kingdom; Royal Marsden Hospital,London, United Kingdom.

323 Modulation of tumor-associated macrophage infilltration duringprimary chemotherapy in breast cancer patients.Lacko A, Swiatoniowski G, Mazur G, Suder E, Surowiak P, Dabrowska M,Klaniecki T. Wroclaw Medical University, Wroclaw, Poland; AcademicMilitary Hospital, Wroclaw, Poland; Lower Silesian Oncology Center,Wroclaw, Poland.

324 Chromogenic in-situ hybridisation (CISH) compared with FISHand IHC for detection of HER2 gene amplification: aninternational validation ring study.van de Vijver MJ, Rueschoff J, Penault-Llorca F, Bilous M, Hanna W.Netherlands Cancer Institute, Amsterdam, Netherlands; Klinikum Kassel,Kassel, Germany; Centre Jean Perrin, Clermond-Ferrand, France;Westmead Hospital, New South Wales, Australia; Sunnybrook &Women’s College, Toronto, Canada.

325 The use of cell line standards and external quality assessment tostandardise assays for HER-2/neu in European cancer centres andthe potential of automated image analysis to provide moreaccurate cut-points for predicting clinical response totrastuzumab.Rhodes A, Borthwick D, Sykes R, Paradiso A. UCL Medical School,London, United Kingdom; Applied Imaging International, Newcastleupon Tyne, United Kingdom; INQAT, NCI-Bari, Italy.

Risk and Prevention: Familial Breast Cancer

326 Communicating genetic risk to family members.Daly MB, Barsevick AM, Montgomery SV, Bingler R, Malick J, Spoltore J,Weil SC. Fox Chase Cancer Center, Philadelphia, PA.

327 Familial aggregation of breast cancer and other female cancers inthe women’s contraceptive and reproductive experiences (CARE)study.Simon MS, Korczak JF, Yee CL. Karmanos Cancer Institute/Wayne StateUniversity, Detroit, MI.

328 Urgent genetic assessment (GA) in the management of newlydiagnosed familial breast cancer (br ca) patients: a feasibilitystudy.Eisen A, Whelan T, Irwin E, Johnson A, Learn L, Levine M. HamiltonRegional Cancer Centre, Hamilton, ON, Canada.

329 Incorporation of genetic testing into primary treatment ofinvasive breast cancer (BrCa).Graham ML, Evans JP, Booker JK, Skrzynia C. Cary Oncology, Cary, NC;Univ. No. Carolina, Chapel Hill, NC.

330 The impact of having relatives affected with breast cancer onpsychological distress in women at increased risk for breastcancer (BC).van Dooren S, Seynaeve C, Rijnsburger R, Kriege M, Bartels K,Duivenvoorden H, Tibben A. ErasmusMC, Rotterdam, Netherlands;ErasmusMC Daniel den Hoed, Rotterdam, Netherlands; LUMC, Leiden,Netherlands.

331 BRCA1 and BRCA2 mutations in Korean breast cancer patients.Hwang UK, Son BH, Yoon HS, Ahn SH, Jo DY, Song KH, Kwak BS.University of Ulsan College of Medicine and Asan Medical Center, Seoul,Korea; MyDNA Laboratory, Seoul, Korea.

332 Increased incidence of lobular breast carcinoma in women with afamily history with parathyroid adenoma.Luts L, Olsson H, Borg A, Bladström A, Johannsson OT. UniversityHospital, Lund, Sweden; University Hospital, Reykjavik, Iceland.

333 Surgical procedures resulting from BRCA gene analysis results.Wilbur JS, Cady B, Legare RD. Women & Infants’ Hospital, Providence, RI.

334 High-risk screening adherance in breast/ovarian cancer families.Wood ME, Grossman CI, McKinnon WC, Dausch BM, Gray A, SolomonER, Compas BE. University of Vermont, Burlington, VT; VanderbiltUniversity, Nashville, TN.

Epidemiology and Outreach: Advocacy / Education

335 Advocate Clinical Trial Accrual and Retention Project (CTARP): amodel.Devine P, Allen J, Becker G, Borwhat M, Carbine N, Fonfa A, Hutchison R,Katz L, Lezotte JE, Williams S, Collyar D, Esserman L, Hylton N,ACRIN/CALGB. University of California at San Francisco, San Francisco,CA.

336 The Alamo breast cancer foundation patient advocate program.Stanford S, Moose J, Eastman D, Covone D, Fletcher E. Alamo BreastCancer Foundation, San Antonio, TX.

337 Breast cancer advocates identify core values for breast cancerresearch through a multidisciplinary collaboration.Visco F, National Breast Cancer Coalition Fund. National Breast CancerCoalition Fund, Washington, DC.

338 Breast cancer advocate involvement in the research process.Visco FM. National Breast Cancer Coalition, Washington, DC.

339 Delays in ethics committee approval – an English perspective.Williams NR, McRae K, Houghton J. University College London, London,United Kingdom.

340 Awareness and barriers to breast cancer screening in Catholicnuns - higher than average mammography screening rates despitepoor risk awareness.Tarabay GR, Klein P, Siegel B, Coty P, Lascher S. Saint Vincent Hospital andMedical Center, New York, NY; Saint Vincent Cancer Center, New York,NY.

341 Post-breast surgery pain syndromes and lymphedema: a web-based approach to patient & physician education onwww.cancersupportivecare.com.Wascher RA, Andrews A, Dollbaum CM, Manual F, Chan JY, Shapiro RM,Rosenbaum EH. John Wayne Cancer Institute, Santa Monica, CA; CancerSupportive Care, Berkeley, CA; University of California at San Francisco,San Francisco, CA; Union Memorial Hospital, Baltimore, MD.

342 Access for women with disabilities.McCarthy-Barnett K. Rhode Island Breast Cancer Coalition, Coventry, RI.

343 Do patients prefer to be seen by a doctor of the same sex?Muir RF, George WD, Wilson CR, Mallon EA, Doughty JC. WesternInfirmary, Glasgow, United Kingdom.

344 Application of the key features model for protocol screening andexecution to the phase IV herceptin/taxane HER-FIRST clinicaltrial.DeFrancisco CM, Billingsely DS, Petszinger TA, Frakes LA. San DiegoCancer Center, Encinitas, CA; San Diego Cancer Center, Vista, CA.

345 Using a community needs assessment to enhance resourceallocations for breast cancer education, screening and treatmentprograms in central North Carolina.Spears PA, Levitas BM, Randall-David E. Susan G. Komen Breast CancerFoundation; Cancer Information Services; Center for Creative Education,Durham, NC.

Treatment: Chemotherapy -- New Drugs and Formulations

346 Final results of a phase 2 study of single-agent CCI-779 in locallyadvanced or metastatic breast cancer failing prior anthracyclineand/or taxane regimens.Chan S, Scheulen ME, Johnston S, Mross K, Piccart M, Hess D, Bouxin N,Azli N. City Hospital, Nottingham, United Kingdom; Essen, Germany;Royal Marsden Hospital, London, United Kingdom; Tumour BiologyCentre, Freiburg, Germany; Institute Jules Bordet, Brussels, Belgium; ZeTup,Saint Gallen, Switzerland; Wyeth Research Oncology, Paris, France.

347 Effect of a farnesyl transferase inhibitor on HER2-positivetumours and ductal carcinoma in situ of the breast.Wärnberg F, White D, Anderson E, Knox F, Clarke RB, Bundred NJ.Christie Hospital/Paterson Institute, Manchester, United KingdomSouthManchester University Hospital, Manchester, United Kingdom.

SAN ANTONIO BREAST CANCER SYMPOSIUM - Thursdayxvi

348 Evidence of greater tumor and red cell partitioning and superiorantitumor activity of cremophor free nanoparticle paclitaxel(ABI-007) compared to taxol.Desai N, Yao Z, Trieu V, Soon-Shiong P, Dykes D, Noker P. AmericanBioScience, Inc, Santa Monica, CA; Southern Research Institute,Birmingham, AL.

349 A phase I dose escalation study of the dual kinase inhibitorGW572016 in combination with paclitaxel.Jones SF, Burris HA, Willcutt NT, Dickson NR, Raefsky EL, Greco A, VersolaMJ, Smith DA, Pandite LN. The Sarah Cannon Cancer Center/TennesseeOncology, Nashville, TN; Glaxo SmithKline, Research Triangle Park, NC.

350 A phase I study of BMS-247550 in combination with capecitabinein patients with metastatic breast cancer previously treated witha taxane and an anthracycline.Thomas E, Bunnell CA, Vahdat LT, Schwartzberg LS, Gralow JR, WhitakerLM, Peck R. MD Anderson Cancer Center, Houston, TX; Dana-FarberCancer Institute, Boston, MA; NY Presbyterian Hospital/Weill MedicalCollege of Cornell University, NY, NY; West Cancer Clinic, Memphis, TN;University of Washington, Seattle, WA; Bristol-Myers SquibbPharmaceutical Research Institute, Wallingford, CT.

351 Liposomal doxorubicin Myocet® in combination with Herceptin®and paclitaxel is active and well tolerated in patients with HER2-positive locally advanced or metastatic breast cancer: a phase IIstudy.Trigo J, Climent MA, Lluch A, Gascon P, Hornedo J, Gil M, Cirera L,Guillem V, Regueiro P, Baselga J. Vall d’Hebron University Hospital, SOLTIGroup, Barcelona, Spain; Instituto Valenciano de Oncología, SOLTI Group,Valencia, Spain; Hospital Clínico de Valencia, SOLTI Group, Valencia,Spain; Hospital Clínic, SOLTI Group, Barcelona, Spain; Hospital 12 deOctubre, SOLTI Group, Madrid, Spain; Institut Catalá d’Oncologia, SOLTIGroup, Barcelona, Spain; Hospital Mutua de Tarrasa, SOLTI Group,Barcelona, Spain; Roche Farma, S.A., Madrid, Spain.

352 Pegylated liposomal doxorubicin and pacltaxel as first linechemotherapy in patients with metastatic breast cancer: phase Istudy with correlative genotype, phenotype andpharmacokinetics.Bourgeois H, Lortholary A, Delozier T, Boisdron-Celle M, Chambeau-FerruA, Abadie-Lacourtoisie S, Joly F, Barbado M, Morel A, Chieze S, ChabrunV, Azema C, Savary J, Tourani J-M, Gamelin E. University Hospital LaMiletrie BP 577, Poitiers, France; CRLCC P. Papin, Angers, France; CRLCC F.Baclesse, Caen, France; Levallois-Perret, France; Rueil-Malmaison, France.

353 A phase I trial of the proteasome inhibitor bortezomib andpegylated liposomal doxorubicin.Dees EC, O’Neil BH, Humes EW, Carey LA, Collichio F, Johri A, Graham ML,Orlowski RZ. University of North Carolina at Chapel Hill, Chapel Hill, NC.

354 Synergistic combinations of conventional chemotherapy witheither a proteosome inhibitor or an NFkB inhibitor: in vitromedian effect analysis in cell lines with potential clinicalimplications.Budman DR, Calabro A. North Shore University Hospital - New YorkUniversity, Manhasset, NY.

355 Preliminary results of a phase II study of intravenous vinflunine assecond line therapy in patients with metastatic breast cancerafter anhracycline-taxane based regimen failure.Campone M, Vorobiof D, Cotes-Funes H, Verrill M, Khoo KS, Slabber CF,Caroff I, Pouget JC, Fumoleau P. Centre Rene Gauducheau, St. Herblain-Nantes, France; Sandton Oncology Centre, Johannesbourg, South Africa;Hospital Universitario 12 de Octubre, Madrid, Spain; Newcastle GeneralHospital, Neawcastle, United Kingdom; National Cancer Centre,Singapore, Singapore; Mary Potter Oncology Cntre, Pretoria, South Africa;Institut de Recherche Pierre Fabre, Boulogne-Billancourt, France.

356 A phase II trial of a novel taxane BAY 59-8862 in patients withmetastatic taxane-resistant breast cancer.Georgoulias V, Santoro A, Amadori D, Jones A, Pilz K, Lankhaar G.University General Hospital of Heraklion, Heraklion, Crete, Greece;Azienda Ospedaliera Humanitas, Rozzano, Milano, Italy; OspedaleL.Pierantoni, Forli, Italy; Royal Free Hospital, London, Greater London,United Kingdom; Bayer Vital GmbH, Leverkusen, Nordhein-Westfalen,Germany; Bayer Plc, Newbury, Berkshire, United Kingdom.

357 Paclitaxel, carboplatin and gefitinib (‘Iressa’, ZD1839) as first-linechemotherapy in patients with advanced breast cancer: a phase IIstudy.Fountzilas G, Pectasides D, Skarlos DV, Kalofonos HP, Papadimitriou C,Linardou H, Kalogera-Fountzila A, Saridaki Z, Briassoulis E, PapadopoulosS, Lambropoulos S, Kosmidis P, Razis E, Gogas H. Hellenic CooperativeOncology Group (HeCOG), Data Office, Athens, Greece.

358 Assessment of neurotoxicity in patients receiving BMS-247550 formetastatic breast cancer.Low J, Croarkin E, Parks R, Zia F, Steinberg S, Berman A, Mannan N, SwainS. CCR, NCI, Bethesda, MD; NIH, Bethesda, MD.

359 A phase I and pharmacokinetic study of an oral novel taxane BAY59-8862 given daily for 5 days every 3 weeks.Tonkin K, Hurwitz H, Lathia C, Gallentine M, Voliotis D, Hobdy E. CrossCancer Institute, AB, Canada; Duke Medical Center, Durham, NCBayerCorporation, West Haven, CT; Yale University, New Haven, CT.

360 Activity of gemcitabine plus capecitabine in patients withmetastatic breast cancer refractory to anthracyclines and taxanes.Andres R, Mayordomo JI, Polo E, Alvarez I, Lara R, Saenz A, Isla D,Escudero P, Tres A. Hospital Clinico Universitario Lozano Blesa, Zaragoza,Spain.

361 Preliminary results of phase II trial of sequential chemotherapy:Navelbine and capecitabine combination followed by docetaxelweekly as front line chemotherapy for advanced breast cancer.Ghosn M, Chahine G, Kattan J, Farhat F, Nasr F, Dagher J, Gasmi J. Hotel-Dieu de France University, Beirut, Lebanon; I.R.P.F., Boulogne, France.

362 Vinorelbine combined with cisplatin in the treatment of advancedbreast cancer failed to anthracyclines and/or taxanes.Shen G, Jiang Z, Song S. Chinese Academy of Military Sciences, Beijing,China.

363 Phase I combination study of oral vinorelbine and oralcyclophosphamide in patients with metastatic breast cancer.ten Tije AJ, Lieverst J, Seynaeve C, Schornagel J, Feragotto N, Blanchot G,ter Steeg JD, Laffranchi B, Verweij J, Schellens JH. Erasmus MC, Rotterdam,Netherlands; The Netherlands Cancer Institute, Amsterdam, Netherlands;Pierre Fabre Medicament, Boulogne, France.

364 A phase I study of oral vinorelbine and paclitaxel in metastaticbreast cancer.Tubiana-Mathieu N, Pienkowski T, Delva R, Vanhoefer U. CentreHospitalier Universitaire Dupuytren, Limoges; Klinika Nowotworow Sutka,Warsaw, Poland; Centre Paul Papin, Angers; UniversitaetKlinikum, Essen,Germany.

Tumor Cell Biology: Drug Resistance

365 Characterisation of genetic changes in tamoxifen resistant breastcancer cells.Scott DJ, Parkes AT, Limer JL, Witton CJ, Barlett JMS, Poola I, Speirs V.University of Leeds, St James’s University Hospital, Leeds, Yorkshire,United Kingdom; Glasgow Royal Infirmary, Glasgow, United Kingdom;Howard University, Washington, DC.

366 MTA-1 (metastasis associated protein-1) is upregulated intamoxifen-resistant breast cancer.Blackwell KL, Dewhirst MW, McDonnell DP, Dressman H, Snyder SA,Marks JR. Duke University Comprehensive Cancer Center, Durham, NC.

367 Transforming growth factor-beta down-regulation: a potentialnovel mechanism of trastuzumab (herceptin) resistance in breastcancer cells.Nahta R, Esteva FJ. U.T. M.D. Anderson Cancer Center, Houston, TX.

368 The impact of extracellular matrix proteins on drug resistance inbreast cancer cells.Shaw CM, Watson RWG, Fitzpatrick JM, Kerin MJ. Mater MisericordiaeUniversity Hospital & Conway Institute of Biomolecular and BiomedicalResearch, University College Dublin, Eccles St, Dublin 7, Ireland.

369 Proteasome inhibitor bortezomib (Velcade™) and trastuzumab inHER-2 overexpressing breast cancer cell lines.Laes J-F, Cardoso F, Durbecq V, Lagneaux L, Hennuy B, Lallemand F, GonzeI, Di Leo A, Kern F, Ross J, Piccart MJ, Sotiriou C. JBI, Brussels, Belgium;BioVallee A.S.B.L., Gosselies, Belgium; Southern Research Institute, AL;Millennium Pharmaceutics, Cambridge, MA.

SAN ANTONIO BREAST CANCER SYMPOSIUM - Thursday xvii

Tumor Cell Biology: Metastasis and Invasion

370 Inositol hexaphosphate (IP6) inhibits key events of cancermetastasis in a human mammary cancer model in vitro.Tantivejkul K, Vucenik I, Shamsuddin AK. University of Maryland Schoolof Medicine, Baltimore, MD; University of Michigan, Ann Arbor, MI.

371 Liver metastases originating from breast adenocarcinoma do notinduce hypoxia and grow without angiogenesis by co-option ofsinusoidal blood vessels.Vermeulen PB, Stessels F, Harris AL, Van Marck EA, Dirix LY. AZ Sint-Augustinus, Wilrijk, Antwerp, Belgium; University Hospital Antwerp,Edegem, Antwerp, Belgium; Weatherall Institute of Molecular Medicine,Headington, Oxford, United Kingdom.

372 Functional maps: a novel way of visualizing patterns of recurrenceof breast cancer.Gray LC, Vaidya JS, Houghton J, Baum M. University of Texas HealthScience Center, Houston, TX; University College, London, UnitedKingdom.

373 Stromal contribution to breast cancer cell invasion: analysis ofpatient-specific and tissue-specific interactions.Holliday DL, Shaw JA, Al Bahlani S, Benmore R, Walker RA, Jones L.Univeristy of Leicester, Leicester, United Kingdom.

374 Establishment of human breast carcinoma cell line with highmetastatic capabilities through in vivo selection.Wu J, Chen C-M, Hou Y-F, Shen Z-Z, Shao Z-M. Breast Cancer Institute,Cancer Hospital, Shanghai, Shanghai, China.

375 AlphaB-crystallin, a novel marker for breast cancer metastasis.Chelouche Lev D, Kluger HM, Rimm DL, Price JE. University of Texas M.D.Anderson Cancer Center, Houston, TX, Yale University School ofMedicine, New Haven, CT.

376 Expression of lipoxygenases and cyclooxygenase-2 in humanbreast cancer and their clinical significance.Jiang WG, Douglas-Jones A, Mansel RE. University of Wales College ofMedicine, Cardiff, Wales, United Kingdom.

377 An Ezrin/E-cadherin complex acts as a putative invasion andmigration suppressor in human beast cancer cells.Martin TA, Mansel RE, Jiang WG. University of Wales College ofMedicine, Cardiff, United Kingdom.

378 Regression of spontaneous lymph node and lung metastases afterendocrine therapy in an experimental breast cancer model.Vanzulli S, Soldati R, Lanari C, Molinolo A. IEO-FM, Academia Nacionalde Medicina, Buenos Aires, Argentina; Instituto de Biologia y MedicinaExperimental, Buenos Aires, Argentina.

379 Aberrant expression and distribution of the ERM family member,ezrin, in human breast cancer.Harrison GM, Gareth W, Mason MD, Mansel RE, Jiang WG. University ofWales College of Medicine, Cardiff, Wales, United Kingdom.

380 Influence of KGF on breast cancer metastasis in nude mousexenografts.Buller CJ, Zang X-P, Brackett DJ, Howard EW, Pento JT. University ofOklahoma, HSC, Oklahoma City, OK.

381 Interleukin-3 increases the expression of Bcl-xl protein in bone-metastatic breast carcinoma cells.Mora EM, Tari AM. Medical Sciences Campus,University of PR, San Juan,PR; MD Anderson Cancer Center, Houston, TX.

382 Alpha6beta4 integrin mediates PI3K-dependent phosphorylationof nonmuscle myosin heavy chain II in breast carcinoma cells invitro.Gilcrease MZ, Zhou X, Welch K. M. D. Anderson Cancer Center, Houston, TX.

7:00-9:00 KOMEN FOUNDATION'S BRINKER AWARD DINNER

– Marriot Rivercenter

The Susan G. Komen Breast Cancer Foundation cordially invitesyou to the 2003 Brinker Awards Dinner presenting the KomenFoundation’s Brinker Award for Scientific Distinction andfeaturing special guest entertainment. The dinner will be held inthe Marriott Rivercenter Hotel. [Ticket Required]

Friday, December 5

7:00-9:00 POSTER SESSION 4 & CONTINENTAL BREAKFAST

(#401-483) – Exhibit Hall C

Detection/Diagnosis: Circulating Markers

401 Increased serum IGF receptor (IGF-IR) in patients with elevatedserum HER-2/neu.Leitzel K, Demers L, Ali SM, Harvey HA, Engle L, Chaudri-Ross H, Lang R,Hackl W, Carney W, Hamer P, Lipton A. Penn State Hershey MedicalCenter, Hershey, PA; Lebanon VA Medical Center, Lebanon, PA; NovartisPharma AG, Basel, Switzerland; Oncogene Science/Bayer Diagnostics,Cambridge, MA.

402 Detection of circulating tumor cells in patients with primary andmetastatic breast cancer by enhanced gradient centrifugation.Mueller V, Stahmann N, Zabel T, Goetz A, Jaenicke F, Thomssen C, PantelK. University Hospital Hamburg-Eppendorf, Hamburg, Germany;Frickenhausen, Germany.

403 Urinary MMPs : potential predictors of breast cancer stage andprogression.Pories SE, Lamb CC, Lewis G, Zurakowski D, Lotz MM, Raza S, Scheib RG,Lenahan C, Borges V, Yee BH, Moses MA. Beth Israel Deaconess MedicalCenter, Boston, MAChildren’s Hospital, Boston, MA; Brigham andWomen’s Hospital, Boston, MA; Dana Farber Cancer Center, Boston, MA;Mount Auburn Hospital, Cambridge, MA.

404 Evaluation of circulating HER2 ECD and EGFR in patients withmetastatic breast cancer treated with low aggressivechemotherapy.Sandri MT, Johansson HA, Zorzino L, Salvatici M, Neumann R, ColleoniM. European Institute of Oncology, Milan, Italy; Bayer Vital GmbH,Leverkusen, Germany.

405 Low-level expression of HER2 and CK19 in normal peripheralblood leukocytes.Roberts LA, Dias CCC, Ngo T, Friedman P, Harris L, Solomon N. AbbottLaboratories, Abbott Park, IL; Dana Farber Cancer Institute, Boston, MA.

406 Serum and plasma levels of total and active matrixmetalloproteinase 2 and 9: any role in breast diseaseclassification?Somiari S, Shriver C, Heckman C, Jordan R, Hu H, Hooke J, Olsen C,Brzeski H, Somiari R. Windber Research Institute, Windber, PA; WalterReed Army Medical Center, Washington, DC; Uniformed ServicesUniversity of the Health Sciences, Bethesda, MD.

407 bFGF and VEGF serum levels in breast cancer patients and healthywomen: useful as diagnostic tools?Volpi A, Granato AM, Nanni O, Falcini F, Folli S, De Paola F, Medri L,Mosconi G, Amadori D. Pierantoni Hospital, Forlì, ItalyMorgagni Hospital,Forlì, Italy; Istituto Oncologico Romagnolo, Forlì, Italy.

408 Effect of adjuvant chemotherapy on circulating levels of theinsulin-like growth factor-I and binding protein-3 in women withbreast cancer. (NOGGO trial).Eggemann H, Kuemmel S, Lueftner D, Krocker J, Ulm K, Zeiser T,Kreienberg R, Blohmer J-U, Elling D. Krankenhaus Berlin-Lichtenberg;Humboldt University Berlin, Charité; Humboldt-Universität Berlin,CharitéCampus Mitte; Technical University Munich; Paracelsus Klinik Henstedt-Ulzburg; Universitätsklinikum Ulm.

409 ADVIA Centaur® HER-2/neu assay has clinical utility in monitoringpatients with metastatic breast cancer.Cheli CD, Mickelson K, Thakur K, Sampson E, Morris D, Kish L, Thiel RP,Lüftner D. Bayer Healthcare, Diagnostics Division, Tarrytown, NY; ThielStatistical Consultants, Oxford, CT; Charite Campus Mitte, Humboldt-Universität, Berlin, Germany.

410 Osteoprotegerin and receptor activator of nuclear factor �Bligand (RANKL) in serum: establishment of provisional referencelimits in healthy adults and breast cancer patients.Lueftner DI, Jozereau D, Lein M, von Hoesslin K, Possinger K, Jung K.Charite Campus Mitte, Berlin, Germany.

SAN ANTONIO BREAST CANCER SYMPOSIUM - Thursdayxviii

411 Novel serum biomarker for monitoring breast cancer patients.Serrero G, Tkaczuk K, Tait N, Dai H. A&G Pharmaceutical Inc, Columbia,MD; University of Maryland Cancer Center, Baltimore, MD.

Detection/Diagnosis: Diagnostic Pathology

412 Identification of an “inflammatory signature”: a study of 83inflammatory breast cancers and controls.Charafe-Jauffret E, Bardou V-J, Tarpin C, Ginestier C, Hassoun J. InstitutPaoli-Calmettes, Marseille, France.

413 Automated enumeration of the Vysis PathVysion HER-2 DNAprobe kit: setting and achieving standards of performance.Tomisek J, Piper J, Blondin B, Browne G, Lörch T. Vysis, Downers Grove, IL;Consultant, Aberlady, East Lothian, United Kingdom; MetaSystems,Altlussheim, Germany.

414 Clinicopathologic features of 59 pleomorphic lobular carcinomasof the breast.Huang HJ, Neven P, Drijkoningen M, Amant F, Berteloot P, Van Ongeval C,Van Steen A, Van Limbergen E, Van Den Bogaert W, Thomas J, ParidaensR, Vergote I, Christiaens M-R. University Hospital, Leuven, Belgium.

415 C-Met overexpression identifies breast cancer patients with poorclinical outcome independent of Her2/neu.Lengyel E, Gauger K, Prechtel D, Lindemann K, Resau JH, Vande WoudeGF, Harbeck N. University of California, San Francisco, San Francisco, CA;Technische Universitaet Muenchen, Muenchen, Bavaria, Germany; VanAndel Research Institute, Grand Rapids, MI; Pathologie Starnberg,Starnberg, Bavaria, Germany.

416 HER-2/neu intratumoral heterogeneity as analyzed by FISH: a non-apparent entity except in mixed histology tumors.Kneuper Hall R, Labarowski G, Metzner-Sadurski J, Wolff D, Self S.Medical University of South Carolina, Charleston, SC; Cancer Centers ofthe Carolinas, Greenwood, SC.

417 The frozen section (FS) is an accurate and cost effective means ofsentinel node evaluation: a cost benefit analysis of 163consecutive cases.Lara JF, Abellar RG, Huston J. Saint Barnabas Medical Center, Livingston,NJ.

418 Quality of HER2 testing by german pathologists.Buehler H, Duvnjak B, Schaller G. University Hospital Marienhospital,Ruhr-Universitaet, Bochum, Germany.

419 Clinical significance of columnar cell hyperplasia in breast tissuespecimens.Dooley WC, Wang J, Thor A, Parker J. The University of Oklahoma,Oklahoma City, OK.

Detection/Diagnosis: Marrow and Blood Micrometastases

420 Bone marrow micrometastasis is a significant predictor of long-term relapse-free survival for breast cancer by a non-proportionalhazards model.Wong GYC, Yu Q, Osborne MP. Strang Cancer Prevention Center, NewYork, NY.

421 Crculating tumor cell (CTC) assays in primary and metastaticbreast cancer: comparative results and clinical implications.Krishnan KJ, Scott J, Frey T, Bauer K, Ewing C, Hwang E-SS, Campbell MJ,Esserman LJ, Park JW. University of California, San Francisco, SanFrancisco, CA; BD Biosciences, San Jose, CA; Chromavision Inc, San JuanCapistrano, CA.

422 Prognostic significance of detection of MUC1 and/or CK19 -expressing mammary carcinoma cells in the peripheral blood ofbreast cancer patients by RT-PCR.Pierga J-Y, Denis MG, Extra J-M, Bourstyn E, Nos C, Dalcortivo L, CloughK, Boudou E, Pouillart P, Magdelenat H, De Cremoux P. Institut Curie,Paris, France; CHU de Nantes, Nantes, France; Hopital Necker, Paris,France; Hopital Saint Louis, Paris, France.

423 Identification of putative cancer cells from the blood of patientswith breast cancer: a comparsion of three techniques.Ring AE, Zabaglo L, Ormerod MG, Smith IE, Dowsett M. Royal MarsdenHospital, London, England, United Kingdom.

424 Detection of micrometastases in peripheral blood byimmunomagnetic cell separation in patients with breast cancer.Lebrecht A, Taubert H, Bluemke K, Ulbrich EJ, Lautenschlaeger C,Holzhausen H-J, Koelbl H, Bilkenroth U. Martin-Luther-University Halle-Wittenberg, Halle, Germany.

Treatment: Endocrine Therapy

425 Prolonged tamoxifen therapy; effects on contralateral breastcancer, endometrial cancer incidence and cardiovascularmortality.Carstensen J, Rosell J, Bengtsson N-O, Bergh J, Hatscek T, Malmstrom P,Rutqvist L-E, Wallgren A, Nordenskjold B. University Hospital, Linkoping,Sweden.

426 Fulvestrant (Faslodex®) versus anastrozole (Arimidex®) for thetreatment of advanced breast cancer: a prospective combinedsurvival analysis of two multicenter trials.Pippen J, Osborne CK, Howell A, Robertson JFR. Houston and Baylor-Sammons Cancer Center, Dallas; Breast Center at Baylor College ofMedicine and the Methodist Hospital, Houston; Christie Hospital,Manchester, United Kingdom; Nottingham City Hospital, Nottingham,United Kingdom.

427 Effects of steroidal and nonsteroidal aromatase inhibitors onmarkers of bone turnover and lipid metabolism in healthyvolunteers.Goss PE, Thomsen T, Banke-Bochita J, Hadji P. Princess Margaret Hospital,Toronto, ON, Canada; Pharm PlanNet Contract Research GmbH,Mönchengladbach, Germany; Parexel GmbH, Berlin, Germany; Philipps-Universität Marburg, Marburg, Germany.

428 Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locallyadvanced breast cancer: second report.Chow LWC, Toi M, Takebayashi Y, Sasano H. University of Hong KongMedical Center, Hong Kong, Hong Kong; Metropolitan Cancer &Infectious Disease Center, Tokyo, Japan; Fukushima University, Fukushima,Japan; Tohoku University, Sendai, Japan.

429 Type 1 insulin-like growth factor receptor expression andactivation in clinical breast cancer.Gee JM, Rubini M, Robertson JF, Ellis IO, Gutteridge E, Nicholson RI.Cardiff University, Cardiff, United Kingdom; University of Ferrara, Ferrara,ItalyNottingham City Hospital, Nottingham, United Kingdom.

430 Short and long term effects of letrozole on tumour histo- andimmuno-pathology in breast cancer patients given neoadjuvanttreatment.Jackson J, White S, Dixon JM, Anderson TJ, Renshaw L, Miller WR.Western General Hospital, Edinburgh, United Kingdom.

431 Multi-center clinical trials of trilostane (modrenal) for advancedbreast cancer in post-menopausal women.Leonard RCF, Bundred N, Buzdar A, Canney P, Rea D, Spittle MF, StewartAL, Verrill M. Singleton Hospital, Swansea, United Kingdom; SouthManchester University Hospital, Manchester, United Kingdom; M DAnderson Cancer Center, Texas; Western Infirmary, Glasgow, UnitedKingdom; Queen Elizabeth Hospital, Birmingham, United Kingdom;Middlesex Hospital, London, United Kingdom; Christie Hospital,Manchester, United Kingdom; Newcastle General Hospital, Newcastleupon Tyne, United Kingdom.

432 Aromasin and its 17-hydro metabolite manifest androgenicactivity which may be responsible for its bone protective effect.Chang C-Y, Jansen M, Sathya G, McDonnell DP. Duke University MedicalCenter, Durham, NC.

433 The effect of letrozole on adrenal steriod hormone biosynthesis.Dixon JM, Renshaw L, Miller WR. Western General Hospital, Edinburgh,United Kingdom.

434 Novel dual modulator of estrogen sulfatase and estrogen receptor(ER) for the treatment of ER+ breast cancer.Chao W-R, Peters RH, Zaveri N, Tanabe M, Yamada Y, Toko T, Asao T,Eshima K. SRI International, Menlo Park, CA; Taiho Pharmaceutical Co.,Hanno, Japan.

SAN ANTONIO BREAST CANCER SYMPOSIUM - Friday xix

435 Exemestane in metastatic breast cancer: effective therapy after 3rd

generation aromatase inhibitor failure.Fernie NL, Zekri JM, Leonard RCF, Coleman RE, Cameron DA. CancerResearch UK Beatson Laboratories, Glasgow, United Kingdom; WestonPark Hospital, Sheffield, United Kingdom; South-West Wales CancerInstitute, Swansea, United Kingdom; Western General Hospital,Edinburgh, United Kingdom.

436 Metabolic flare by positron emission tomography (PET) predictsfor response to tamoxifen more accurately than her-2 status inadvanced postmenopausal ER+ breast cancer.Mortimer JE, Dehdashti F, Siegel BA, Katzenellenbogan JA, Welch MJ.Washington University, St. Louis, MO; Eastern Virginia Medical School,Norfolk, VA; University of Illinois, Urbana, IL.

437 Fulvestrant in metastatic breast cancer.Steger GG, Bartsch R, Wenzel C, Pluschnig U, Hussian D, Mader RM,Zielinski CC. University of Vienna, Vienna, Austria.

438 Improved responses with the combination of exemestane(aromasin) with the cyclooxygenase-2 inhibitor celecoxib inpostmenopausal patients with ER positive advanced breastcancer.Canney PA. Western Infirmary, Glasgow, United Kingdom.

439 Fulvestrant (Faslodex®) demonstrates clinical benefit in heavilypretreated postmenopausal women with advanced breast cancer:a single-center experience.Franco S, Perez A, Tan-Chiu E, Frankel C, Vogel C. Cancer ResearchNetwork, Plantation.

440 The effect of exemestane (Aromasin®) on the lipidemic profile ofbreast cancer patients: preliminary results of the TEAM trialGreek sub-study.Markopoulos C, Polychronis A, Farfarelos C, Zobolas V, Bafaloukos D,Papadiamantis J, Misitzis J. Hellenic Breast Surgical Society, Greece.

441 Prospective study of uterine sonographic changes after 3 monthsendocrine treatment in postmenopausal breast cancer patients:tamoxifen is estrogenic while aromatase inhibitors induce atrophyand can reverse the effect of tamoxifen.Morales L, Timmerman D, Neven P, Konstantinovic ML, Ameye L, VanHuffel S, Vergote I, Paridaens R. University Hospitals Leuven; CatholicUniversity of Leuven, Leuven, Belgium.

442 Prospective study on the effect of endocrine treatments onmenopausal symptoms in breast cancer patients.Morales L, Neven P, Timmerman D, Konstantinovic ML, Van Huffel S,Ameye L, Vergote I, Paridaens R. University Hospitals Leuven; CatholicUniversity of Leuven, Leuven, Belgium.

443 Phase II study of neo-adjuvant exemestane in postmenopausalpatients with operable breast cancer.Tubiana-Hulin M, Spyratos F, Becette V, Mauriac L, Romieu G, Bibeau F,Bièche I, Bourgeois H, Chollet P. Centre René Huguenin, Saint Cloud,France; Institut Bergonié, Bordeaux, France; Centre Val d’ Aurelle,Montpellier, France; Chu La Milétrie, Poitiers, France; Centre Jean Perrin,Clermont-Ferra, France.

444 A phase II trial of letrozole and trastuzumab for ER and/or PgRand HER2 positive metastatic breast cancer.Wong ZW, Isaacs C, Harris L, Ellis MJ. Duke University Medical Center,Durham, NC; Lombardi Cancer Center, Georgetown University MedicalCenter, Washington, DC; Dana-Farber Cancer Institute, Boston, MA.

445 Letrozole reduces bone mass in breast cancer patients asmeasured by digital radiometry of clavicle and rib.Wojtacki J, Zielinski KW, Wiraszka R, Nowaczyk M, Hajdukiewicz W,Lesniewski-Kmak K, Lamentowicz K, Piotrowska M. PCK MaritimeHospital, Gdynia, Poland; Medical University, Lodz, Poland; SpecialisticVoivodeship Hospital, Radom, Poland; Gdansk, Poland; Cancer Center,Olsztyn, Poland; Military Medicine Institute, Warsaw, Poland.

Treatment: Surgery

446 Recurrence following skin sparing mastectomy and immediatebreast reconstruction for breast cancer.Brown IM, Wilson CR, Doughty JC, Weiler-Mithoff E, George WD.Western Infirmary, Glasgow, United Kingdom; Canniesburn Hospital,Glasgow, United Kingdom.

447 Donut mastopexy lumpectomy: an oncoplastic operationpermitting breast preservation for large breast malignancies.Anderson BO, Reed DR, Mann GN, Austin-Seymour M, Moe RE.University of Washington, Seattle, WA.

448 For outpatient breast surgery patients, paravertebral blockadeimproves pain control, shortens length of stay, and has a highdegree of patient satisfaction when compared with currentgeneral anesthetic techniques.Lesnikoski BA, Pollard K, Eltzschig HK, Posner M, Iglehart JD. Brigham &Women’s Hospital/Harvard Medical School, Boston, MA; Dana FarberCancer Institute, Boston, MA.

449 Paget’s disease of the breast: a long-term follow-up study.Kawase K, DiMaio DJ, Tucker SL, Ross MI, Feig BW, Ames F, Kuerer H,Meric-Berstam F, Singletary E, Babiera G, Buchholz T, Hunt KK. Universityof Texas M. D. Anderson Cancer Center, Houston, TX.

450 Local infiltration for breast surgery is effective for reducing post-operative pain: a randomized, double-blind placebo controlledoutcome study.Lesnikoski BA, Welch K, Concepcion M, Kissin I, Christian R, Osteen R,Lynch E. Brigham & Womens Hospital/Harvard Medical School, Boston,MA.

451 Adjuvant chemotherapy after mastectomy is not delayed byimmediate reconstruction.Aft RL, Schootman M, Jeffe DB. Washington University, St. Louis, MO.

452 Lack of local surgical treatment strongly decreases prognosis ofnon-metastatic breast cancer women < 65 years.Vlastos G, Fioretta G, Verkooijen H, Schubert H, Kurtz J, Schaefer P,Sappino P, Bouchardy C. Geneva University Hospitals, Geneva,Switzerland; Geneva University, Geneva, Switzerland.

453 Effects of the type and volume of cancer in the surgical margin onthe development of ipsilateral breast tumor recurrence afterbreast conserving therapy.Takahashi K, Nishimura S, Tada K, Makita M, Tada T, Iwase T, YoshimotoM, Akiyama F, Sakamoto G, Kasumi F. Cancer Institute Hospital, Tokyo,Japan; Cancer Institute, Tokyo, Japan.

454 A randomised trial of the effect of quilting Latissimus Dorsi flapdonor site on seroma formation.Daltrey I, Schuijvlot M, Cook J, Fowler C, Rayter Z, Winters ZE. Universityof Bristol and Bristol Breast Unit, Bristol, United Kingdom.

455 Intraoperative radiotherapy following lumpectomy for breastcancer.Dirbas FM, Daniel BL, Goffinet DR. Stanford University Medical Center,Stanford, CA.

456 Evaluation of cosmesis after immediate breast reconstruction.Shokrollahi K, Daltrey I, Rayter Z, Winters ZE. University of Bristol andBristol Breast Unit, Bristol, United Kingdom.

Tumor Cell Biology: Endocrinology

457 Influence of ovarian secretions, oral contraceptives, and hormonereplacement therapy on progesterone concentrations in breastfluids.Chatterton RT, Geiger AS, Khan SA. Feinberg School of Medicine,Northwestern University, Chicago, IL.

458 Comparative aromatase enzyme kinetic studies on fadrozole,formestane, letrozole, anastrozole and exemestane.Batzl-Hartmann C, Evans DB, Bhatnagar AS. Im Stadtwald, Saarbruecken,Germany; Novartis Pharma AG, Basel, BS, Switzerland; Muttenz, BL,Switzerland.

459 Expression of 17�-hydroxysteroid dehydrogenases and correlationto prognosis in postmenopausal breast cancer patients.Gunnarsson C, Kirschner K, Hellqvist E, Stål O. Department ofBiomedicine and Surgery, Linköping, Sweden.

460 Mechanism of estradiol-induced regression ofT47D:A18/PKC�tumors involve the estrogen receptor andinteraction with the extracellular matrix.Tonetti DA, Chisamore MJ, Ahmed Y, Zhao H, Zhang Y, Sztark A.University of Illinois at Chicago, Chicago, IL; Northwestern University,Chicago, IL.

SAN ANTONIO BREAST CANCER SYMPOSIUM - Fridayxx

461 The effects of estradiol and fulvestrant on gene expression inprimary breast cancer cells and in established breast cell lines.Brookman-Amissah N, Price RK, Foxon R, Zvelebil MJ, Mackay A, O’HareMJ, Stein RC. University College London, London, United Kingdom.

462 Dehydroepiandrosterone sulphate serum levels in women withbreast cancer and growth actions of its metabolites 5alpha-dihydrotestosterone and 5-androstene-3beta,17beta-diol onMCF7, T47D, and MDAMB231 breast cancer cell lines.Aspinall SR, Stamp S, Davison A, Shenton BK, Lennard TWJ. University ofNewcastle, Newcastle upon Tyne, Tyne and Wear, United Kingdom.

463 Effect of nomegestrol acetate on human estrogen sulfotransferaseactivity in the hormone-dependent MCF-7 and T-47D breastcancer cell lines.Pasqualini JR, Paris J, Shields-Botella J, Chetrite GS. Institut de Puericulture,Paris, France; Laboratoires Merck-Theramex, Monaco, Monaco.

Tumor Cell Biology: Gene Therapy

464 Targeting matrilysin in human breast cancer cells using retroviraltransgenes and its clinical implications.Jiang WG, Watkins G, Mansel RE. University of Wales College ofMedicine, Cardiff, Wales, United Kingdom.

Tumor Cell Biology: Immunology and Immunotherapy

465 Vaccination with trastuzumab mimotopes elicits antibodiesrecognizing Her-2/neu.Riemer A, Jensen-Jarolim E, Wagner S, Pehamberger H, Scheiner O,Zielinski CC. University of Vienna, Vienna, Austria.

466 Vaccination of breast cancer patients against the universal tumorantigen telomerase.Domchek SM, Stein S, DeMichele A, Schuchter LM, Fox KR, VonderheideRH. University of Pennsylvania, Philadelphia, PA.

467 Of mice, macrophages and mammary glands.Barsky SH. UCLA School of Medicine, Los Angeles, CA.

468 In vivo expansion of tumor-specific CD8+ T cells and intra-antigenic epitope spreading in breast cancer patients receiving apreventive HER2/neu peptide vaccine.Gurney JM, Storrer CE, Woll MM, Fischer CM, Kotula L, Gahan JC, JacksonKA, Shriver CD, Ponniah S, Peoples GE. Walter Reed Army MedicalCenter, Washington, DC; Uniformed Services University of HealthSciences, Bethesda, MD.

469 T-cell function correlates with oncological status and diseasestage in breast cancer.Kell MR, Beddy D, Conneely J, O’Toole PJ, Winter DC, Watson W,Fitzpatrick JM, Kerin MJ. Mater Misericordiae Hospital, University CollegeDublin, Breast Check Eccles Unit, Conway Institute., Dublin, Ireland.

470 Clinical grade dendritic cells generated from patients withadvanced breast cancer for therapeutic vaccination.Characterization and comparison with immune and clinicalresponse.Svane IM, Pedersen AE, Johnsen HE, Thorn M, Kamby C, Nielsen D,Gaarsdal E, Nikolajsen K, Claesson MH. Herlev University Hospital, Herlev,Denmark; Panum Institute, Copenhagen, Denmark.

471 Cellular immunotherapy in late stage breast cancer patients byusing reactivated autologous memory T-cells (MTC) derived frombone marrow (BM).Schuetz F, Ehlert K, Beckhove P, Schneeweiss A, Bastert G. University ofHeidelberg, Heidelberg, Germany; German Cancer Research Center,Heidelberg, Germany.

472 Targeting immortality: quantification of specific cytotoxic Tlymphocyte immunity against synthetic human telomerasereverse transcriptase peptides in breast cancer patients.Amarnath SM, Dyer CE, Ramesh A, Iwuagwu O, Greenman J, Drew PJ.University of Hull, Hull, England, United Kingdom.

Tumor Cell Biology: Molecular Biology

473 Rexinoid-regulated biomarkers: Up-regulation of Id-1 correlateswith rexinoid-induced growth suppression of normal andmalignant breast cells.Seo H-S, Kim H-T, Kong G, Desprez P-Y, Lamph WW, Johnson KA, BrownPH. Baylor College of Medicine, Houston, TX; Geraldine Brush CancerResearch Institute California Pacific Medical Center, San Francisco, CA;Ligand Pharmaceuticals, Inc., San Diego, CA; National Cancer Institute,National Institutes of Health, Bethesda, MD.

474 Microarray analysis of formalin fixed paraffin-embedded tissue:the development of a gene expression staging system for breastcarcinoma.Baunoch D, Moore M, Reyes M, Cotter P, Bloom K, Erlander M, Ma X-J,Sgroi D. US Labs, Irvine, CA; Arcturus, Carlsbad, CA; Harvard Med School,MGH, Boston, MA.

475 Array CGH identifies genes commonly amplified in breastcarcinoma.Witton CJ, Ruffalo T, Cooke TG, King W, Bartlett JMS. Glasgow University,Glasgow, United Kingdom; Vysis Inc, Downers Grove, IL.

476 Down-regulation of ER-� expression with lovastatin in MCF-7 cellscultured with and without tamoxifen.Roman SL, Hohl RJ. University of Iowa, Iowa City, IA.

477 Gene profile correlated to doxorubicin response in advancedbreast cancer.Folgueira MAAK, Carraro DM, Brentani H, Soares FA, Mourao Netto M,Barbosa EM, Caldeira JRF, Oliveira CT, Kaiano JHL, Martins WK, SnitcovskyIML, Alves FB, Reis LFL, Brentani MM. Faculdade de Medicina daUniversidade de Sao Paulo, Sao Paulo, SP, Brazil; Instituto Ludwig paraPesquisa do Cancer, Sao Paulo, SP, Brazil; Hospital do Cancer A. C.Camargo, Sao Paulo, SP, Brazil; Instituto Brasileiro de Controle do Cancer,Sao Paulo, SP, Brazil; Hospital Amaral Carvalho, Jau, SP, Brazil.

478 Indentification of genomic alterations in sub-types of breastcancer using array CGH.Loo LWM, Grove DI, Neal CL, Cousens LA, Schubert EL, Williams EM,Delrow JJ, Trask BJ, Hsu L, Peggy PL. Fred Hutchinson Cancer ResearchCenter, Seattle, WA.

479 Detection of breast cancer related genes by restriction landmarkgenomic scanning (RLGS).Asaga S, Ueda M, Jinno H, Kikuchi K, Ikeda T, Kitajima M. Keio UniversitySchool of Medicine, Tokyo, Japan; TEPCO Hospital, Tokyo, Japan.

480 Elevated expression of transcription regulatory proteins twist andslug in human breast cancer and their clinical significance.Martin TA, Watkins G, Mansel RE, Jiang WG. University of Wales Collegeof Medicine, Cardiff, United Kingdom.

481 The mRNA expression of hTERT in human breast carcinomascorrelates with VEGF expression but not PCNA expression.Kirkpatrick K, Newbold R, Mokbel K. The Princess Grace Hospital,London, United Kingdom.

482 BP1 overexpression is implicated in cell cycle regulation in thebreast cancer cell line MCF7.Fu SW, Berg PE. The George Washington University Medical Center,Washington, DC.

483 Glucosylceramide synthase, an effector of drug resistance, isoverexpressed by breast cancer and upregulated by 17�-estradiol.Liu Y-Y, Giuliano AE, Cabot MC. John Wayne Cancer Institute at SaintJohn’s Health Center, Santa Monica, CA.

9:00-12:00 GENERAL SESSION 4 – Ballroom C

9:00 22. Improved antitumor therapy with Herceptin and Faslodex fordual targeting of HER-2 and estrogen receptor signaling pathwaysin human breast cancers with overexpression of HER-2/neu gene.Pietras RJ, Marquez DC, Chen H-W, Ayala R, Ramos LB, Slamon DJ. UCLASchool of Medicine, Los Angeles, CA.

SAN ANTONIO BREAST CANCER SYMPOSIUM - Friday xxi

9:15 23. Cardiac safety analysis of the first stage of NSABP B-31, arandomized trial comparing the safety and efficacy ofAdriamycin® and cyclophosphamide (AC) followed by Taxol® tothat of AC followed by Taxol® plus Herceptin® in patients (Pts)with operable, node-positive (N+), HER-2 overexpressing breastcancer (HER2+BC).Geyer, Jr. CE, Bryant J, Romond E, Tan-Chiu E, Ewer M, Keefe D, ShannonR, Yothers G, Brown A, Fehrenbacher L, Vogel V, Seay TE, Flynn PJ,Wolmark N. NSABP Operations and Biostatistical Center, Pittsburgh, PA

9:30 24. Induction of apoptosis without change in cell proliferation inprimary breast cancers with neoadjuvant trastuzumab.Chang JC, Mohsin S, Weiss H, Hilsenbeck SG, Gutierrez C, Lucci A, KalidasM, Chamness GC, Osborne K, Elledge R. Baylor College of Medicine andthe Methodist Hospital, Houston, TX; Baylor College of Medicine,Houston, TX.

9:45 25. Inhibiting the EGFR/HER2 pathway with gefitinib and/ortrastuzumab restores tamoxifen sensitivity in HER2-overexpressing tumors.Bharwani L, Schiff R, Mohsin SK, Hilsenbeck SG, DiPietro M, Wakeling AE,Osborne CK. Baylor College of Medicine, Houston, TX; AstraZeneca,Macclesfield, United Kingdom.

10:00 26. Molecular classification of tamoxifen-responsive and -resistantbreast carcinomas by gene expression profiling.Jansen M, Foekens J, Van Staveren I, Dirkzwager-Kiel M, Look M, Meijer-Van Gelder M, Dorssers L, Klijn J, Berns E. JNI, Rotterdam, ZH,Netherlands.

10:15 27. Potential involvement of PELP1/MNAR in tamoxifenresistance.Balasenthil S, Broaddus R, Kumar R, Gustafsson J-A, Vadlamudi RK. UTMD Anderson Cancer Center, Houston, TX; Karolinska Institute,Huddinge, Sweden.

10:30 28. Drug metabolizing enzyme polymorphisms and outcome innode-positive breast cancer patients: differential impact ofglutathione-S-transferase subtypes.DeMichele A, Aplenc R, Botbyl J, Gor P, Foulkes A, Stadtmauer E, RebbeckT. University of Pennsylvania, Philadelphia, PA.

10:45 29. Gene expression signatures associated with clinical outcome inbreast cancer via laser capture microdissection.Ma X-J, Wang W, Salunga R, Tuggle T, Stecker K, Baer TM, Erlander MG,Wittliff JL. Arcturus, Carlsbad, CA; University of Louisville, Louisville, KY.

11:00 30. Microarray-based gene expression signatures for in vitro drugsensitivity in breast cancer. Girard L, Tripathy D, Shah J, Sulahian R, Baggerly K, Coombes K, Gray J,Gazdar AF, Minna JD. UT Southwestern Medical Center, Dallas, TX;UTMD Anderson Cancer Center, Houston, TX; University of California atSan Francisco, San Francisco, CA.

11:15 31. A web-based survey of fertility issues in young women withbreast cancer.Partridge AH, Gelber S, Knudsen K, Laufer M, Rosenberg R, Michele P,Rein A, Winer EP. Dana-Farber Cancer Institute, Boston, MA; YoungSurvival Coalition; Brigham and Women's Hospital, Boston, MA.

11:30 32. Long-term satisfaction with bilateral prophylactic mastectomyand immediate breast reconstruction in genetically predisposedwomen.Bresser PJC, Seynaeve C, Van Gool AR, Brekelmans CTM, Meijers-HeijboerHJ, van Geel BN, Menke-Pluijmers MBE, Claessens AAG, DuivenvoordenHJ, Klijn JGM, Tibben A. Erasmus Medical Center, Rotterdam,Netherlands; Erasmus Medical Center Daniel den Hoed, Rotterdam,Netherlands; Leiden University Medical Center, Leiden, Netherlands.

11:45 33. Prevalence of BRCA1 and BRCA2 mutations in womendiagnosed with bilateral invasive breast cancer.Parlanti AA, Burbidge LA, Shappell HL, Reid JE, Deffenbaugh AM, FryeCA, Critchfield GC. Myriad Genetic Laboratories, Salt Lake City, UT.

12:00-1:00 LUNCH [Ticket Required] – Exhibit Hall D

1:00-2:00 CASE DISCUSSION 2 – Ballroom C

2:00-4:00 MINI-SYMPOSIUM 3 – Ballroom C

The Estrogen Receptor – Still SurprisesSuzanne Fuqua, PhD, Co-ModeratorBaylor College of Medicine, Houston, TXandSteffi Oesterreich, PhD, Co-ModeratorBaylor College of Medicine, Houston, TX

2:00 Introduction

2:00 Molecular insights into endocrine resistance - implication forfuture therapiesStephen R.D. Johnston, MA, PhD, FRCPRoyal Marsden HospitalLondon, England, UK

2:30 ER interactions with AP-1Peter J. Kushner, PhDUniversity of California, San FranciscoSan Francisco, CA

3:00 Estrogen signaling from the plasma membrane in breast cancerEllis R. Levin, MDLong Beach Veterans Administration Medical CenterLong Beach, CA

3:30 BRCA1 and EREliot M. Rosen, MD, PhDLong Island Jewish Medical CenterNew Hyde Park, NY

4:00-4:30 PLENARY LECTURE 3 – Ballroom C

Breast MRI - Where We Are TodayBruce L. Daniel, MDStanford University Stanford, CA

4:30-6:30 POSTER DISCUSSION 3 AND 4 – Park View Atrium

(#1026-1038)

1026 Risk-benefit profile of raloxifene: influence of breast cancer riskfactors.Cauley J, Cummings S, Secrest R, Disch D, Mershon J. University ofPittsburgh, Pittsburgh, PA; University of California, San Francisco, CA; EliLilly and Company, Indianapolis, IN.

1027 Breast cancer prevention using RXR-selective retinoid (Targretin®)in high risk women – initial report of a phase II randomizedclinical trial.Mohsin SK, Elledge RM, Arun B, Miller A, Wu K, Johnson K, Lamph WW,Brown PH. Baylor College of Medicine, Houston, TX; University of TexasM.D. Anderson Cancer Center, Houston, TX; University of Texas HealthScience Center, San Antonio, TX; National Cancer Institute, Bethesda, MD;Ligand Pharmaceuticals, San Diego, CA.

1028 Antiangiogenic tetrathiomolybdate protects against Her2/neu-induced breast carcinoma by hypoplastic remodeling of themammary gland.Pan Q, Kleer CG, Bao LW, Merajver SD. University of Michigan MedicalSchool, Ann Arbor, MI.

1029 Ospemifene inhibits the growth of DMBA-induced mammarytumors in mice.Morello-Read KC, Marchisano C, Wurz GT, DeGregorio MW. Universityof California, Davis, Sacramento, CA.

1030 Glutamine and breast cancer prevention: effect on insulin-likegrowth factor-binding proteins.Harms SA, Todorova VK, Kaufmann Y, Luo S, Babb KB, Klimberg VS.University of Arkansas for Medical Sciences, Little Rock, AR; CentralArkansas Veterans Healthcare System, Little Rock, AR.

1031 A stable-isotope mass spectrometric method for measuring breastepithelial cell proliferation in vivo in women: a promisingbiomarker for chemoprevention studies.Misell LM, Hwang ES, Williams N, Hellerstein MK. KineMed, Inc., 5980Horton St., Suite 470, CAUniversity of California, San Francisco, SanFrancisco, CA; University of California, Berkeley, Berkeley, CA.

SAN ANTONIO BREAST CANCER SYMPOSIUM - Fridayxxii

1032 Estrogen related biomarkers and cellular atypia in ductal lavage(DL) samples from women at high risk for breast cancer.Bhandare D, Golewale N, Geiger A, Nayar R, Chatterton R, Khan S.Feinberg School of Medicine of Northwestern University, Chicago, IL.

1033 MRI is a potential intermediate marker for tamoxifen response inbreast cancer prevention.Finlayson CA, Lewin JM, Rabinovitch R, Robinson WA, Seligman PA, EliasAD, Arya J, Isaacs P. University of Colorado Health Science Center, Denver,CO.

1034 Feasibility of breast tissue sampling in a chemoprevention trialwith histologic biomarker endpoints.Palomares MR, Goldstein L, Lehman CD, Hopper L, Gralow JR. Universityof Washington, Seattle, WA; Phenopath Laboratories, Seattle, WA.

1035 Prophylactic (bilateral) mastectomy prevents contralateral breastcancer (CBC) , without positive impact on survival in BRCAmutation carriers with a previous history of unilateral breastcancer.Seynaeve C, Meijers-Heijboer H, Menke M, van Putten W, Bartels C, vanden Ouweland A, van Geel B, Klijn J, Crepin E, Kliffen M, Brekelmans C.Erasmus MC - Daniel den Hoed Cancer Center, Rotterdam, Netherlands.

1036 Estrogen receptor and proliferation are elevated and deregulatedin hyperplastic unfolded lobules.Allred DC, Mohsin SK, Medina D. Baylor College of Medicine, Houston,TX.

1037 Influence of ductal lavage(DL) findings on tamoxifen decision forhigh risk women.Didwania A, Golewale NH, Khan SA, Priyanath A, Gann P, Hou N.Northwestern Univeristy Feinberg School of Medicine, Chicago, IL.

1038 An estrogen receptor variant with dominant negative activityexerts beneficial influences on mammary tumor development intransgenic mice.Davis VL, Cline JM, Shaikh F, Hughes CL. Duquesne University, Pittsburgh,PA; Wake Forest University School of Medicine, Winston-Salem, NC;Cedars-Sinai Medical Center, Los Angeles, CA; Quintiles, Inc., ResearchTriangle Park, NC.

(#1039-1052)

Radiation Therapy and Breast Conservation

1039 Cosmetic outcome after targeted intraoperative radiotherapy(targit) for early breast cancer.Vaidya JS, Wilson A, Houghton J, Tobias JS, Joseph D, Wenz F, Hilaris B,Massarut S, Keshtgar M, Sainsbury R, Taylor I, D’Souza D, Saunders C,Corica T, Ezio C, Mauro A, Baum M. Middlesex and Whittington Hospitals,University College London, London, London, United Kingdom; MiddlesexHospital, London, London, United Kingdom; Sir Charles Gairdner Hospital,Perth, Australia; Institut für Klinische Radiologie, Mannheim, Germany; OurLady of Mercy New York Medical Centre, New York Medical College, NewYork, NY; Centro di Riferimento Oncologico, Aviano, Italy.

1040 Withdrawn

1041 Excision only for small tubular cancers of the breast.Leonard CE, Howell KA, Shapiro H, Ponce J, Kercher J. Rocky MountainCancer Centers, Littleton, CO; HealthOne Alliance, Denver, CO; ColoradoCancer Registry, Denver, CO; Arapahoe Surgical Associates, Littleton, CO.

1042 Radiosensitization of locally advanced breast cancer withherceptin – initial toxicity results of a phase II trial.Sartor CI, Graham M, Carey L, Dees C, Ollila D, Sherron R, Halle J. UNCSchool of Medicine and Lineberger Comprehensive Cancer Center,Chapel Hill, NC.

1043 Comparing the cost of partial versus whole breast irradiationfollowing breast conserving surgery for early-stage breast cancer.Suh WW, Pierce LJ, Vicini FA, Hayman JA. University of Michigan, AnnArbor, MI; William Beaumont Hospital, Royal Oak, MI.

1044 Long-term results of the British Columbia randomized trial (BCRT)of locoregional radiation (RT) in early breast cancer (BrCa), withcomparative analyses of the N1-3 versus N4+ cohorts.Ragaz J, Phillips N, Manji M, Spinelli JJ, Wilson KS, Knowling M, Coppin C,Weir L, Olivotto I, Coldman AJ. BC Cancer Agency, Vancouver, B.C., Canada.

1045 Predictors of local-regional recurrence in patients with locally-advanced breast cancer treated with neoadjuvant chemotherapy,mastectomy, and radiation.Huang EH, Tucker SL, Strom EA, McNeese MD, Kuerer HM, HortobagyiGN, Buzdar AU, Valero V, Perkins GH, Schechter NR, Hunt KK, Sahin AA,Buchholz TA. The University of Texas M. D. Anderson Cancer Center,Houston, TX.

1046 Factors predictive of having four or more positive axillary lymphnodes in patients with involved sentinel lymph nodes:implications for selection of radiation treatment fields.Shahar KH, Hunt KK, Thames HD, Ross MI, Perkins GH, Kuerer HM, StromEA, McNeese MD, Meric F, Schechter NR, Sahin AA, Middleton LP,Buchholz TA. The University of Texas M. D. Anderson Cancer Center,Houston, TX.

1047 Clinical stage T3 disease or pathologic involvement of four ormore lymph nodes predict for local-regional recurrence in stage IIbreast cancer treated with neoadjuvant chemotherapy andmastectomy without radiation.Garg A, Strom EA, McNeese MD, Buzdar AU, Hortobagyi GN, KuererHM, Perkins GH, Singletary SE, Hunt KK, Schechter N, Sahin AA, Valero V,Tucker SL, Buchholz TA. The University of Texas M. D. Anderson CancerCenter, Houston, TX.

1048 Cell-microenvironment mediated radiation response in breastcancer.Park C, Zhang H, Peng M, Bissell M. University of California, SanFrancisco, CA; Lawrence Berkeley National Laboratory, Berkeley, CA.

1049 Potentiation of radiation-induced subcutaneous fibrosis byconcomitant use of tamoxifen in adjuvant breast cancer treatment.Azria D, Jeanneret Sozzi W, Zouhair A, Gourgou S, Coucke PA, MirimanoffRO, Ozsahin M. CRLC Val d’Aurelle, Montpellier, France; CHUV,Lausanne, Switzerland.

1050 Breathing adapted radiotherapy of breast cancer reduces cardiacand pulmonary irradiation.Pedersen AN, Korreman S, Nyström H, Specht L. Rigshospitalet,Copenhagen, Denmark.

1051 Forward-planned breast intensity modulated radiotherapy(IMRT): a novel method using a 3-D laser camera.Coles CE, Hoole AC, Twyman N, Wilkinson J, Wilson CB, Moody AM.Addenbrookes Hospital, Cambridge.

1052 Early toxicity and cosmesis with MammoSite compared withinterstitial brachytherapy for accelerated partial breastirradiation.Shah NM, Tenenholz T, Berle L, Arthur D, DiPetrillo T, Bornstein B,Kaufman S, Cardarelli G, Zheng Z, Rivard M, Wazer D. Tufts-New EnglandMedical Center, Boston, MA; Brown University, Rhode Island Hospital,Providence, RI; Medical College of Virginia of VCUHS, Richmond, VA.

4:30-7:00 POSTER SESSION 5 & RECEPTION – Exhibit Hall C

(#501-573)

Prognosis and Response Predictions: Prognostic Factors

501 Tumor response as surrogate end-point for survival in metastaticbreast cancer patients: a meta-analysis.Del Mastro L, Sormani MP, Venturini M, Bastholt L, Bastit P, Danova M,Focan C, Fountzilas G, Marschner N, Paul J, Rosso R, Bruzzi P. NationalCancer Res. Inst., Genoa, Italy; Univ. Hospital, Odense, Denmark; CentreHospitalier, Lorient Cedex, France; Policlinico S. Matteo, Pavia, Italy; CentreHosp. St. Joseph, Liege, Belgium; Aristotle University, Thessaloniki, Greece;Clinic Tumor Biology, Freiburg, Germany; Beatson Onc. Centre, Glasgow,United Kingdom.

502 Notch-1 and Notch-2 and their possible clinical significance inhuman breast cancer.Parr C, Mansel RE, Jiang WG. University of Wales College of Medicine,Cardiff, Wales, United Kingdom.

503 Comparison of survival of screen detected breast cancers withsymptomatic cancers of same age (50-65 years) in one unit.Prasad R, Knox FW, Wilson M, Barr L, Baildam AD, Byrne G, Nigel BJ.South Manchester University Hospitals, Manchester, United Kingdom.

SAN ANTONIO BREAST CANCER SYMPOSIUM - Friday xxiii

504 Gene expression profiles and molecular markers to predictdistant metastasis of early stage breast cancers.Wang Y, Atkins D, Zhang Y, Yang F, Jatkoe T, Talantov D, Sieuwerts A,Timmermans M, Berns E, Klijn J, Foekens J. Johnson & Johnson Company,San Diego, CA; Erasmus Medical Center / Daniel den Hoed, Rotterdam,Netherlands.

505 Carbonic anhydrase IX, a biomarker of hypoxia, as a poorprognostic factor in invasive breast cancer: results from 321 casesin a tissue microarray series.Chia SKL, Makretsov N, Cheang M, Yorida E, Hayes M, Gilks B, Harris AL,Huntsman D. British Columbia Cancer Agency, Vancouver, BC, Canada;Vancouver General Hospital, Vancouver, BC, Canada; Institute ofMolecular Medicine, Oxford, United Kingdom.

506 Molecular cytogenetic identification of sub-groups of grade IIIinvasive ductal breast carcinomas with different clinical outcomes.Jones C, Ford E, Gillett C, Ryder K, Merrett S, Reis-Filho JS, Fulford LG,Hanby A, Lakhani SR. Institute of Cancer Research, London, UnitedKingdom; Guy’s Hospital, London, United Kingdom; St James’ Hospital,Leeds, United Kingdom; The Royal Marsden Hospital, London, UnitedKingdom.

507 Prognostic and predictive value of receptor tyrosine kinase (c-erbB-2, VEGFR2), VEGF and phosphorylated p38 MAP kinase(MAPK) following adjuvant endocrine therapy.Linderholm BK, Andersson JS, von Schoultz E, Fernstad R, Linderholm M,Skoogh L, Bergh J. Radiumhemmet, Karolinska Inst. and Hospital,Stockholm, Sweden; Karolinska Hospital, Stockholm, Sweden; St GöransHospital, Stockholm, Sweden.

508 Decreased survival after conversion to serum HER-2/neu positive.Lipton A, Leitzel K, Ali SM, Demers L, Harvey HA, Chaudri-Ross H, Lang R,Hackl W, Hamer P, Carney W. Penn State Hershey Medical Center, Hershey,PA; Lebanon VA Medical Center, Lebanon, PA; Novartis Pharma AG, Basel,Switzerland; Oncogene Science/Bayer Diagnostics, Cambridge, MA.

509 Prognostic factors determine groups with different prognoses inpre- and perimenopausal women with estrogen receptor-positive,node-positive breast cancer treated with goserelin (Zoladex®) orCMF – results from the ZEBRA study.Sauerbrei W, Schumacher M, Cuzick J, Jonat W, Kaufmann M. UniversityHospital Freiburg, Freiburg, Germany; Cancer Research UK, London,United Kingdom; University of Kiel, Kiel, Germany; UniversitätsklinikFrauenklinik, Frankfurt, Germany.

510 Higher PAI-1 levels in lymph node metastases than incorresponding primary tumor tissue correlate significantly withpoor patient outcome in breast cancer.Zemzoum I, Celik K, Kiechle M, Schmitt M, Hoefler H, Harbeck N.Technical University, Munich, Germany.

511 Epidermal growth factor receptor expression correlates with poorsurvival in breast cancer patients treated with doxorubicin-basedneoadjuvant chemotherapy.Buchholz TA, Ang KK, Tu X, Kuerer HM, Esteva FJ, Hortobagyi GN,Cristofanilli M, Singletary SE, Zhang H-Z, Sahin AA. The University ofTexas M. D. Anderson Cancer Center, Houston, TX.

512 HER-2 status in primary breast cancer patients treated in the UKTACT trial – relationship with tumour size, grade, nodalinvolvement and ER status.Johnston SRD, Johnson L, Dowsett M, Bartlett JMS, Ellis I, Bliss JM, Hall E,Barrett-Lee PJ, Ellis P. Institute of Cancer Research, Sutton, Surrey, UnitedKingdom; Royal Marsden Hospital, London, London, United Kingdom;Glasgow Royal Infirmary, Glasgow, Scotland, United Kingdom; Universityof Nottingham, Nottingham, Notts, United Kingdom; Velindre HospitalNHS Trust, Cardiff, Wales, United Kingdom; Guy’s, Kings & St Thomas’sNHS Trust, London, London, United Kingdom.

513 Family history and tumour type: analysis of 2584 patients withbreast cancer comparing in situ with early invasive tumours.Giovannini M, Pedersini R, Frisinghelli M, Auriemma A, Fiorio E, MiccioloR, Cetto GL, Molino A. University of Verona, Verona, Verona, Italy;University of Trento, Trento, Trento, Italy.

514 Serum HER-2/neu dynamics in metastatic breast cancer as anindependent prognostic factor.Schippinger W, Bauernhofer T, Regitnig P, Ploner F, Krippl P, Hofmann G,Lax S, Carney W, Neumann R, Wernecke K-D, Samonigg H. University ofGraz, Graz, Austria; Oncogene Science, Cambridge, MA; Bayer VitalGmbH, Leverkusen, Germany; Humboldt University of Berlin, Institute ofMedical Biometry, Berlin, Germany.

515 Relationship between a prognostic score and a Cox regressionmodel in patients with metastatic breast cancer.Schmid P, Wischnewsky MB, Possinger K. Charite Campus Mitte, HumboldtUniversity, Berlin, Germany; University of Bremen, Bremen, Germany.

516 Prognostic value of circulating autoantibodies in women withprimary breast cancer.Cheung K-L, Tan S-M, Graves R, Pinder S, Robertson J. University ofNottingham, Nottingham City Hospital, Nottingham, United Kingdom.

517 E-cadherin and �-catenin expression in relation to otherprognostic factors and survival in human breast cancer.Goyal A, Jiang WG, Mansel RE. University of Wales College of Medicine,Cardiff, South Glamorgan, United Kingdom.

518 Intramammary tumor location does not influence prognosis, butthe prevalence of axillary lymph node metastases.Janni W, Rack B, Schmidt M, Strobl B, Thieleke W, Gerber B, Sommer H,Friese K. LMU, Munich, Germany.

519 Does depth of invasive breast cancer predict axillary metastasis?Cunningham JE, Jurj AL, Stonerock AE, Oman L, Cupples TE. University ofSouth Carolina, Columbia, SC; South Carolina Cancer Center, Columbia, SC.

520 Age is an independent predictive factor for lymph nodemetastases in non-pleomorphic lobular carcinoma of the breastbut not in the pleomorphic variant.Huang HJ, Neven P, Drijkoningen M, Amant F, Berteloot P, Van Ongeval C,Van Steen A, Van Limbergen E, Van Den Bogaert W, Thomas J, ParidaensR, Vergote I, Christiaens M-R. University Hospital, Leuven, Belgium.

521 The expression and prognostic value of the guanine nucleotideexchange factors (GEFs) TRIO, VAV1 and TIAM-1 in human breastcancer.Lane J, Martin TA, Mansel RE, Jiang WG. University of Wales College ofMedicine, Cardiff, Wales, United Kingdom.

522 Novel genetic markers for prediction of postoperative prognosisin estrogen receptor-negative breast cancer.Nagahata T, Onda M, Sato T, Nishikawa K, Tsumagari K, Nagai H, KasumiF, Yokoyama S, Tsunoda T, Emi M. Nippon Medical School, Kawasaki,Kanagawa, Japan; Nippon Kayaku Co., Ltd., Kita-ku, Tokyo, Japan; CancerInstitute Hospital, Toshima-ku, Tokyo, Japan; Nagano Red Cross Hospital,Nagano, Nagano, Japan; RIKEN, Yokohama, Kanagawa, Japan.

523 Novel molecular prognostic markers for breast cancer; analysiswith 25K cDNA microarray.Onda M, Nagahata T, Tsunoda T, Kasumi F, Nagai H, Emi M. Institute ofGerontology, Nippon Medical School, Kawasaki, Kanagawa, Japan; RIKEN,Yokohama, Kanagawa, Japan; Cancer Institute Hospital, Toshima-ku,Tokyo, Japan.

524 Proportion, percentage, or ratio of axillary nodes: which is thebest prognostic factor?Vinh-Hung V, Verschraegen C, Voordeckers M, Van de Steene J, Storme G.AZ-VUB, Jette, Belgium; The University of New Mexico, Albuquerque, NM.

525 A comparison of keratinocyte growth factor receptor expressionin breast and other cancer tissue.Zang X-P, Lerner MR, Brackett DJ, Pento JT. University of Oklahoma, HSC,Oklahoma City, OK.

526 DCIS heterogeneity affects prognostic assessment.Chapman JW, Axelrod DE, Miller NA, Qian J, Christens-Barry WA, LickleyHLA, Fu Y, Yuan Y, Hanna WM. University of Waterloo, Waterloo,Canada; Rutgers University, Piscataway; University of Toronto, Toronto,Canada; Equipoise Imaging LLC, Ellicott City.

527 Do we need HER2/neu testing in all patients with primary breastcancer?Taucher S, Rudas M, Mader RM, Gnant M, Dubsky P, Bachleitner T, RokaS, Fitzal F, Kandioler D, Sporn E, Mittlboeck M, Jakesz R. UniversityMedical School, Vienna, Austria.

SAN ANTONIO BREAST CANCER SYMPOSIUM - Fridayxxiv

528 Serum carboxyterminal telopeptide of type I collagen is aprogrostic marker in breast cancer patient with bone metastasis.Wakita K, Kohno N, Takao S, Konishi M. Yodogawa Christian Hospital,Osaka, Japan; Hyogo Medical Center for Adults, Akashi, Japan; SaiseikaiNakatsu Hospital, Osaka, Japan.

529 Are prognosis factors for breast cancer different in the elderly?Consequence on the treatment.Dravet F, Campone M, Berton-Rigaud D, Pioud R, Sagan C, Classe JM.Centre Rene Gauducheau, Nantes St Herblain, France; CHU R &GLaennec, Nantes St Herblain, France.

Treatment: Chemotherapy - General

530 Multicenter randomized phase III study evaluatingepirubicin–cyclophosphamide versus epirubicin–docetaxel forfirst-line treatment of metastatic breast cancer: good tolerabilityand efficacy of epirubicin–docetaxel in heavily pretreatedpatients with high tumor load.Blohmer JU, Hauschild M, Hilfrich J, Kleine-Tebbe A, Lichtenegger W, theNord-Ostdeutsche Gesellschaft für Gynäkologische Onkologie (NOGGO)Study Group. Universitätsklinik Berlin Charité, Berlin, Germany;Henriettenstiftung Hannover, Hannover, Germany.

531 Combination anthracycline and taxane chemotherapy in first linemetastatic breast cancer: a meta-analysis.Petrella TM, Trudeau M. Toronto Sunnybrook Regional Cancer Centre,Toronto, ON, Canada.

532 Safety profile of docetaxel in older patients with metastaticbreast cancer.Aapro MS, Olsen SR, Alakl M, Murawsky M, Hurria A. Clinique DeGenolier, Genolier, Switzerland; Aventis Pharmaceuticals, Bridgewater, NJ;Aventis Pharmaceuticals, Antony, France; Memorial Sloan-KetteringCancer Center, New York, NY.

533 Non-smokers have more neutropenia due to gemcitabine, aloneor in combination with docetaxel.Laufman LR, Spiridonidis CH, Laufman H, Baker L, Young D. HematologyOncology Consultants, Inc, Columbus, OH; University of Michigan, AnnArbor, MI; Ohio State University, Columbus, OH.

534 A randomized, phase II trial of weekly paclitaxel versus weeklypaclitaxel+carboplatin for first-line metastatic breast cancer.Robert N, Loesch D, Lindquist D, Ratnam S, Hyman W, Whittaker T, LogieK, Kruger S, Pippen J, Liu L, Goldstein L, Asmar L. US Oncology, Inc.,Houston, TX; Fox Chase Cancer Center, Philadelphia, PA.

535 A multi center phase II study of E7070 in anthracycline and taxanepre treated metastatic breast cancer.Fumoleau P, Viens P, Cottu P-H, De Grève J, Marty M, Delaloge S, Miles D,O’Reilly S, Wardley A, Schmid P, Ravic M, Yule SM. Centre RenéGauducheau, Nantes, France; Institut Paoli Calmettes, Marseille, France;Hôpital des Diaconesses, Paris, France; VUB Academisch Ziekenhuis, Jette,Belgium; Institut Gustave-Roussy, Villejuif, France; Guy’s Hospital, London,United Kingdom; Clatterbridge Oncology Centre, Wirral, United Kingdom;Christie Hospital, Manchester, United Kingdom; Charité Universitätsklinikum,Berlin, Germany; Eisai Limited, London, United Kingdom.

536 Longitudinal serum results of HER-2/neu, EGFR and CA27.29 in arandomized trial comparing dose-intense, biweekly epirubicinfollowed by paclitaxel to 3-weekly epirubicin pluscyclophosphamide followed by paclitaxel for adjuvant therapy ofnodal-positive (1-3 LN) breast cancer.Lueftner DI, Eggemann H, Schildhauer S, Geppert R, Wernecke K,Weigand M, Budner M, Zeiser T, Kohls A, Possinger K, Elling D. ChariteCampus Mitte, Berlin, Germany; Oskar-Ziethen-Krankenhaus, Berlin,Germany; Charite Campus Virchow, Berlin, Germany; Universität, Ulm,Germany; Humaine-Klinikum, Bad Saarow, Germany; Paracelsusklinik,Henstedt-Ulzburg, Germany; Evangelisches Krankenhaus, Ludwigsfelde,Germany.

537 Phase II study of weekly pegylated liposomal doxorubicin anddocetaxel as first-line chemotherapy for metastatic breast cancer.Holmes F, Blum JL, Kruger S, Ratnam S, Liu L, Boehm KA, Asmar L,O’Shaughnessy JA. US Oncology, Inc., Houston, TX.

538 Epirubicin dose-response effect in node-positive breast cancerpatients is independent of HER2 overexpression: 10-yearretrospective analysis of French Adjuvant Study Group 05 trial.Arnould L, Fargeot P, Bonneterre J, Fumoleau P, Kerbrat P, Voigt J-J, RocheH, Montcuquet P, Chapelle-Marcillac I, Bremond A. Centre Georges-Francois Leclerc, Dijon, France; Centre Oscar Lambret, Lille, France; CentreRene Gauducheau, Nantes, France; Centre Eugene Marquis, Rennes,FranceInstitut Claudius Regaud, Toulouse, France; Clinique Saint-Vincent,Besancon, France; Pharmacia SA, Guyancourt, France; Centre Leon Berard,Lyon, France.

539 Optimizing doses of a first line chemotherapy treatmentcontaining epirubicin, paclitaxel and capecitabine (TEX) inmetastatic breast cancer.Einbeigi Z, Bergström D, Hatschek T, Malmberg M. Sahlgrenska UniversityHospital, Göteborg, Sweden; Roche AB, Stockholm, Sweden; KarolinskaHospital, Stockholm, Sweden; Helsingborg Hospital, Helsingborg, Sweden.

540 Gemcitabine 120 min. iv. infusion (10 mg/m _ /min), is a safe andeffective schedule in advanced breast cancer patients.Morandi P, Merlini L, Molino A, Bassan F, Pedersini R, Nicoletti L,Santacatterina R, Zamberlan F. S Bortolo General Hospital, Vicenza, Italy;Verona, Italy; Thiene, Italy; Eli-Lilly, Italy.

Treatment: Hormone Replacement Therapy

541 Dietary phytoestrogens stimulate breast cancer cell proliferationvia estrogen receptor-mediated signalling mechanisms.Limer JL, Burdall SE, Speirs V. University of Leeds, Leeds, West Yorkshire,United Kingdom.

542 Current HRT (hormone replacement therapy) use at diagnosis ofbreast cancer does not adversely affect survival fromsymptomatic or screen detected breast cancers in post-menopausal women.Prasad R, Wilson M, Morris J, Byrne G, Bundred NJ. South ManchesterUniversity Hospitals, Manchester, United Kingdom; University Hospital ofSouth Manchester, Manchester, United Kingdom.

543 A descriptive survey of treatments for menopausal symptoms inhealthy women and breast cancer patients.Van de Put B, Evers G, Morales L, Van Ongeval C, Van Steen A, ParidaensR. Catholic University of LeuvenUniversity Hospitals Leuven, Leuven,Belgium.

544 In vitro studies of breast cancer and implications in vivo.Franke HR, Vermes I. Medisch Spectrum Twente Hospital Group,Enschede, Netherlands.

Treatment: Other Therapies

545 Intravenous and oral ibandronate reduces the risk of skeletalrelated events in metastatic bone disease from breast cancer.Body J-J, Tripathy D, Pecherstorfer M, Bergstrom B. Universite Libre deBruxelles, Brussels, Belgium; University of Texas Southwestern MedicalCenter, Dallas, TX; Wilhelminenspital, Vienna, Austria; F. Hoffmann-LaRoche Inc., Nutley, NJ.

546 Improving clinical outcomes and treatment convenience with oralibandronate for metastatic bone disease.Bell R, Coleman R, Bergstrom B. Cancer Services Medical Oncology,Geelong, VIC, Australia; Weston Park Hospital, Sheffield, United Kingdom;F. Hoffmann-La Roche Inc., Nutley, NJ.

547 Safety and tolerability of oral ibandronate therapy in patientswith metastatic bone disease.Diel IJ, Pecherstorfer M, Body J-J, Tripathy D, Bergstrom B. CGG-KlinikGmbH, Mannheim, Germany; Wilhelminenspital, Vienna, Austria;Universite Libre de Bruxelles, Brussels, Belgium; University of TexasSouthwestern Medical Center, Dallas, TX; F. Hoffmann-La Roche Inc.,Nutley, NJ.

548 Intravenous and oral ibandronate alleviates pain in patients withskeletal metastases from breast cancer.Tripathy D, Body J-J, Diel IJ, Bergstrom B. University of TexasSouthwestern Medical Center, Dallas, TX; Universite Libre de Bruxelles,Brussels, Belgium; CGG-Klinik GmbH, Mannheim, Germany; F. Hoffmann-La Roche Inc., Nutley, NJ.

SAN ANTONIO BREAST CANCER SYMPOSIUM - Friday xxv

549 Hyperthermia enhances drug delivery and efficacy of pegylatedliposomal doxorubicin in chest wall metastases of breast cancer.Park JW, Krishnan KJ, Stauffer P, Diedrich C, Hsu J, Rugo H, Sneed P. UCSFComprehensive Cancer Center, San Francisco, CA.

Tumor Cell Biology: Angiogenesis

550 Interleukin-7 induced lymphangiogenesis is mediated byautocrine secretion of vascular endothelial growth factor-D(VEGF-D) in endothelial cells.Al-Rawi MAA, Mansel RR, Jiang WG. University of Wales College ofMedicine, Cardiff, Wales, United Kingdom.

551 Predictive value of the efficacy of treatment with letrozole ofendostatin and bFGF serum levels.Alba E, Gonzalez FJ, Antonio L, Ramon C. Hospital Clinico Universitario“Virgen de la Victoria”, Malaga, Malaga, Spain; Instituto Valenciano deOncología, Valencia, Valencia, Spain; Hospital Universitari Dr. Josep Trueta,Girona, Girona, Spain.

552 Angiomotin and angiomotin like proteins, their expression andcorrelation with angiogenesis in human breast cancer.Jiang WG, Watkins G, Mansel RE. University of Wales College ofMedicine, Cardiff, Wales, United Kingdom.

553 Withdrawn

554 Quantitative study of the angiogenic profile of inflammatory andnon-inflammatory breast cancer using real-time RT-PCR.Van der Auwera I, Benoy I, Elst H, Van Laere S, Van Marck EA, Colpaert C,Van Dam P, Vermeulen PB, Dirix LY. AZ Sint-Augustinus, Wilrijk, Antwerp,Belgium; University Hospital Antwerp, Edegem, Antwerp, Belgium.

555 Inhibitory effect of tumor progression and gene expressionprofiling using GW654652, KDR/Flk-1 tyrosine kinase inhibitor.Huh J-I, Calvo A, Stafford J, Cheung M, Kumar R, Gadisetti C, Green JE.NCI/NIH, Bethesda, MD; GlaxoSmithKline, Research Triangle Park, NC.

556 Correlation between Endothelin-1, Endothelin-A- and Endothelin-B-Receptor expression, VEGF expression and angiogenesis inbreast cancer: high throughput tissue microarray analysis.Wulfing P, Kersting C, Tio J, Zilkens K, Diallo R, Wulfing C, Bocker W,Kiesel L. University of Munster, Munster, Germany.

Tumor Cell Biology: Cell Biology

557 Enhancing targeted radiotherapy with 64Cu-ATSM by 2-deoxyglucose: mechanism of action.Aft R, Lewis J, Zhang F, Welch M. Washington University, St. Louis, MO.

558 The putative signalling pathways in Interleukin-7 (IL-7) inducedgrowth of breast cancer cells.Al-Rawi MAA, Mansel RE, Jiang WG. University of Wales College ofMedicine, Cardiff, South Glamorgan, United Kingdom.

559 Breast cancer cell adhesion to mineralised matrices is enhancedby her2/neu amplification and aberrant Ras signaling.Pickering LM, Mansi JL, Colston KW. St. George’s Hospital MedicalSchool, London, United Kingdom.

560 Expression of RBMX, the X-chromosome homologue of the Y-chromosome RBM gene, correlates inversely with the expressionof CD105 (endoglin) in breast cancer.Gomez-Esquer F, Martinez-Arribas F, Agudo D, Nunez-Villar M-J, Lucas R,Tejerina A, Schneider J. Universidad Rey Juan Carlos, Madrid, Spain;Fundacion Tejerina, Madrid, Spain.

561 Effects of endogenous adenosine on cell proliferation in anti-hormone-sensitive and resistant MCF-7 human breast cancer cells.Clark JH, Broadley KJ, Nicholson RI, Kidd EJ. Cardiff University, Cardiff,South Glamorgan, United Kingdom.

Tumor Cell Biology: Genetics

562 Genomic patterns of loss of heterozygosity in disease free stromaadjacent to primary breast carcinomas: potential clues to cancerdevelopment and metastasis.Ellsworth DL, Ellsworth RE, Love B, Deyarmin B, Lubert SM, Mittal V,Somiari RI, Shriver CD. Windber Research Institute, Windber, PA;Invitrogen Life Science Software, Frederick, MD; Walter Reed ArmyMedical Center, Washington, DC.

563 Building a gene expression predictive classifier of lymph nodepositive breast cancer.Hergenroeder PF, Peters DG, Handley D, Lyons-Weiler J, Dabbs D, BrufskyAM. UPMC, Pittsburgh, PA; University of Pittsburgh, Pittsburgh, PA;Magee Womens’ Hospital UPMC, Pittsburgh, PA.

564 Array-based comparative genomic hybridization (aCGH) analysisof premenopausal breast cancer.Varma G, Pryshchepava A, Huang H, Groth J, Varma R, Nowak N,McQuaid D, Conroy J, Mahoney M, Moysich K, Falkner K, Geradts J.Roswell Park Cancer Institute, Buffalo, NY.

565 Loss of heterozygosity in primary breast carcinomas andmetastatic tumors of the axillary lymph nodes.Ellsworth RE, Ellsworth DL, Deyarmin B, Sarachine M, Hooke J, Somiari RI,Shriver CD. Windber Research Institute, Windber, PA; Walter Reed ArmyMedical Center, Washington, DC.

566 Differential gene expression patterns in lymphoblastoid cell lines frompatients heterozygous for BRCA1 and BRCA2 germline mutations.Brazil LC, Dexter T, Fenwick KI, Ross GM, Weber B, Vivanco M, AshworthA. Institute of Cancer Research, London, United Kingdom; University ofPennsylvania, Philadelphia, PA.

567 Associations between breast cancer susceptibility genepolymorphisms and clinicopathological features.Han W, Kang D, Park IA, Kim SW, Noh D-Y. Seoul National UniversityCollege of Medicine, Seoul, Republic of Korea.

568 Tissue microarrays: accurate assessment of protein and DNAtargets requires 3 cores per tumor sample.Bane AL, Tjan S, Have C, Earle TL, Andrulis IL, O’Malley FP. SamuelLunenfeld Research Institute, Mount Sinai Hospital, University of Toronto,Toronto, ON, Canada.

569 HER2, estrogen receptor and methylenetetrahydrofolate genepolymorphisms in breast cancer.Dalay N, Akisik E, Deligezer U. Istanbul University Oncology Institute,Istanbul, Turkey.

570 A common 936 C/T gene polymorphism of vascular endothelialgrowth factor is associated with decreased breast cancer risk.Krippl P, Langsenlehner U, Renner W, Samonigg H. Karl-FranzensUniversity, Graz, Austria.

Tumor Cell Biology: Stages of Cancer Development

571 High throughput proteomics and biological variation analysis ofdifferentially expressed proteins in infiltrating ductal carcinomaof the breast.Somiari RI, Russell S, Sullivan A, Somiari SA, Brzeski H, Hu H, Jordan R,Hooke J, Shriver CD. Windber Research Institute, Windber, PA; WalterReed Army Medical Center, Washington, DC.

572 Characterization of a molecular genetic profile for lobular neoplasia.Mastracci TL, Tjan S, O’Malley FP, Andrulis IL. Samuel Lunenfeld ResearchInstitute, Mount Sinai Hospital, Toronto, ON, Canada; University of Toronto,Toronto, ON, Canada; Mount Sinai Hospital, Toronto, ON, Canada.

573 A subset of normal and hyperplastic appearing mammary ductalcells display invasive features.Man YG, Mattu R, Zhang R, Yousefi M, Sang QXA, Shen T. The ArmedForces Institute of Pathology, Washington, DC; Florida State University,Tallahassee, FL; Temple University Hospital, Philadelphia, PA.

Saturday, December 6

7:00-9:00 POSTER SESSION 6 & CONTINENTAL BREAKFAST

(#601-685) – Exhibit Hall C

Prognosis and Response Predictions: Prognostic Factors - Methods

601 HER2 status determination: significance of chromosome 17polysomy identified using 2-colour FISH.Gaiser T, Hofmann MK, Kneitz H, Maas G, Rueschoff J, Henkel T, Weng L,Schmidtgen C, Gross C. Klinikum Kassel, Kassel, Germany; Penzberg, Germany.

SAN ANTONIO BREAST CANCER SYMPOSIUM - Fridayxxvi

602 HER-2/neu overexpression: immunohistochemistry (IHC) orfluorescence in-situ hybridization (FISH)?Bubis JA, Weaver DL, Wells WA, Cole BF, Memoli V, Cates J, Schwartz G,Muss HB, Kaufman PA. Dartmouth-Hitchcock Medical Center andNorris Cotton Cancer Center, Lebanon, NHFletcher-Allen Health Care &Vermont Cancer Center, Burlington, VT.

603 A novel IHC high-throughput screening process for breastprognostic markers identified on cDNA microarrays.Platero S, Hudson R, Nelson R, Katherine K, Sporn T, Timothy F. TripathOncology, Durham, NC; Duke University Medical Center, Druham, NC.

604 HER2 status population screening of breast carcinoma in Poland -immunohistochemical evaluation of 5946 cases.Olszewski WT, Olszewski WP, Mrozkowiak A, Zablotna R. Institute ofOncology, Warsaw, Poland; Roche Polska, Warsaw, Poland.

605 Correlation of serum HER-2/neu extracellular domain levels inmetastatic breast cancer with the expression of HER-2/neudetermined by immunohistochemistry in primary tumors.Witzel I, Thomssen C, Pantel K, Neumann R, Carney W, Loening T,Jaenicke F, Mueller V. University Hospital Hamburg-Eppendorf, Hamburg,Germany; Oncogene Diagnostics, Cambridge, MA; Bayer Vital GmbH,Leverkusen, Germany.

606 Interlaboratory validation of HER2 testing using tissue microarray.Diaz LK, Gupta R, Kidwai N, Sneige N, Wiley EL. Feinberg School ofMedicine Northwestern University, Chicago, IL; MD Anderson CancerCenter (MDACC), Houston, TX.

607 Development of a novel tissue acquisition protocol for biomarkerstudies in early stage breast cancer.Tebbit CL, Ellis M, Marks JR, Bentley RC, Mann G, Soo MS, Rosen E, BakerJ, Leight G, Olson JA. Duke University Medical Center, Durham, NC.

608 Micromethod for determination of uPA and PAI-1 frompreoperative core-needle biopsies in breast cancer.Abraha RS, Thomssen C, Harbeck N, Mueller V, Baack K, Schmitt M,Jaenicke F. Universitaetsklinikum Eppendorf, Hamburg, Germany;Technische Universitaet Munich, Munich, Germany.

609 Differential protein expression in inflammatory and non-inflammatory breast cancer using a tissue microarray.Van den Eynden G, Van Laere S, Van der Auwera I, Colpaert C, Kleer CG,Vermeulen PB, Dirix LY, Van Marck EA. AZ Sint-Augustinus, Wilrijk,Antwerp, Belgium; University Hospital Antwerp, Edegem, Antwerp,Belgium; University of Michigan Medical School, Ann Arbor, MI.

610 Correlation of CellAnalysis QCA imaging system with ERquantification by radioimmunoassay and manualimmunohistochemistry.Clatch R, Diaz L, Wang D. Lake Forest Hospital, Lake Forest, IL;Northwestern Memorial Hospital, Chicago, IL.

611 Quantitative image analysis of GOLDFISH, (a first generationgold-facilitated autometallographic bright field in-situhybridization assay) for HER2 gene amplification in invasivebreast cancer.Hicks D, Ruddy T, Borthwick D, Hainfeld J, Pettay J, Downs-Kelly E, Budd T,Powell R, Tubbs R. Cleveland Clinic Foundation, Cleveland, OH; AppliedImaging Corporation, Santa Clara, CA; Nanoprobes, Yaphank, NY.

612 Gene expression profiling predicts clinical outcome of nodenegative breast cancer using cDNA microarray.Tsumagari K, Onda M, Chiziiwa K, Nagahata T, Kasumi F, Akiyama F,Sakamoto G, Emi M. Gerontology Institution, 1-396 Kosugi-choNakahara-ku Kawasaki, Kanagawa, Japan; Miyazaki Medical College, 5200Kihara Kiyotake-cho Miyazaki-gun, Miyazaki, JapanCancer Institute Tokyo,1-18-1 Toshima-ku, Tokyo, Japan.

Epidemiology and Outreach: Racial Aspects

613 African-American patients with breast cancer have worse overallsurvival than Caucasian and Hispanic patients after mastectomyand doxorubicin-based chemotherapy: data from twoindependent data sets.Woodward WA, Huang EH, McNesse MD, Perkins GH, Tucker SL, StromEA, Schechter NR, Middleton LP, Hunt KK, Hortobagyi GN, Gwyn KM,Buchholz TA. MD Anderson Cancer Center, Houston, TX.

614 Differences in prognostic biomarkers in postmenopausal AfricanAmerican and Caucasian Women.Rao SB, Liang N-C, Walker SD. Union Memorial Hospital, Baltimore, MD;University of Maryland, Baltimore, MD.

615 Body mass index and prognostic factors among Mexican-American women with breast cancer.Santillan AA, Riedner CC, Saltzstein EC. Texas Tech University BreastCancer Center, El Paso, TX.

616 Prevalence of steroid receptors and HER 2/neu in breast canceramong Mexican-American women.Santillan AA, Riedner CC, Saltzstein EC. Texas Tech University BreastCancer Center, El Paso, TX.

Epidemiology and Outreach: Epidemiology

617 Temporal patterns in infiltrating ductal and lobular carcinomarates and their relationships to combined hormone replacementtherapies.Chu KC, Anderson WF. NCI, Bethesda, MD.

618 Comparison of preinvasive and invasive breast carcinomas in thesurveillance, epidemiology, and end results program.Anderson WF, Chu KC. National Institutes of Health, Bethesda, MD.

619 Trends in inflammatory breast carcinoma incidence and survival:the surveillance, epidemiology, and end results program at theNational Cancer Institute.Hance KW, Anderson WF, Devesa SS, Levine PH. National CancerInstitute, Bethesda, MD; George Washington University, Washington, DC.

620 Markedly improved survival in patients with systemic metastaticbreast cancer during a twenty year period - population basedregistry data from the Stockholm health care region.Lekberg TG, Rutqvist L-E, Adolfsson J, Almbrandt J, Johansson H, FornanderT, Rotstein S, von Shoultz E, Bergh J. Karolinska Institute and Hospital,Stockholm, Sweden; Huddinge University Hospital, Stockholm, Sweden.

621 Breast biopsy utilization: a population-based study.Ghosh K, Melton III LJ, Sellers TA, Grant CS, Sterioff S, Brandt KR, SumanVJ, Hartmann LC. Mayo Clinic, Rochester, MN.

622 The demographics of breast cancer survival; is it sociology orbiology?Hiotis KL, Ye W, Sposto R, Skinner KA. New York University, New York,NY; University of Southern California, Los Angeles, CA.

623 Bone mineral density in women with and without a history ofbreast cancer (BC).Van Poznak CH, Elkin E, Norton L, Hudis C. Memorial Sloan-KetteringCancer Center, New York, NY.

624 The incidence and time course of venous thromboembolismamong Californians with breast cancer.Chew HK, Wun T, Zhou H, Harvey D, White RH. UC Davis, Sacramento,CA; UC Davis, Davis, CA.

625 Comparative analysis of patient demographics and tumorcharacteristics from HER-2/neu amplified FISH database andMUSC tumor registry database.Kneuper Hall R, Skorupa A, Metzner-Sadurski J, Wolff D, Gupta R.Medical University of South Carolina, Charleston, SC; Cancer Centers ofthe Carolinas, Greenwood, SC; Virginia Commonwealth University,Richmond, VA.

626 The frequency of breast conserving therapy and factorsinfluencing its use for the treatment of early stage breastcarcinoma in Kentucky.Musich DP, Tucker TC, Paris KJ, Spanos, Jr. WJ. University of Louisville,Louisville, KY; University of Kentucky, Lexington, KY.

627 The characteristics of breast cancer and gastrointestinal (GI)carcinomas occuring in the same patients.Pappo I, Karni T, Stahl-Kent V, Sandbank J, Wassermane I, Halevy A. AssafHarofeh Medical Center, Zerifin, Israel.

628 The role of socioeconomic status on annual incidence of ductalcarcinoma in situ diagnosis.Sattelberg KH, Dick AW, Sorbero MES, Griggs JJ. University of Rochester,Rochester, NY; RAND, Pittsburgh, PA.

SAN ANTONIO BREAST CANCER SYMPOSIUM - Saturday xxvii

629 Development of second malignancy in conjunction with primarybreast cancer; implications for surveillance and prevention.Siziopikou KP, Soldat-Schumacher S, Sluderski R, Gattuso P. LoyolaUniversity Medical Center, Maywood, IL; Rush Presbyterian St. Luke’sMedical Center, Chicago, IL.

630 High frequency of G/C transversion on p53 gene in breast cancers.Chen F-M, Hou M-F, Wang J-Y, Ou-Yang F, Hsieh J-S, Lin S-R. KaohsiungMedical University Hospital, Kaohsiung, Taiwan.

631 Determinants of survival after inflammatory breast cancer. Apopulation based study.Verkooijen H, Vlastos G, Fioretta G, Neyroud I, Kurtz J, Schaefer P, SappinoP, Bouchardy C. Geneva University, Geneva, Switzerland; GenevaUniversity Hospitals, Geneva, Switzerland.

632 Male breast cancer: why is the incidence increasing?Hodgson NC, Button J, Franceschi D, Moffat FL. Univeristy of Miami,Miami, FL.

Treatment: Chemotherapy - High Dose

633 Superiority of tandem high-dose chemotherapy overconventionally-dosed chemotherapy in unselected patients withmetastatic breast cancer: the International Randomized BreastCancer Dose Intensity Study.Crown J, Leyvraz S, Perey L, Verrill M, Guillem V, Efremidis A, Garcia-Conde Bru J, Welch R, Montes A, Piazza E, Rappaport B, Pienkowski T,Skotnicki A, Cameron D, Vahdat L, Bobev DG, Bertelli G, Leonard R,Baselga B. EBDIS Headquarters, 12 Herbert Place, Dublin 2, Ireland.

634 Up front tandem high-dose chemotherapy compared to standardchemotherapy with doxorubicin and paclitaxel in metastaticbreast cancer: updated results of a randomized trial.Schmid P, Schippinger W, Nitsch T, Huebner G, Kreienberg R, Schultze W,Hausmaninger H, Wischnewsky MB, Lüftner D, Samonigg H, Possinger K.Charite Campus Mitte, Humboldt University, Berlin, Germany;Universitätsklinikum, Graz, Austria; Franziskus Hospital, Bielefeld, Germany;Westpfalz-Klinikum, Kaiserslautern, Germany; Universitätsfrauenklinik, Ulm,Germany; Humaine Klinikum, Bad Saarow, Germany; Landesklinik, Salzburg,Austria; University of Bremen, Bremen, Germany.

Treatment: Chemotherapy - Support/Antiemetics

635 Palonosetron is more effective than ondansetron/dolasetron inpreventing chemotherapy-induced nausea and vomiting inpatients with breast cancer: combined results of 2 phase 3 trials.Hudis CA, Hainsworth JD, Perez EA, Macciocchi A. Memorial Sloan-Kettering Cancer Center, New York, NY; Sarah Cannon Cancer Center,Nashville, TN; Mayo Clinic Jacksonville, Jacksonville, FL; Helsinn HealthcareSA, Pambio-Noranco, Lugano, Switzerland.

636 The oral neurokinin-1 antagonist aprepitant added to standardantiemetics provided equal efficacy in female and male patientsreceiving highly emetogenic chemotherapy: combined data from2 phase III clinical trials.Gralla RJ, Carides AD, Ianus J, Elmer M, Evans JK, Horgan KJ. New YorkLung Cancer Alliance, New York City, NY; Merck Research Laboratories,West Point, PA.

637 Randomized, double-blind study comparing homeopathy(cocculine) to placebo in prevention of nausea/vomiting amongpatients receiving adjuvant chemotherapy for breast cancer.Genre D, Tarpin C, Braud AC, Camerlo J, Protiere C, Eisinger F, Viens P.Institut Paoli Calmettes, Marseille, France.

638 Epoetin alpha prevents anemia and transfusions in patients (pts)receiving dose-dense sequential chemotherapy (ETC).Moebus V, Kurbacher C, Nitz U, Untch M, Eidtmann H, duBois A, KuhnW, Lueck H-J, Thomssen C, Jackisch C. Staedtische Kliniken, Frankfurt,Germany; University of Koeln, Germany; Univ of Duesseldorf, Germany;Univ of Muenchen/Grosshadern, Germany; Univ of Kiel, Germany; HSK-Kliniken Wiesbaden, Germany; Univ of Bonn, Germany; Univ ofHannover, Germany; Univ of Hamburg, Germany; Univ of Marburg,Germany.

639 Early treatment of mild anemia with once-weekly epoetin alfasignificantly improves hemoglobin and quality of life in early-stage breast cancer patients during conventional adjuvantchemotherapy.Hudis CA, Williams D. Memorial Sloan-Kettering Cancer Institute, NewYork, NY; Ortho Biotech Products, L.P., Bridgewater, NJ.

640 Darbepoetin alfa 3.0 mcg/kg every 2 weeks improves hemoglobinand quality of life in a subset of breast cancer patients in acommunity-based trial of patients with chemotherapy-inducedanemia.Blayney DW, Vadhan-Raj S, Mirtsching BC, Tomita D, Colowick A.Wilshire Oncology Medical Group, Pomona, CA; University of Texas MDAnderson Cancer Center, Houston, TX; Center for Oncology Researchand Treatment, Dallas, TX; Amgen, Inc., Thousand Oaks, CA.

641 Dosing patterns and clinical outcomes of erythropoietic agentsfor the treatment of anemia in patients with nonmyeloidmalignancies receiving chemotherapy.Schwartzberg L, Tomita D, Stolshek B. The West Clinic, Memphis, TN;Amgen Inc., Thousand Oaks, CA.

642 A risk model to predict chemotherapy dose attenuation inpatients with breast cancer.Agboola O, Crawford J, Dale D, Lyman GH, for the ANC Study Group.University of Rochester Medical Center, Albany, NY; Duke UniversityMedical Center, Durham, NC; University of Washington, Seattle, WA;University of Rochester Medical Center, Rochester, NY.

643 Erythropoietin reduces chemotherapy-induced anemia duringadjuvant dose-intensified, short-duration epirubicin andcyclophosphamide therapy for node positive breast cancerpatients.Kahlert S, Bauerfeind I, Ditsch N, Untch M. Klinikum Grosshadern,Ludwig-Maximilians-Universitaet, Munich, Germany.

644 Control of chemotherapy induced nausea and vomiting and effecton daily life of breast cancer patients: evidence from the ANCHORstudy.Daugaard G, de Pouvourville G, Cruciani G, Hansen M, Mavros P, DeusonRR. Rigshospitalet, Copenhagen, Denmark; Institut Gustave Roussy(I.G.R.), Villejuif, France; Ospital Lugo di Ravenna, Lugo di Ravenna, Italy;Hilleroed Hospital, Hilleroed, Denmark; Merck & Co., Inc., WhitehouseStation, NJ.

645 The impact of chemotherapy-induced nausea and vomiting onbreast cancer patients, health resource utilization and costs inGermany.Ihbe-Heffinger A, Ehlken B, Bernard R, Berger K, Eichler H-G, Deuson RR,Thodtmann J, Lordick F. Klinikum Rechts der Isar, Technische Universitat,Munich, Germany; Medical Economic Research Group, Munich,Germany; Merck & Co., Inc., Whitehouse Station, NJ; University of ViennaMedical School, Vienna, Austria.

Treatment: Cost-Effectiveness

646 Cost-effectiveness projections of anastrozole vs. tamoxifen asinitial adjuvant therapy in ER-positive early breast cancer.Hillner BE. Virginia Commonwealth University, Richmond, VA.

647 The cost-effectiveness of microarray analysis in premenopausalwomen with early stage breast cancer.Oestreicher N, Veenstra DL, Linden HM, Ramsey SD, van ‘t Veer L.University of Washington, Seattle, WA; Fred Hutchinson Cancer ResearchCenter, Seattle, WA; Netherlands Cancer Institute, Amsterdam,Netherlands.

648 Canadian cost-effectiveness analysis of anastrozole versustamoxifen in early breast cancer.Verma S, Rocchi A, Cheung S. Ottawa Regional Cancer Centre, Ottawa,ON, Canada; Axia Research, Hamilton, ON, Canada; AstraZeneca,Mississauga, ON, Canada.

649 A cost benefit analysis of first line letrozole in hormone sensitiveadvanced breast cancer using time to chemotherapy as a measureof benefit.Dranitsaris G, Rayson D. Cancer Cancer Ontario, Toronto, ON, Canada;Queen Elizabeth II Health Sciences Centre, Halifax, NS, Canada.

SAN ANTONIO BREAST CANCER SYMPOSIUM - Saturdayxxviii

Treatment: Patient Management

650 Evaluation of compliance with guidelines for the treatment ofearly stage breast cancer.Jain P, Frolkis JP, Silverman P, Shenk R, Hanks S, Wiesner G, Fu P,Overmoyer B. Case Western Reserve University/University Hospitals ofCleveland, Cleveland, OH.

651 Is pregnancy safe after breast cancer?Vlastos G, Verkooijen H, Keller J, Fioretta G, Neyroud I, Kurtz J, Schaefer P,Sappino P, Bouchardy C. Geneva University Hospitals, Geneva,Switzerland; Geneva University, Geneva, Switzerland.

652 Lobular atrophy a predictive marker of chemotherapy inducedmenopause.Badve S, Miller KD, Goulet R, Mehrotra SP. Indiana University School ofMedicine, Indianapolis, IN.

653 The inflammatory breast cancer registry: preliminary findingsfrom 50 patients.Levine PH, Zolfaghari L. The George Washington University School ofPublic Health and Health Services, Washington, DC.

654 Synchronous bilateral breast cancer: incidence, presentation andfindings.Crowe JP, Patrick RJ, Rybicki LA, Grundfest-Broniatowski SF, Kim JA, LeeKB. The Cleveland Clinic Foundation, Cleveland, OH.

655 The efficacy and safety of black cohosh for managing menopausalsymptoms in breast cancer survivors.Morris K, Look RM, Hudson V, Toth-Fejel S, Pommier R, Walts D, HomerL, Johnson N. Legacy Cancer Services and Oregon Health & SciencesUniversity, Portland, OR.

656 Patterns of and relationships between anemia and fatigue duringadjuvant chemotherapy treatment for early stage breast cancer: asingle institution study.Stricker CT, Stein S, Matthews G. Hospital of the University ofPennsylvania, Philadelphia, PA.

657 Canadian oncologists’ attitudes towards guideline developmentand outcomes of clinical trials based on results of the ATAC trial.Verma S, Trudeau M. Ottawa Regional Cancer Centre, Ottawa, ON, Canada;Toronto Sunnybrook Regional Cancer Centre, Toronto, ON, Canada.

Treatment: Psychosocial Aspects

658 “Doctor, don’t toss that coin”. Breast cancer patients’ preferencesfor different descriptions of randomisation compared withphysicians’ practice.Jenkins VA, Fallowfield LJ. Brighton and Sussex Medical School, Brighton,East Sussex, England, United Kingdom.

659 Psychosocial adjustment of Hispanic families affected by breast cancer.Ramirez AG, Aparicio-Ting FE, Miller AR, San Miguel de Majors SL, Pollock BH.Baylor College of Medicine, San Antonio, TX; Cancer Therapy and ResearchCenter, San Antonio, TX; San Antonio Cancer Institute, San Antonio, TX.

660 Effects of physician-patient communication on breast cancersurvivors’ satisfaction with information.Mallinger JB, Griggs JJ, Sorbero MES, Brooks B, Waterman MR, Shields CG.University of Rochester, Rochester, NY; RAND, Pittsburgh, PA.

661 Adjuvant taxane and block sequential anthracycline regimenspredict post treatment cognitive morbidity.Verrill MW, Rodgers J, Morse RC, Kendell K, Wesnes K, Marshall I,Manktelow TC. Newcastle General Hospital, Newcastle upon Tyne,United Kingdom; University of Newcastle, Newcastle upon Tyne, UnitedKingdom; CDR Research Ltd, Reading, United Kingdom.

662 The short-term neuropsychological effects of chemotherapyamong breast cancer survivors.Collins B, Bielajew C, Stewart A, Tomiak E. Ottawa Hospital, Ottawa, ON,Canada; University of Ottawa, Ottawa, ON, Canada; Ottawa RegionalCancer Centre, Ottawa, ON, Canada.

Tumor Cell Biology: Antiestrogens

663 Using proteomics to identify changes in protein profilesassociated with tamoxifen treatment of MCF-7 cells.Murphy CE, Craven R, Banks R, Lansdown M, Speirs V. University ofLeeds, Leeds, West Yorkshire, United Kingdom; Cancer Research UK,Leeds, West Yorkshire, United Kingdom; United Leeds Teaching Hospitals,Leeds, West Yorkshire, United Kingdom.

664 The presence and timing of tamoxifen and its effect on theradiosensitivity of MCF-7 breast cancer cells.Singla R, Albuquerque K, Creech S, Albain KS, Vaughan A. LoyolaUniversity Medical Center, Maywood, IL.

Tumor Cell Biology: Antigens and Markers

665 Osteoprotegerin (OPG) and tumor necrosis factor-related apoptosisinducing ligand (TRAIL) are expressed in human breast tumors.Van Poznak CH, Cross SS, Hudis C, Norton L, Panageas KS, Coleman RE,Holen I. Memorial Sloan-Kettering Cancer Center, New York, NY;University of Sheffield, Sheffield, United Kingdom.

666 Prostate epithelium derived Ets factor is over expressed in humanbreast and ovarian cancers and shows better cancer associationthan Her-2/neu, CA-125, Bcl-2, survivin and telomerase.Ghadersohi A, Odunsi K, Winston JS, Lele S, Collins Y, Greco WR, Liang P,Sood AK. Roswell Park Cancer Institute, Buffalo, NY.

Tumor Cell Biology: Tumor Biology

667 Cyclooxygenase-2 inhibition and tumour growth: celecoxibincreases apoptosis in HER2 positive cell lines.Barnes NLP, Warnberg F, White D, Anderson E, Bundred NJ. SouthManchester University Hospital, Manchester, United Kingdom; PatersonInstitute for Cancer Research, Manchester, United Kingdom.

668 Low to moderate protein expression of HER2/neu in breast cancerby immunohistochemistry (IHC) correlates with low level ErbB2gene amplification by fluorescence in situ hybridization (FISH);updated results.Rugo HS, Moore D, Chen Y-Y, Magrane G, Hwang ES, Waldman FM.University of California San Francisco, San Francisco, CA.

669 Inhibition of breast cancer development in vivo by long-termconsumption of the low toxic phenylacetate derivative, 4-chlorophenylacetate.Sidell N, Tekmal RR. Emory University, Atlanta, GA; UTHSCSA, San Antonio, TX.

670 A subset of mammary epithelial cells overlying focally disruptedmyoepithelial cell layers shows an unusual immunostainingpattern for proliferation-related proteins.Man YG, Zhang R, Mattu R, Shen T, Sang QXA. Armed Forces Instituteof Pathology, Washington, DC; Temple University Hospital, Philadelphia,PA; Florida State University, Tallahassee, FL.

671 Potential importance of PKC-alpha activity in defining breasttumor luminal/basal phenotype.Lacroix M, Laes J-F, Hennuy B, Cardoso F, Lallemand F, Gonze I, Leclercq G,Piccart M, Sotiriou C. Jules Bordet Institute, Brussels, Belgium; BioVallée,Gosselies, Belgium.

672 The effects of fulvestrant and gefitinib on proliferation,progesterone - receptor and pS2 expression in normal humanbreast epithelium in vivo.Moore HA, Anderson E, Clarke RB, Warmberg F, Barnes NL, Wakeling AE,Bundred NJ. Christie Hospital NHS Trust, Manchester, United Kingdom;AstraZeneca Pharmaceuticals, Manchester, United Kingdom; SouthManchester University Hospital, Manchester, United Kingdom.

673 Quantification of receptor tyrosine kinase (RTK) signaltransduction expression in human carcinomas and cell culturemodel systems by automated digital microscopy (ADM) correlateswell with western blot analysis.Webster S, Gottlieb K, Yamamoto K, Torre-Bueno J, Bauer K.ChromaVision Medical Systems, San Juan Capistrano, CA; University ofSouthern California, Los Angeles, CA.

674 Partial intron expression ELF3 mRNA in peripheral blood mononuclearcells (PBMC's) in patients (pts) with breast cancer (Br ca).Dosik M, Kaplan MH, Wang X-P. North Shore University Hospital, Manhasset,NY; North Shore Hematology/Oncolgy Associates, Setauket, NY.

SAN ANTONIO BREAST CANCER SYMPOSIUM - Saturday xxix

675 Gene expression profile analysis of human breast cancer: usingcDNA microarrys.Lee YH, Kim HS, Jung JH, Park HY, Jung EK, Kim MK, Kim JC. KyungpookNational University, Daegu, Korea.

676 Proliferative activity evaluated by MIB-1 predicts the time andtype of recurrence in breast cancer.Nishimura R, Matsuda M, Miyayama H. Kumsamoto City Hospital,Kumamoto City, Kumamoto, Japan.

677 Regulation of the cyclin-dependent kinase inhibitors, p27kip1 andp21cip1, by Rho requires ERK activation in breast cancer cells.Welsh CF. University of Miami School of Medicine, Miami, FL.

678 Vitamin D system is altered in breast cancer patients.Lyra EC, Silva IA, Katayama MLH, Torloni H, Nonogaki S, Goes JCS,Brentani MM, Folgueira MAAK. Faculdade de Medicina da Universidadede Sao Paulo, Sao Paulo, SP, Brazil; Instituto Brasileiro de Controle doCancer (IBCC), Sao Paulo, SP, Brazil; Hospital das Clinicas da FMUSP, SaoPaulo, SP, Brazil; Hospital do Cancer A. C. Camargo, Sao Paulo, SP, Brazil.

679 Comprehensive quantitative analysis of proteins co-dysregulatedwith overexpressing Her-2 cell lines using multi-range 2D-DIGEand mass spectrometry.Sullivan AG, Russell S, George A, Katenhusen R, Somiari RI, Shriver C.Windber Research Institute, Windber, PA; Walter Reed Army MedicalCenter, Washington, DC.

680 Partially unspliced cytoplasmic mRNA of the ELF-3 gene in humanbreast cancer (Br ca) cell lines and Br ca tissue.Kaplan MH, Wang X-P, Dosik MH. North Shore University Hospital,Manhasset, NY; North Shore Hematology/Oncology Associates, Setauket, NY.

681 Hepatocyte growth factor (HGF) regulates tight junction MAGUKprotein expression in human breast cancer cells.Martin TA, Watkins G, Mansel RE, Jiang WG. University of Wales Collegeof Medicine, Cardiff, United Kingdom.

682 Vitamin D in breast cancer.McCarthy K, Laban CA, Bonner SE, Bustin SA, Ogunkolade WB, Khalaf S,Jenkins PJ, Carpenter R. Barts and The London Queen Mary School ofMedicine, London, United Kingdom.

683 Clinical outcome and human epithelial growth factor receptor(HER) 1-4 status in 79 invasive breast carcinomas withbromodeoxyuridine evaluated proliferation indices.Tovey SM, Witton CJ, Stanton PD, Reeves JR, Cooke TG, Bartlett JM.Glasgow Royal Infirmary, Glasgow, United Kingdom.

684 Microarray analysis of gene expression in blood of patients withbreast disease.Hu H, Shriver CD, Malicki L, Jordan R, Brzeski H, Somiari S, Lubert S,Hooke J, Somiari R. Windber Research Institute, Windber, PA; WalterReed Army Medical Center, Washington, DC.

685 Cox-2 over-expression is an early event in mammary carcinogenesis.Singh-Ranger G, Khalifa K, Jenkins A, Thomas V, Mokbel K. St, George’sHospital, London, United Kingdom.

Detection / Diagnosis: Axillary / Sentinel Nodes

686 Improvement of the sensitivity of detectingimmunohistochemically stained tumor cells in breast cancersentinel nodes by supervised automated microscopy.Mesker WE, Torrenga H, Borthwick D, van Diest PJ, Tanke HJ. Leiden.University Medical Center, Leiden, Netherlands; VU University Hospital,Amsterdam, Netherlands; Santa Clara, CA

9:00-9:30 PLENARY LECTURE 4 – Ballroom C

Robert Allen, MD

9:30-11:00 GENERAL SESSION 5 – Ballroom C

9:30 34. Chemo-endocrine effects of adjuvant therapies for postmenopausalnode-negative breast cancer according to ER, PgR, and Her2 assessedcentrally.Viale G, Gelber RD, Mastropasqua MG, Maiorano E, Aldrighetto S, Price KN,Castiglione-Gertsch M, Goldhirsch A. European Institute of Oncology, Milan,Italy; University of Milan, Milan, Italy; University of Bari, Bari, Italy; InternationalBreast Cancer Study Group, Bern, Switzerland.

9:45 35. Patterns of loco-regional failure (LRF) in patients receiving neoadjuvantchemotherapy (NC): results from NSABP B-18. Mamounas EP, Wang J, Bryant J, Fisher B, Wickerham LD, Wolmark N. University ofPittsburgh, Pittsburgh, PA.

10:00 36. An international, randomized phase III clinical trial of STn-KLH(Theratope®) therapeutic cancer vaccine in metastatic breast cancerpatients.Miles D, Ibrahim N, Roché H, Guillem V, Martin M, Perren T, Cameron D, Glaspy J,Dodwell D, Parker J, Tres A. Guy’s Hospital, London, United Kingdom; MDAnderson Cancer Center, Houston, TX; Centre Claudine Régaud, Toulouse, France;Inst Valenciano de Oncologia, Valencia, Spain; Hosp. Clinico Univ. San Carlos, Madrid,Spain; St James Univ Hospital, Leeds, United Kingdom; Western General Hospital,Edinburgh, United Kingdom; UCLA School of Medicine, Los Angeles, CA;Cookridge Hospital, Leeds, United Kingdom; Biomira, Inc, Edmonton, AB, Canada;Univ. Lozano Blesa, Zaragoza, Spain.

10:30 38. The search for surrogates - physiologic imaging in a breast cancerxenograft model during treatment with SU11248.Miller KD, Miller M, Mehrotra S, Hutchins G, Badve S, Murray LJ, Sledge GW.Indiana University, Indianapolis, IN; Sugen, Inc.

10:45 39. EGF10004: a randomized, multicenter, phase Ib study of the safety,biologic activity and clinical efficacy of the dual kinase inhibitor GW572016.Burris HA, Hurwitz H, Dees C, Dowlati A, Blackwell K, Ellis M, Overmoyer B, Jones S,Willcutt N, Smith DA, Harris JL, Spector NA. Tennessee Oncology Associates SarahCannon Cancer Center, Nashville, TN; Duke University Medical Center, Durham,NC; Univeristy of North Carolina at Chapel Hill, Chapel Hill, NC; Case WesternReserve University, Cleveland, OH; GlaxoSmithKline, Research Triangle Park, NC.

11:00-12:30 MINI-SYMPOSIUM 4 – Ballroom C

Breast Cancer Care – Reaching and Treating Minorities and the ElderlyRita Kramer, MD, Co-ModeratorBaylor/Methodist Breast Care Center, Houston, TXandC. Kent Osborne, MD, Co-ModeratorBaylor College of Medicine, Houston, TX

11:00 Introduction

11:00 Local-regional management issues in the elderlyIan Fentiman, MDGuy's HospitalLondon, England, UK

11:30 Optimal care in minority populationsHarold P. Freeman, MDRalph Lauren Center for Cancer Care and PreventionNew York, NY

12:00 Systemic breast cancer therapy in the elderlyHyman B. Muss, MDUniversity of VermontBurlington, VT

Supported by an educational grant from Aventis Pharmaceuticals

12:30 ADJOURNMENT,

26th Annual San Antonio Breast Cancer Symposium

1:00-4:30 SABCS OFFICIAL SATELLITE SYMPOSIUM

– Marriott Rivercenter

Molecular Markers in Breast Cancer - Moving From the 20th tothe 21st CenturyThis CME-accredited program will provide an exciting overview ofemerging genomic technologies that will improve the way breast cancer isdiagnosed and treated. Focusing on very recent developments in this field,this program will highlight practical applications that will becomecommercially available in the near term as well as more experimentalapproaches with longer-term implications for clinical practice.

Lunch & Symposium sponsored by

Helix Medical Communications LLC

For information, contact:

Daniel SchneiderPhone: (650) 357-8600 x104 • Fax: (650) 357-8602daniel.schneider@helix-medcom.com

Supported by an educational grant from Genomic Health, Inc.

SAN ANTONIO BREAST CANCER SYMPOSIUM - Saturdayxxx

Breast Reconstructions: The Perforator Flap Technique

Louisiana State University Health Sciences Center New Orleans, LA